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Kaseiineihin perustuvat formulaatiot ovat lupaavia materiaaleja lääkeaineiden 
säädeltyyn vapauttamiseen. Kaseiinit ovat maidon pääproteiineja, ja niiden 
bioyhteensopivuus, alhainen toksisuus ja luonnollinen metabolia fysiologisissa 
systeemeissä tekevät kaseiineista erittäin sopivia materiaaleja farmaseuttisiin 
formulaatioihin. Polyelektrolyytti kompleksi nanopartikkeleita voidaan valmistaa hyvin 
miedoissa olosuhteissa ja ne ovat stabiileja ruoansulatuskanavassa, jonka vuoksi ne 
sopivat oraaliseen annosteluun kantajamateriaaleiksi peptidi ja proteiini lääkkeiden 
säädeltyyn vapautukseen. 
Työn tarkoituksena oli syntetisoida kaseiini-polyakryylihappo polyelektrolyytti 
kompleksi nanopartikkeleita eri massasuhteilla, ja tutkia malliaineena toimivan 
rodamiini 6G:n vapautumisprofiilia näistä nanopartikkeleista. Nanopartikkelien 
kaseiinikuori ristisilloitettiin kahdella erilaisella ristisilloittajalla, koska haluttiin tutkia 
pinnan muokkauksen vaikutusta nanopartikkelien kokoon ja malliaineen 
vapautumisprofiiliin. Tavoitteena oli saavuttaa malliaineen säädelty vapautuminen 
muokkaamalla kaseiinikuoren paksuutta ja tiiviyttä.  
Nanopartikkelien kokoa ja kokojakaumaa tutkittiin dynaamisella valonsironnalla. 
Pinnan varausta tutkittiin nanopartikkelien elektroforeettisen liikkuvuuden mittauksella. 
Morfologiaa tutkittiin elektronimikroskopialla, ja kaseiinikuoren paksuuden vaikutusta 
rodamiini 6G:n vapautumiseen tutkittiin dialyysimetodilla. Syntetisoidut nanopartikkelit 
olivat muodoltaan pyöreitä, mutta kokojakauma oli suuri. Rodamiini 6G:n 
vapautuminen nanopartikkeleista oli hitaampaa kuin referenssinä käytetyn vapaan 
rodamiini 6G:n vapautuminen, mutta kaseiinikuoren paksuuden vaikutus 
nanopartikkeleihin ladatun rodamiini 6G:n vapautumiseen jäi osittain epäselväksi. 
Optimaalisella pinnan muokkauksella lienee kuitenkin mahdollista saavuttaa säädelty 
vapautumisprofiili kaseiini-polyakryylihappo nanopartikkeleihin ladatuille yhdisteille 
tulevaisuudessa. 
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I. LITERATURE REVIEW 
1. INTRODUCTION 
By definition, controlled drug delivery systems provide some control over the drug 
delivery in the body, and the control can be temporal or spatial or a combination of both 
(Sinko, P.J., Singh, Y., 2011). The goal is to control drug level in the target tissues or 
cells and avoid undesirable drug level fluctuations in plasma. This should ensure fewer 
side-effects and more effective therapies when compared to conventional dosage forms. 
Drug release from a controlled drug delivery system can be zero-order, variable or 
bioresponsive. In zero-order release the drug release does not vary with time and a 
relatively constant drug level in plasma is preserved over an extended period of time. In 
variable release the drug is released at variable rates to mimic natural biorhythms or 
circadian rhythms. Bioresponsive release is achieved when the drug release is triggered 
by biological stimulus like changes in pH, concentration of certain biologically active 
substances or temperature. In the field of pharmaceutical nanotechnology several 
different approaches and nanocarriers have been developed to achieve these goals (Pinto 
Reis et al., 2006).  
Pharmaceutical nanoparticles are solid colloidal particles sized between 1 to 1000 nm in 
diameter that can be used as drug carriers (Parveen et al., 2012). Pharmaceutical 
nanotechnology focuses on the development of these carrier materials, and on different 
encapsulation strategies that can be used to associate bioactive compounds or drugs into 
nanosized carrier materials. Based on the carrier material, the nanosized controlled 
release drug delivery systems can be divided into several categories such as polymeric 
nanoparticles, solid lipid nanoparticles, liposomes, dendimers and polymeric micelles 
(Betancourt et al. 2009a). The controlled release of a bioactive agent from a nanocarrier 
can be achieved by modifying the carrier composition. Modifications can be achieved 
by using various types of polymers or lipids, changing the molecular weights of the 
components or by modifying the surface characteristics by crosslinking or adding 
separate components to the surface.  The use of various polymeric materials allows the 
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modification of physicochemical characteristics, drug release properties and biological 
behaviour of nanoparticles.  
In recent years, there has been a rising need to develop novel drug delivery systems for 
the oral delivery of peptide and protein drugs (Lee, 2002;Parveen and Sahoo, 2006). 
The carrier systems should optimally provide protection and improve the 
pharmacokinetics of easily degradable peptides and proteins that often have short half-
lives in vivo. It is important that both the preparation mechanism of the carrier and the 
encapsulation process impart minimal stress to the sensitive protein and peptide drugs. 
Polymeric polyelectrolyte complex nanoparticles can be synthesized under very mild 
conditions, and could therefore potentially be ideal carriers for controlled release and 
permeation enhancement of peptide and protein drugs through the oral route (Hu et al., 
2002; Jintapattanakit et al., 2007).  
In this work polyelectrolyte complex nanocapsules were prepared via electrostatic 
complex formation between casein and poly(acrylic acid). Casein and poly(acrylic acid) 
have both been widely studied for drug delivery purposes due to their excellent 
biocompatibility (Elzoghby et al., 2011; Molnar et al., 2009; Park and Robinson, 1987). 
The aim of this work was to synthesize and characterize poly(acrylic acid) templated 
casein-poly(acrylic acid) nanoparticles. It was hypothesised that controlled release of an 
encapsulated compound could be achieved by modifying the shell thickness and 
stiffness of these nanoparticles. The experimental part of this work will describe the 
synthesis method and physical characteristics of casein-poly(acrylic acid) nanoparticles. 
In addition, the dialysis method development and in vitro release studies of a model 
compound rhodamine 6G will be described.  
In essence, the purpose of this work was to gain information about this novel 
nanocarrier system, as currently only a few studies have been focused on the 
combination of casein and poly(acrylic acid) as building blocks for polyelectrolyte 
complex nanoparticles (unpublished observation Laaksonen, 2011; Liu et al., 2011; Liu 
et al., 2010). The literature review part will focus on the properties of polymeric 
nanoparticles and their applicability as carriers for controlled drug delivery. Some of the 
most interesting, and relevant in terms of this work, new casein based controlled release 
formulations will also be described.  
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2. NANOPARTICLES AS DRUG DELIVERY SYSTEMS 
Drug loaded polymeric nanoparticles are typically prepared from biodegradable 
polymers, which degrade chemically under physiological conditions and do not require 
removal after being placed in the body (Kumari et al., 2010; Soppimath et al., 2001). 
The biocompatibility of selected materials is also important. Biocompatibility is defined 
as the ability of a material to perform with an appropriate host response in a specific 
application (Zuckerman and Kao, 2009). In other words, low toxicity and lack of 
immune response are the requirements for biocompatible drug delivery systems. 
Biocompatibility testing of medical devices and drug delivery systems contains a large 
set of in vitro tests and in vivo animal test that are performed to evaluate if a certain 
material is biocompatible or not. International Organization for Standardization (ISO) 
and the American Society for Testing Materials Standards have constructed ISO 10993 
standards that specify the requirements and the procedures that are used in the 
evaluation of biocompatibility (International Organization for Standardization, 2012).  
Currently there is a limited availability of toxicity data of the nanoparticles that are used 
in drug delivery applications (De Jong and Borm, 2008). Due to small size of 
nanoparticles they have the ability to access cells, cell compartments and cross 
biological barriers. This could result in unexpected adverse reactions, and therefore the 
toxicity evaluation should be done on a case-by-case approach and long-term. In spite 
of this, the use of nanoparticles for drug delivery has revolutionized drug therapy. 
The term polymeric nanoparticle applies to both nanospheres and nanocapsules, and 
their structures are presented in Figure 1 (Kumari et al., 2010). Nanospheres are solid 
particles with a matrix type of structure. Drugs may be adsorbed on the surface of the 
sphere or entrapped or dissolved in the polymer matrix. Nanocapsules consist of an 
inner core cavity surrounded by a polymeric membrane. Drugs are usually trapped in 
the inner core of nanocapsules but may also be adsorbed on the surface. Drug loading 
can be achieved either during the nanoparticle synthesis or by incubation into preformed 
nanoparticles.  
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Figure 1. The structure of nanocapsules and nanospheres (Kumari et al., 2010). 
Nanocapsules consist of an inner core cavity, which is surrounded by a polymeric 
membrane. Nanospheres have a matrix structure. Drugs can be adsorbed on the surface 
or entrapped inside of these nanocarriers by various formulation methods. 
In general, diffusion of the drug and biodegradation of the carrier vehicle control the 
drug release from biodegradable nanoparticles (Soppimath et al., 2001). Several factors 
can contribute to the release rate of encapsulated or surface adsorbed drugs from 
nanocapsules- and spheres. These include desorption of the surface-bound or adsorbed 
drug, diffusion of the drug through the matrix structure or the polymeric membrane, 
erosion of the matrix or a combined erosion and diffusion process. 
There are several different methods available for the preparation of polymeric 
nanoparticles, and these methods can be roughly divided into two main categories 
(Pinto Reis et al., 2006). The preparation method is usually selected based on the 
properties the carrier material and the drug molecule to be encapsulated. Efficient 
entrapment of a drug molecule can be optimized by choosing the best preparation 
method and suitable polymer materials for the carrier. The nanoparticle synthesis can be 
achieved either by using preformed polymers or macromolecules or the synthesis may 
require polymerization of monomers. Nanoprecipitation, different polymerization and 
emulsification techniques as well as nebulization techniques are among the most widely 
used methods.  
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It has been proposed that polyelectrolyte complexation may be the easiest way to 
prepare nanoparticles directly in aqueous solution (Harada and Kataoka, 1995; Pan et 
al., 2007). In addition to simple preparation method, the polyelectrolyte complex 
nanoparticles could also potentially be used as carriers for drugs, DNA or enzymes 
(Thünemann et al., 2004). Formation of polyelectrolyte complexes will be described in 
the section 2.4.  
2.1 Properties and stability of nanoparticles 
This section will focus on factors that contribute to the stability of nanodispersions. The 
effect of surface characteristics, size and size distribution of nanoparticles on stability 
and in vivo biodistribution of nanoparticles will be described with examples.  Also, 
nanoparticle targeting strategies will be described briefly. Surface functionalization of 
nanoparticles can provide tools for prolonging the blood circulation time and targeting 
of nanoparticles, which is highly desirable for drug carriers in pharmaceutical 
applications (Mout, 2012). 
2.1.1 Size uniformity of nanoparticles 
Size uniformity of nanoparticles is one of the most important characteristics that 
nanocarriers in pharmaceutical formulations should have (He et al., 2010). Therefore 
the size distribution of nanoparticles should be very narrow. Polydispersity index (PDI) 
is a parameter obtained from dynamic light scattering measurements that defines the 
particle size distribution of nanoparticles (Nidhin et al., 2008). PDI values up to 0.1 
represent monodisperse size distribution i.e. the nanoparticles are uniformly sized if the 
PDI value is below 0.1 (Baalousha and Lead, 2012; Nidhin et al., 2008; Peracchia et al., 
1999). It has also been proposed that PDI values below 0.2 represent monodispersity in 
pharmaceutical formulations (Danhier et al., 2009). If the PDI values are above 0.1-0.2 
it means that the size distribution of nanoparticles is very broad.  
High PDI values are problematic in terms of stability and in vivo biodistribution. 
Increase in PDI values may refer to aggregation or presence of doublets in the 
formulation (Sukhorukov et al., 1998). This may be a sign of poor stability, but it may 
also indicate that there is a problem in the formulation during the formation of 
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nanoparticles. Because the size affects the in vivo biodistribution and consequent 
therapeutic effect of nanosized drug carriers, it is important to control the size and PDI 
of drug carriers (He et al., 2010). Aggregates or uneven size distribution in the 
nanoparticulate drug carrier formulation can cause dangerous blockages in the blood 
vessels and small capillaries of the human body.  
2.1.2 Stabilization of nanodispersions 
Derjaguin, Landau, Verwey and Overbeek have developed a DLVO theory, which 
describes the stability of colloidal systems (Derjaguin and Landau, 1941; Verwey and 
Overbeek, 1948). In short, this theory suggests that the stability of a colloidal particle in 
solution depends upon its total potential energy function (VT), which is a balance 
between several competing contributors. The most important factor is the balance 
between attractive van der Waals forces (VA) and repulsive electrical double layer 
forces (VR). These forces exist between particles as they approach each other in solution 
due to random Brownian motion. DLVO theory suggests that an energy barrier caused 
by the repulsive forces prevents two particles from approaching one another and 
aggregating. However, if the collision of two particles has enough energy to overcome 
the energy barrier, the attractive forces will pull the particles together and cause 
irreversible aggregation. Simplified presentation of DLVO theory is presented in Figure 
2. 
Steric stabilization and electrostatic stabilization are the two possible ways to stabilize 
colloidal dispersions as those impart repulsive forces or energetic barriers to a colloidal 
system (Kesisoglou et al., 2007). Steric stabilization can be achieved by adsorbing 
polymers onto the particle surface, and as particles approach each other their steric 
layers encroach, which creates osmotic stress that acts to keep the particles separate. 
Electrostatic stabilization is obtained by adsorbing charged molecules onto the particle 
surface, which creates charge repulsion that provides an electrostatic potential barrier to 
particle aggregation. Typically steric stabilization alone is sufficient to stabilize the 
nanoparticles and prevent irreversible aggregation, but there may still be enough 
attractive forces between the particles to cause loose and reversible flocculation. Steric 
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stabilization can be combined with electrostatic stabilization for additional repulsive 
contribution to avoid flocculation. 
 
Figure 2. Potential energy as a function of interparticle distance for particles in solution 
(modified from Derjaguin and Landau, 1941; Verwey and Overbeek, 1948). Total 
potential energy function (VT) and the stability of colloidal system depends on the sum 
of attractive van der Waals forces (VA) and repulsive electrical double layer forces (VR). 
The energy barrier prevents particles from aggregating irreversibly together.  
2.1.3 The surface charge of nanoparticles 
The surface charge (ζ-potential) is a fundamental property of nanoparticles, and also one 
of the stability determining parameters in colloidal nanodispersions (Müller et al., 
2001). The stability of colloidal nanodispersions is often interpreted in terms of the ζ-
potential, because it is more readily accessible than the surface potential. As a general 
rule, ζ-potential with a minimum value of ±30 mV is required for physical stabilization 
if only electrostatic repulsion is used to stabilize nanodispersions. If electrostatic and 
steric stabilization are combined, then ±20 mV is usually adequate.  
Typically nanoparticulate dispersions, which are stabilized electrostatically, are more 
stable the higher the absolute ζ-potential values are, because repulsive forces prevent 
effectively the aggregation of nanoparticles (Leroueil-Le Verger et al., 1998). Leroueil-
Le Verger and colleagues have encapsulated an antihypertensive drug israpidine into 
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biocompatible and biodegradable nanoparticles that were prepared with the 
nanoprecipitation method from poly(d,l-lactide), poly(d,l-lactide-co-glycolide) and 
poly(ε-caprolactone). The ζ-potential value of these nanoparticles was modified by 
varying their polymer composition. Israpidine loaded nanoparticles exhibited ζ-potential 
values between -19 mV to -35 mV, and the highest physical stability was achieved with 
the -35 mV ζ-potential values. They suggested that ζ-potential value of about -25 mV 
would be optimal for good stabilization. This value is in accordance with the general 
recommendations.  
There are also other methods available for altering the ζ-potential value of nanoparticles 
in addition to polymer composition modification. For example, crosslinking (i.e. 
formation of covalent or ionic bonds) of surface functional groups can be utilized for 
altering the ζ-potential values (Ding et al., 2010). And also the surface can be modified 
with charged polyelectrolytes that can be used to manipulate the surface ζ-potential 
values of nanoparticles (Sukhorukov et al., 1998). 
2.1.4 The effect of surface charge on cellular uptake of nanoparticles 
The in vivo fate of nanoparticles has to be considered in addition to nanoparticle 
stability when a pharmaceutical formulation is developed. The mononuclear phagocyte 
system (MPS), which is a part of immune system in the human body, can be a major 
obstacle for nanoparticle based drug delivery (Van Furth et al., 1972). 
Reticuloendothelial system (RES) is another widely used definition for MPS in the 
literature. MPS/RES contains phagocytic cells, such as monocytes and macrophages. 
There is an abundance of monocytes in the blood circulation and tissues such as liver 
(Kupffer cells), spleen, lymph nodes and lungs.  
Phagocytic cells are specialized in clearing the blood, lymph and tissues of foreign 
micro-organisms and particles (Van Furth et al., 1972). The surface charge, 
hydrophobicity and size of nanoparticles all have an effect on the uptake by MPS/RES 
(Gaur et al., 2000; Storm et al., 1995). Opsonins are proteins present in the blood serum 
that bind to the surface of nanoparticles and act as a bridge between the nanoparticles 
and the phagocytes. Opsonization process is one of the most important biological 
barriers to nanoparticle based controlled drug delivery.   
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Ding and colleagues have studied cell internalization of nanoparticles with positively 
charged chitosan-gold hybrid nanospheres (Ding et al., 2010). They studied the in vitro 
cellular uptake with nanoparticles that had 40.6 mV, 30.51 mV and 19.39 mV ζ-
potential values.  Cell internalization was significantly faster for nanoparticles with 
higher positive ζ-potential values, but a too high positive charge resulted in cell 
membrane destabilization and induced cell damage and cytotoxicity. Also He and 
colleagues have had similar results when they studied the effects of particle size and 
surface charge on cellular uptake and biodistribution of nanoparticles (He et al., 2010). 
In their study, the positively charged nanoparticles showed a higher phagocytic uptake 
than the negatively charged nanoparticles when the ζ-potential values were similar 
regardless of the nanoparticle composition. They also reported that the in vitro 
macrophage uptake of nanoparticles increased as the surface potential (either positive or 
negative) rose, and the uptake of larger nanoparticles was favoured by phagocytic cell 
lines. In this study, it was clearly demonstrated that size and surface charge of 
nanoparticles are more important parameters than nanoparticle composition when the 
fate of cellular uptake is considered during formulation development. 
The fast internalization of cationic nanoparticles is not surprising, because cells and 
biocomponents such as plasma proteins have a slightly negative charge (Konno et al., 
2001). Cationic surface charge of nanoparticles can therefore promote interactions with 
oppositely charged proteins and cell membranes, and hence increase the rate and extent 
of internalization of nanoparticles (Konno et al., 2001; Shenoy and Amiji, 2005).  
He and colleagues also conducted in vivo biodistribution studies with tumour bearing 
mice, and they have suggested that keeping the size and surface charge below 150 nm 
and -15 mV respectively would provide enhanced in vivo accumulation of nanoparticles 
into the tumours (He et al., 2010). This phenomenon was probably caused by the lesser 
phagocytic uptake of negatively charged small nanoparticles, which enabled the 
accumulation of negatively charged nanoparticles into the tumour tissues more 
effectively when compared to positively charged nanoparticles. Therefore, the slightly 
negative surface charge could be in fact beneficial, even though cationic nanoparticles 
are usually internalized faster into cells and tissues On the contrary, large negative 
surface charge of nanoparticles induces unfavourable immunological reactions, and 
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therefore it is recommended that the negative ζ-potential values should be kept minimal 
to ensure good biocompatibility with plasma proteins (Konno et al., 2001).  
Based on these studies some general remarks and conclusions can be made. First, the 
drug carrier system must not induce toxicity in the in vivo environment. Second, for 
successful pharmaceutical nanoformulations the stability of the formulation has to be 
ensured in order to gain an acceptable shelf life for the product. Also, the functionality 
of the formulation is another aspect of stability. In a stable formulation nanoparticles are 
not aggregated and can be administered safely into the human body to achieve a 
therapeutic effect. Third, if the ζ-potential required for electrostatic stabilization is too 
high it may cause problems in the in vivo environment, because the nanoparticles with 
high ζ-potential values usually interact with plasma proteins and MPS/RES 
significantly. This problem may be addressed by modifying the carrier itself, but usually 
a more effective way is to modify the surface characteristics of the carrier during 
formulation optimization. All in all, a suitable balance between size, surface charge and 
surface composition should enable the development and optimization of stable, safe and 
effective polymeric drug nanocarriers.  
2.1.5 Active and passive targeting 
The use of hydrophilic coatings on the surface of nanoparticles has become important, 
because these coatings mask nanoparticle surfaces and prolong the blood circulation 
time of drug loaded nanoparticles, by preventing the adsorption of plasma proteins that 
promote the recognition by MPS/RES (Storm et al., 1995). However, in some cases the 
MPS/RES uptake of drug loaded nanoparticles can be beneficial for drug therapy if the 
goal is to target monocytes or macrophages (Bender et al., 1996). 
The size and surface hydrophobicity of nanoparticles determine the amount of adsorbed 
blood components, and nanoparticles with a hydrophobic surface are rapidly opsonized 
and massively cleared by the fixed macrophages of the MPS/RES (Soppimath et al., 
2001). For example, Gaur and colleagues have studied the effect of nanoparticle size 
and surface hydrophobicity on RES uptake (Gaur et al., 2000). They concluded that 
small hydrophilic nanoparticles (< 100 nm) were able to avoid RES uptake effectively, 
11 
 
  
whereas nanoparticles with more hydrophobic surface and larger size were more 
effectively cleared by RES.  
The accumulation of drug-loaded nanoparticles in the target site instead of their 
retention and circulation in the circulatory system of the body is important, because the 
drug has to reach the target in order to achieve the therapeutic effect (Ruoslahti et al., 
2010). This can be ensured by active or passive targeting. Passive targeting exploits 
anatomical differences between diseased and normal tissues to deliver drugs to the 
target site. For example, tumours as well as infection and inflammation sites are leakier 
than normal tissues. This enables the accumulation of nanosized drug carriers into these 
tissues. In order to achieve the passive targeting the drug carrier system must have 
adequate blood circulation time.  
One of the most frequently used approaches in formulation development is to modify 
the nanoparticle surfaces with the hydrophilic steric stabilizer polyethylene glycol 
(PEG) (Peracchia et al., 1999). Nanoparticle surface masking with hydrophilic PEG 
results in longer blood circulation time of nanoparticles when the density of PEG on the 
surface of nanoparticles is adequate. The prolonged blood circulation time of 
nanoparticles enables the passive targeting.  By coating the surface with PEG it is also 
possible to mask the surface charge of nanoparticles, which is useful if the surface 
charge is too high and promotes the recognition by the immune system (Danhier et al., 
2009). Other commonly used steric stabilizers that prolong the blood circulation time of 
nanoparticles and reduce the uptake by MPS/RES include poloxamines, poloxamers and 
polysorbates (Tween 80) (Illum et al., 1987; Kreuter, 1993; Troster et al., 1990). 
Usually water compatible, neutral, flexible and well hydrated polymers are preferred in 
surface masking (Storm et al., 1995). 
Active targeting is more effective than passive targeting and it exploits receptor specific 
ligands, such as antibodies, peptides or nucleic acids, on the surface of nanoparticles 
(Ruoslahti et al., 2010). These ligands promote site specific targeting to diseased tissues 
that carry molecular markers, which are usually not expresses in normal cells. Active 
targeting is used to achieve increased efficacy of drug therapy, and to reduce side-
effects. For example, Sugahara and colleagues have coated the surface of nanoparticles 
that carry an anticancer drug paclitaxel with iRGD peptide (Sugahara et al., 2009). This 
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peptide targets nanoparticles specifically to tumour tissues and enhances the permeation 
of the carrier into the tumours, which results in more effective drug therapy. 
2.2 Commercially successful nanomedicine 
Currently there are over twenty commercially successful nanomedicine products on the 
market, and some examples of these are given in the Table 1 (Wagner et al., 2006). 
Nanoparticulate drug delivery systems provide additional benefits, such as fewer side-
effects to patients, when compared to conventional dosage forms. Nanomedicine 
products have made it possible to treat diseases and disease stages that would otherwise 
be impossible to treat with conventional dosage forms. Liposomes are currently the 
most successful carriers on the market by number, but also nanocrystals, polymer 
protein conjugates and polymeric nanoparticle formulations have been commercially 
successful.  
Table 1. Examples of commercially successful nanomedicine products on the market 
(modified from Wagner et al., 2006). Liposomes are currently the most successful 
carriers on the market by number, but also polymer protein conjugates, nanocrystals and 
polymeric nanoparticle drug delivery systems are available. 
Commercial name/ 
Company 
Composition 
 
Indication 
AmBisome/ 
Gilead, Fujisawa 
Amphotericin B  
in liposome carrier 
Fungal infections 
Myocet/ 
Zeneus Pharma 
Doxorubicin  
in liposome carrier 
Breast cancer 
Epaxal Berna/  
Berna Biotech 
Virosomal hepatitis vaccine Vaccine against 
Hepatitis A 
Pegasys/Nektar, 
Hoffmann-La Roche 
PEG-α-interferon 2a Hepatitis C 
Tricor/ Elan Drug 
Delivery, Abbott 
Nanocrystallized fenofibrate Lipid regulation 
Abraxane/  
Abraxis BioScience,  
Astra Zeneca 
Paclitaxel stabilized by 
albumine 
Cancer 
 
AmBisome is a liposome based formulation that reduces the well-known infusion 
related toxicity of antifungal drug amphotericin B by attenuating the release of 
cytokines in vivo (Meunier et al., 1991; Ringden et al., 1991; Walsh et al., 1998). 
Myocet is another liposome based commercial preparation (Batist et al., 2002). In this 
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preparation the anticancer drug doxorubicin is encapsulated into a liposome carrier, 
which reduces the cumulative cardiotoxicity of doxorubicin by altering the 
pharmacokinetics and toxicity profile of doxorubicin. Epaxal contains inactivated 
hepatitis A viruses adsorbed to the surface of special liposomes (virosomes) (Bovier, 
2008). This vaccine against hepatitis A causes fewer local side-effects that the 
conventional vaccines against hepatitis A that contain aluminium as an adjuvant. 
Nanocrystal formulation strategy has been widely used in bioavailability enhancement 
of poorly soluble drugs, and Tricor is an example of a commercial product prepared 
with this type of formulation strategy (Shegokar and Müller, 2010). Pegasys is used in 
the treatment of hepatitis C, and the dosing regimen of the drug interferon α-2a has been 
prolonged with the polyethylene glycol segment in this product (Rajender Reddy et al., 
2002). Finally, Abraxane is an example of biopolymer based nanoparticle drug delivery 
system (Ibrahim et al., 2002). Albumine stabilizes the chemotherapy drug paclitaxel in 
this formulation, and also enables the utilization of endogenous albumin pathways in the 
enhancement of intratumor concentrations of paclitaxel.  
2.3 Oral route for protein and peptide delivery 
At the present time the therapeutic applications of nanoparticle based drug delivery 
systems are diverse ranging from cancer therapy to vaccine delivery and even 
antimicrobial treatment (Wagner et al., 2006). However, there is still a need to develop 
suitable carriers for oral delivery of sensitive peptide and protein drugs (des Rieux et al., 
2006). In order to gain the therapeutic effect, peptide and protein drugs have to be first 
absorbed through the intestine wall to reach the systemic blood circulation. The goal 
may also be to achieve a local therapeutic effect in the gastrointestinal tract. In any case, 
the integrity of peptide and protein drugs is important for their therapeutic efficacy. 
Unfortunately peptide and protein drugs are very sensitive for degradation in the harsh 
environment of the gastrointestinal tract, which results in poor bioavailability. Because 
of this reason, protein and peptide drugs have typically been administered by injection. 
Nevertheless, the oral route could provide less invasive administration route and 
ultimately improve patient compliance.   
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In spite of numerous studies, it is still not clearly identified which materials could 
provide the best carriers for oral delivery of peptides and proteins (Delie, 1998). It 
seems that submicron sized carriers could effectively enhance the permeation and 
absorption of peptides and proteins. Nanoparticles in particular have a large surface 
area, which could be beneficial in absorption enhancement of peptide and protein drugs. 
The drug carrier systems of peptide and protein therapeutics should not only provide 
protection in the gastrointestinal tract against proteases and digestive enzymes, but also 
enhance the permeation and bioavailability of encapsulated therapeutics (Delie and 
Blanco-Príeto, 2005; Morishita and Peppas, 2006). The structural integrity of the 
sensitive cargo should also be preserved during the drug incorporation into the carrier 
structure. Polyelectrolyte complexation technique has been proposed as a potentially 
useful technique for the preparation of stable polymeric insulin nanocarriers for oral 
delivery purposes (Jintapattanakit et al., 2007). This technique could probably be 
extended for the preparation of suitable polymeric nanocarriers to other peptide and 
protein drugs as well. 
Association of peptides and proteins with polymeric colloidal carriers or hydrogels has 
been one of the most promising strategies against degradation in the harsh environment 
of the gastrointestinal tract (Chaturvedi et al., 2012). For example, the proteolytic 
degradation of human calcitonin and insulin was prolonged in the rat intestine due to 
encapsulation of these peptides into poly(isobutyl cyanoacrylate) nanocapsules (Lowe 
and Temple, 1994). In another study, insulin was encapsulated into poly(acrylic acid)-
cysteine nanoparticles that protected insulin physically against degradation by digestive 
enzymes trypsin, α-chymotrypsin, and elastase during the in vitro degradation studies 
(Perera et al., 2009). Hence, polymeric nanoparticles have been shown to protect 
peptides physically against degradation in the intestine environment, regardless of the 
exact polymeric composition of the nanocarrier. 
Interestingly, poly(acrylic acid) has the ability to inhibit proteolytic enzymes, and 
therefore protect peptides against lumenal degradation in the intestine (Bai et al., 1996). 
Poly(acrylic acid) has also mucoadhesive properties that can improve and prolong the 
absorption time of encapsulated peptides in the intestine (Bai et al., 1996; Park and 
Robinson, 1987). Because poly(acrylic acid) can protect peptides against degradation in 
15 
 
  
the intestine, and also improve the absorption of peptide drugs, it seems like a rational 
approach to concentrate on the development of poly(acrylic acid) based nanoparticle 
carriers for the oral delivery of protein and peptides drugs. 
2.4 Polyelectrolyte complex nanocapsules  
Polyelectrolytes are polymers that contain a large number of elementary charges 
distributed along the macromolecular chain and possess a net negative or positive 
charge at near neutral pH value (Lankalapalli and Kolapalli, 2009). Polyelectrolytes can 
be classified into natural, synthetic or chemically modified biopolymers based on their 
origin. Electrochemical classification divides them into polyanions, polycations or 
polyampholytes. Strong polyelectrolytes are made of monomers of strong acids or 
bases, and therefore the number of nominal charges does not relate to changes in pH 
(Kaur et al., 2012). Because weak polyelectrolytes are prepared from monomers of 
weak acids or bases, the number of nominal charges can be easily adjusted by pH. 
Proteins are natural polyelectrolytes and usually polyampholytes by their nature. 
Natural origin polyelectrolytes rarely have an even charge distribution along their 
backbone.  
Polyelectrolyte complexes have been widely studied for controlled drug delivery 
purposes (Kaur et al., 2012; De Kruif et al., 2004; Lankalapalli and Kolapalli, 2009). 
Polyelectrolyte complexes can be prepared in mild conditions in aqueous solutions 
through electrostatic interactions between oppositely charged molecules. Mild synthesis 
conditions are beneficial for encapsulation of peptide and protein drugs. This section 
also introduces the layer-by-layer constructed polyelectrolyte capsules as potential 
controlled drug delivery systems. Microfluidics as a platform for polyelectrolyte 
complex synthesis is described briefly as it may provide solutions to large-scale 
manufacturing of polyelectrolyte complexes. 
2.4.1 Polyelectrolyte complex formation  
There are several factors that contribute to the formation and stability of polyelectrolyte 
complexes (Kaur et al., 2012; Lankalapalli and Kolapalli, 2009). The most important 
factors are polyelectrolyte concentration, charge density and distribution of ionized 
16 
 
  
groups, ionic strength and pH of the reaction medium, molecular weight of 
polyelectrolytes as well as mixing ratio and mixing order. Some examples of 
polyelectrolytes that have been used in the preparation of polyelectrolyte complexes are 
presented in Table 2. Drugs or other bioactive compounds can be entrapped into 
polyelectrolyte complexes during or after the complex formation or the drug/bioactive 
compound itself may act as a polyion in the complex formation. All in all, 
polyelectrolyte complex nanoparticles can be prepared from several different materials 
by selecting suitable pairs for the formation of polyelectrolyte complexes and by 
optimizing the synthesis conditions. The formation of casein-poly(acrylic acid) 
nanoparticles, which are also polyelectrolyte complex nanoparticles, will be described 
in more detail in the section 3.3.3.  
Table 2. Polyelectrolytes that have been used as building blocks for polyelectrolyte 
complexes (modified from Lankalapalli and Kolapalli, 2009). Polyelectolytes are 
classified in the table according to their origin. The electrochemical classification is 
included in parentheses.  
Natural 
polyelectrolytes 
Chemically modified 
biopolymers 
Synthetic polyelectrolytes 
Nucleic acids  
(Polyanion) 
Chitosan  
(Polycation) 
Poly(vinylbenzyl trialkyl 
ammonium)  
(Polycation) 
Poly (L-lysine)  
(Polycation) 
Pectin  
(Polyanion) 
Poly(acryamidoalkyl-trialkyl 
ammonium)  
(Polycation) 
Carrageenan  
(Polyanion) 
Starch based 
(Polyanion/-cation) 
Poly(styrenefulfonic acid) 
(Polyanion) 
Alginates  
(Polyanion) 
Cellulose based 
(Polyanion/-cation) 
Poly(acrylic or methacrylic acid)  
(Polyanion) 
Hyaluronic acid 
 (Polyanion) 
Dextran based 
(Polyanion/-cation) 
Maleic acid/diallyamine 
copolymer  
(Polyampholyte) 
 
Shu and colleagues have studied the formation of chitosan-poly(l-aspartic acid)-
polyethylene glycol polyelectrolyte nanoparticles in bulk solution under mild conditions 
at different molar ratios of chitosan to poly(l-aspartic acid) (Shu et al., 2009). Chitosan 
solution was added dropwise in different molar ratios into poly(l-aspartic acid) solution 
under constant magnetic stirring during the synthesis of these nanoparticles. Chitosan 
contains several amino groups and is therefore a polycation whereas the polyanion 
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poly(l-aspartic acid) contains carboxyl groups. The electrostatic attraction between 
positively charged amino groups and negatively charged carboxyl groups was the 
driving force in the polyelectrolyte complex formation. Charge ratio of the anionic-to-
cationic species had an effect on the formation and properties of the complex, and also 
ionic strength of the medium affected the formation of the polyelectrolyte complex.  
Nanoparticles could only be formed up to a certain mass ratio after which the 
precipitation occurred due to negligible amount of stabilizing net charge on the surface 
of nanoparticles (Shu et al., 2009). Another interesting feature was the ζ-potential shift 
from negative to positive values when the molar ratio of chitosan in relation to poly(l-
aspartic acid) was increased. This is, of course, a direct consequence of a higher amount 
of positively charged amino groups in the nanoparticle complex. Low salt concentration 
favours the formation and growth of polyelectrolyte complex nanoparticles, whereas a 
higher salt concentration may drastically interfere with the electrostatic attraction 
between oppositely charged polymer chains by masking the oppositely charged groups 
thus reducing their interaction (Shu et al., 2009). Therefore the salt concentration of the 
reaction mixture has to be optimized. These experimental observations also apply to 
other polyelectrolyte complexes (Anal et al., 2008; Ye et al., 2006).  
Bovine serum albumin was used as a model protein and it was encapsulated into 
polyethylene modified chitosan-poly(l-aspartic acid)- nanoparticles with relatively high 
encapsulation efficiency values (60-90%) (Shu et al., 2009). The release of bovine 
serum albumin was studied in vitro in three pH values 1.2, 2.5 and 7.4 that simulate the 
pH of the stomach after a meal, the pH environment of a fasting stomach and the pH of 
the blood stream respectively. The release of bovine serum albumin was sustained in the 
pH of 2.5 whereas the release was fastest in the pH 7.4. Therefore, chitosan-poly(l-
aspartic acid)-polyethylene glycol nanoparticles were proposed for controlled peptide 
and protein drug delivery through the oral route. It is, of course, possible to obtain this 
kind of pH controlled release behaviour of encapsulated compounds from other 
polyelectrolyte complexes as well, because the pH affects the swelling behaviour of the 
polyelectrolyte complex. 
The preparation method of chitosan-poly(acrylic acid) (CH-pAA) nanoparticles closely 
resembles the synthesis performed in the experimental part of this work with casein and 
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poly(acrylic acid), and is therefore of great interest (Hu et al., 2002; unpublished 
observation Laaksonen, 2011). The synthesis of CH-pAA nanoparticles is basically a 
polyelectrolyte complex formation between negatively charged carboxyl groups of pAA 
and positively charged amino groups of CH (Hu et al., 2002). Hu and colleagues have 
studied the formation of hydrophilic biodegradable CH-pAA nanoparticles with two 
different synthesis methods in order to control the size, morphology and surface charge 
of CH-pAA nanoparticles. CH-pAA nanoparticles were prepared by template 
polymerization and dropping methods. In the former case CH-pAA nanoparticles were 
obtained by template polymerization of acrylic acid (AA) in CH solution, and in the 
latter case CH-pAA nanoparticles were prepared by adding solution of positively 
charged CH (pKa~6.5) dropwise to a solution of negatively charged pAA (M=100kDa, 
pKa~4.75) and vice versa.  
In the template polymerization CH template and AA monomers were homogenously 
dispersed prior to polymerization of AA, and the resultant positively charged CH-pAA 
nanoparticles had smaller size and PDI values than the ones that were prepared with the 
dropping method (Hu et al., 2002). Addition of CH solution to pAA solution resulted in 
negatively charged nanoparticles with a CH core and a CH-pAA shell membrane. The 
negative charge was attributed to the excess of pAA in the solution as pAA also 
adsorbed onto the surface of CH-pAA nanoparticles. In comparison, the addition of 
pAA solution to CH solution resulted in the formation of positively charged 
nanoparticles with a pAA core and a dense CH-pAA complex membrane. The dropwise 
addition of pAA or CH to the reaction mixture did not result in homogenous dispersion, 
but instead in instantaneous polyelectrolyte complex formation.  
Because the reaction mixture was not homogenous, the CH-pAA nanoparticles that 
were prepared with the dropping method had larger size and higher PDI values than the 
CH-pAA nanoparticles that were prepared with polymerization of AA monomers 
utilizing CH template (Hu et al., 2002). In general, it may be quite challenging to 
synthesize small nanoparticles with low PDI values in bulk solution by dropwise 
addition of polyelectrolytes to the reaction mixture. On the other hand, during small 
scale preliminary studies the simple dropping method can provide information about the 
morphology and optimal synthesis conditions for the formation of nanoparticles. 
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Therefore, the dropping method is a suitable and convenient method in the early phase 
of research and development of polyelectrolyte complex nanoparticulate drug carriers. 
CH-pAA nanoparticles could potentially be used as pH sensitive carriers for hydrophilic 
drugs, proteins and peptides (Hu et al., 2002). The release of a model compound silk 
peptide from CS-pAA nanoparticles varied as a function of pH, because the pH has an 
effect on the ionization of both amine groups of CH and carboxylic groups of pAA, and 
therefore the swelling of CH-pAA nanoparticles and consequent release of silk peptide 
depends on the pH of the release medium. To further study the ability of CH-PAA 
nanoparticles to perform as drug carriers the same research group has also synthesized 
hollow doxorubicin loaded nanoparticles (Hu et al., 2004; Hu et al., 2007). Crosslinking 
the CH shell layer with glutaraldehyde further stabilized the CH shell structure making 
it denser. Because crosslinking makes the CH shell more compact, it was possible to 
restrict the diffusion of encapsulated doxorubicin by crosslinking the CH shell (Hu et 
al., 2007). It is reasonable to assume that also other hydrophilic drugs could be 
encapsulated and released in controlled manner from this type of drug delivery vehicle. 
2.4.2 Layer-by-layer coating of a core template 
The layer-by-layer (LbL) technique includes consecutive adsorption of oppositely 
charged polyelectrolytes onto a surface, and it was originally developed for the 
preparation of multilayers onto a charged planar surface (Decher, 1997). Polyelectrolyte 
capsules are an application of the LbL technique, and can be prepared with LbL coating 
of a core template followed by the dissolution of the core template (Caruso et al., 1998; 
Donath et al., 1998).  The stepwise formation of polyelectrolyte capsules is described in 
Figure 3 (Donath et al., 1998). Interior of these capsules excludes the encapsulated 
material from direct contact with the surrounding and provides shelter. This feature is 
highly beneficial for the protection of sensitive cargo, such as therapeutic peptides, from 
degradation in vivo. 
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Figure 3. Stepwise formation of a polyelectrolyte capsule with a spherical core template 
(Donath et al., 1998). The initial steps (a-d) consist of consecutive adsorption of 
oppositely charged polyelectrolytes onto a core template, which results in multilayer 
polyelectrolyte shell formation. The core can be removed with a change in pH or 
solvent (e), which results in the formation of hollow polyelectrolyte capsules (f). 
Several materials such as carbonate particles, polystyrene latex, melamine 
formaldehyde, silica and biological cells have been exploited as sacrificial templates 
that are dissolved after the shell formation with suitable solvents (Moya et al., 2003; 
Pastoriza-Santos et al., 2001; Peyratout and Dähne, 2004; Sukhorukov et al., 1998; 
Sukhorukov et al., 2004; Volodkin et al., 2004). The size and shape of the spheres can 
be controlled to some extent as the template core has structural effects on the shell 
formation.  
For instance, Sukhorukov and colleagues have prepared completely biocompatible 
polyelectrolyte microcapsules with alginate and monodisperse calcium carbonate 
templates for encapsulation of proteins (Sukhorukov et al., 2004). They studied various 
synthetic polyelectrolyte pairs as well as biopolymer pairs and notices that there were 
stability issues, such as capsule aggregation and degradation during the core removal, 
when biopolymer pairs were used as shell material. This was attributed to the lower 
charge density of biopolymers when compared to synthetic materials. They used 
crosslinking for the shell reinforcement to improve the stability of the biopolymer shell 
structure.  
The permeability and porosity of polyelectrolyte capsule wall depends on the chemical 
composition and molecular weight of the shell components, and this should be taken 
21 
 
  
into account when a carrier is designed to accommodate for a specific cargo (Qiu et al., 
2001a; Qiu et al., 2001b). Permeation of ibuprofen microcrystals through various 
polyelectrolyte multilayer films has been studied in situ by UV-Vis spectroscopy, and 
both the shell thickness and cavities in the polyelectrolyte multilayers had an effect to 
the permeation rate of ibuprofen.  This example shows it is possible to obtain controlled 
release by controlling the thickness and porosity of the polyelectrolyte multilayer. It 
should also be possible to achieve controlled release of encapsulated compounds with 
colloidal carriers by varying the shell thickness of the carrier vehicle. 
Several polyelectrolyte capsules with stimuli responsive release of encapsulated cargo 
have been described (De Geest et al., 2007). These could be used in time and space 
controlled drug delivery. For example, Mauser and colleagues have prepared pH 
responsive polyelectrolyte microcapsules from weak polyelectrolytes poly(allylamine 
hydrochloride) and poly(methacrylic acid) assembled on a removable calcium carbonate 
templates  (Mauser et al., 2004). The microcapsules exhibited pH dependent swelling 
behaviour due to varying degree of ionization of the polyelectrolyte pair components in 
different pH values. Crosslinking was used to stabilize these microcapsules, but it also 
resulted in the loss of pH responsive swelling behaviour.  
Therefore, it can be concluded that generally crosslinking can be a beneficial tool in the 
shell stabilization of microcapsules or nanocapsules, but it can also result in the loss of 
designed functionality of the drug carrier system. Other widely studied stimuli 
responsive potential drug delivery systems include light responsive, magnetic field and 
glucose responsive polyelectrolyte capsules (De Geest et al., 2006; Lu et al., 2005; Radt 
et al., 2004). But it seems that the preparation methods for these carriers are very labour 
intensive and challenging to scale-up, and therefore their applicability as commercial 
scale drug carriers could be limited. 
2.4.3 Microfluidic synthesis  
The previous sections 2.4.1 and 2.4.2 have focused on describing the formation and 
applications of polyelectrolyte based nanoparticles. The syntheses have been executed 
in bulk solutions in the examples. However, the scale-up of the syntheses that are 
performed in bulk solutions could be very challenging if not impossible. Yet another 
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approach is to prepare nanoparticles with microfluidic synthesis platforms as it is 
possible to achieve a very low size distribution of nanoparticles with this approach, and 
this is of course desirable for pharmaceutical manufacturing (Hung and Lee, 2007). 
There are several microfluidics devices available and those devices could resolve the 
scale-up problems during the synthesis of polyelectrolyte complexes. 
For example, laminar flow microfluidics devices have been used in the preparation of 
polyelectrolyte microcapsules in mild reaction conditions (Shchukin et al., 2004). 
Microfluidics devises contain specific reactor microchannels where it is possible to 
control the reaction conditions during the polyelectrolyte complexation. This enables 
the control over the spatial delivery of two or more oppositely charged polyelectrolytes, 
and allows fast inter polyelectrolyte complex formation with high spatial precision. 
Also, the mild reaction conditions inside the reactor microchannels during the 
polyelectrolyte complex formation make microfluidics an ideal method for the 
complexation of proteins with other polyelectrolytes. In the future, microfluidic devices 
may be the answer for the industrial scale manufacturing of pharmaceutical 
polyelectrolyte complexes.  
3. CASEIN BASED FORMULATIONS AS CONTROLLED RELEASE DRUG 
DELIVERY SYSTEMS  
Protein based drug delivery systems hold great promise due to their remarkable 
biocompatibility, biodegrability, low toxicity and natural metabolism in physiological 
systems (Elzoghby et al., 2012b; Maham et al., 2009). Proteins are also generally 
recognised as safe (GRAS) raw materials with high nutritional value and abundant 
renewable sources.  These reasons combined with high drug loading capacity, due to 
multiple binding sites present in protein molecules, contribute to the superiority of 
proteins over synthetic polymers in drug delivery systems (Elzoghby et al., 2012b). The 
drug loading mechanisms into protein nanoparticles include for instance electrostatic 
attractions, hydrophobic interactions and covalent bonding.  
However, the batch to batch variation of protein materials, which are usually 
heterogeneous mixtures of different sizes and molecular weights, may cause problems 
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in the synthesis scale-up of protein nanoparticles for industrial applications (Elzoghby et 
al., 2012b). It may also be challenging to achieve controlled release properties with 
hydrophilic animal based proteins due to the rapid solubilisation of these proteins in 
aqueous environment. Chemical crosslinkers, such as glutaraldehyde and formaldehyde, 
can be used to stabilize and harden the protein nanoparticles, which prolongs the 
solubilisation process. But because chemical crosslinkers are usually toxic, the residual 
unreacted crosslinker molecules present inside the protein nanoparticles can cause 
toxicity during the in vivo degradation if not purified properly (Elzoghby et al., 2012b; 
Mattson, 1993). For this reason, a lot of research work has been focused on 
investigation of new safe crosslinkers, for the stabilization of protein nanoparticles, as 
alternatives to toxic chemical crosslinkers (Elzoghby et al., 2012a; Huppertz and de 
Kruif, 2008). 
Protein nanoparticles for drug delivery have been prepared from animal origin proteins 
such as gelatin, collagen, albumin, milk proteins, silk proteins and elastin (El Samaligy 
and Rohdewald, 1983; Gunasekaran et al., 2007; Herrero-Vanrell et al., 2005; Kratz, 
2008; Leo et al., 1997; Yan et al., 2009). Also plant proteins such as zein, gliadin, soy 
proteins and lectins have been used as materials for protein nanoparticles, because plant 
proteins reduce the risk of spreading animal protein related diseases (Ezpeleta et al., 
1996; Irache et al., 1995; Lai and Guo, 2011; Russell-Jones et al., 1999).  
Milk proteins are natural vehicles that are specialized in the delivery of nutrients and 
immune system components from mother to the neonates (Livney, 2010). These 
proteins are also an essential part of the daily diet in many parts of the world.  
Inexpensive price and many beneficial structural properties make milk proteins suitable 
vehicles for the delivery of various bioactive molecules such as drugs. Biocompatibility 
of milk proteins is usually excellent for oral delivery applications. Only a small fraction 
of the population, which varies between different countries, is allergic to certain milk 
proteins. Caseins, whey proteins and milk fat globule membrane proteins are the major 
milk proteins. However, quantitatively caseins are the main milk proteins as casein 
content in milk is 24-28 g/l, whereas milk contains whey proteins and milk fat globule 
membrane proteins only 5-7 g/l and 0.4 g/l respectively.  
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The major milk proteins caseins are good materials for conventional and controlled 
release drug delivery systems (Elzoghby et al., 2011; Neha et al., 2012). Caseins have 
many structural and physicochemical features that provide functionality in drug delivery 
systems. These properties include the ability to bind ions and small molecules, self-
assembly properties, excellent surface-activity and ability to stabilize emulsions as well 
as superb gelation and water binding capacities. A number of bioactive molecules have 
been associated to casein in order to modify the release behaviour and/or to improve the 
bioavailability of the associated molecules (Elzoghby et al., 2011). 
Casein as a film-forming agent together with oleic acid as a plasticizer produces a 
continuous coat with high tensile strength, which makes this combination a potential 
film coating for tablets (Abu Diak et al., 2007). Drug release rate from tablets with 
casein and oleic acid film coating can be modified with heat treatment after the film 
coating, because the temperature of the heat treatment affects the tensile strength of the 
film coating. The heat treatment induces intermolecular crosslinking between the amino 
and carboxyl groups in casein and requires high temperatures (100 °C) to occur (Lauber 
et al., 2000).  Without the heat treatment casein coatings are suitable for immediate 
release coatings, whereas post-coating heat treatment can be used to manufacture film 
coatings that control the drug release from tablets (Abu Diak et al., 2007). Casein can 
therefore be regarded as a potential film-forming agent for the coating of 
pharmaceutical dosage forms.  
Caseins can also be used as emulsion stabilizers due to their amphiphilic nature, which 
arises from blocks of polar and non-polar amino acid residues (Modler, 1985). Due to 
their open amphiphilic structures, the caseins can diffuse freely at interfaces and 
concentrate at the air-water or oil-water interfaces. This reduces the surface or 
interfacial tension and hence reduces the mechanical energy required to form a foam or 
emulsion and stabilize these systems. Caseins and other food proteins have been used 
successfully as nanoemulsion stabilizers due to their excellent surface activity and lower 
toxicity than traditional surfactants (He et al., 2011; Maher et al., 2011). Therefore, 
caseins could be used more widely in pharmaceutical nanoemulsions as surfactants, to 
stabilize the colloidal emulsions and enhance the delivery of poorly water-soluble drugs 
within nanoemulsions. Also, casein-based floating beads for controlled oral drug 
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delivery have been developed, by utilizing the bubble-forming and emulsifying 
properties of caseins, to increase the residence time of drugs in the stomach (Bulgarelli 
et al., 2000). 
Hydrogels that are based on natural or synthetic polymers are especially interesting 
materials for controlled drug release applications, because of their good 
biocompatibility with soft tissues, the ease of drug loading into the gel matrix and the 
high degree of control that can be achieved by selecting the physical and chemical 
properties of the polymer network (Chaturvedi et al., 2012; Park and Robinson, 1987; 
Song et al., 2009). Caseins have a number of favourable characteristics that make 
caseins suitable materials for hydrogel-based drug delivery systems e.g. high 
hydrophilicity, good biocompatibility in oral delivery applications, lack of toxicity and 
availability of reactive sites for chemical modification (Elzoghby et al., 2011). Genipin 
crosslinked pH-responsive casein hydrogels have been prepared for the controlled 
release of bovine serum albumin (Song et al., 2009). Genipin crosslinked casein 
hydrogels could potentially be used as carriers for other protein drugs as well in the pH- 
triggered targeted drug delivery to specific areas in the gastrointestinal tract. 
Casein microparticles have been developed as carriers for controlled release of various 
cytotoxic drugs (Chen et al., 1987; Jayakrishnan et al., 1994). Crosslinked casein 
microspheres have been successfully used as parenteral biodegradable carriers in in vivo 
animal studies for sustained delivery of drugs via intraperitoneal, intramuscular, direct 
intratumoral injection or intra-arterially for embolization in solid tumor deposits 
(Bayomi and El-Sayed, 1994; Knepp et al., 1993; Puthli and Vavia, 2008; Willmott et 
al., 1989). In recent years, casein based nanoformulations have been prepared to deliver 
both nutraceuticals and synthetic drugs (Elzoghby et al., 2011; Neha et al., 2012). Drug 
delivery systems based on casein have been prepared for example via polyelectrolyte 
ionic complexation, crosslinking and heat gelation. Other mechanisms for nanoparticle 
formation have been based on caseins tendency to self-assemble and form micelles. 
Casein based nanoformulations are promising materials for controlled drug delivery 
applications. In the following sections 3.1-3.3 the physicochemical properties and 
allergenicity of caseins as well as some preparation methods for the nanoformulations 
will be described more closely.  
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3.1 Physicochemical properties of caseins 
The caseins have high proline content, distinctive hydrophobic and hydrophilic domains 
and open flexible rheomorphic conformation (Holt and Sawyer, 1993; Swaisgood, 
1993). Caseins, as rheomorphic proteins, can assume any one of several energetically 
favourable conformations in solution and adapt to their environment by altering their 
conformation, and therefore they are more flexible than globular proteins (Horne, 
2002). The casein protein family consists of four amphiphilic phosphoproteins αs1-, αs2-, 
β- and κ-casein, each of which has its own amino acid composition, genetic variations 
and functional properties (Holt and Sawyer, 1993).  
Table 3 summarizes some properties of different casein fractions in bovine milk 
(Modler, 1985). The different casein monomers have slightly different properties. 
Isoelectric points of different casein forms are between 4.1 and 5.8, and molecular 
weights range between 19 and 25 kDa. The high proline content in caseins, especially in 
β-casein, results in the open structure which is easily accessible to gastric proteases. 
Also, the extremely good heat stability of caseins is contributed to their open structure 
and lack of defined tertiary structure. For example, it is possible to heat sodium 
caseinate at 140 °C for a short period of time without causing significant physical 
changes (Guo et al., 1989).  
Table 3. Properties of different casein fractions in bovine milk (modified from Modler, 
1985). The different casein fractions have slightly different molecular weights, 
isoelectric points and amino acid compositions.  
Protein Total 
casein 
(%) 
Molecular 
weight (kDa) 
Isoelectric 
point 
Phospahate 
residues/ 
molecule 
Proline 
residues/ 
molecule 
αs1-Casein 44 - 46 22.068 – 
23.724 
4.2 – 4.76 8 - 10 17 
αs2-Casein 12 25,230 Not 
determined 
10 - 13 10 
β-Casein 32 - 35 23.944 – 
24.092 
4.6 – 5.1 4 - 5 35 
κ-Casein 2 - 4 19.007 – 
19.039 
4.1 – 5.8 1 20 
 
Caseins, like many other proteins, have minimum solubility near their isoelectric points 
and at the isoelectric point (pI) they precipitate (Bingham, 1971). The isoelectric point 
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is the pH value at which a certain molecule carriers no net electrical charge. 
Temperature and pH affect the solubility of β-casein and κ-casein near their isoelectric 
points. When the temperature is decreased from 25 °C to 5 °C, it enhances the solubility 
of β-casein near the pI significantly, whereas for κ-casein only a slight solubility 
increase can be observed. The αs1-casein is considerably less soluble than β-casein and 
κ-casein, and the effect of temperature on the solubility near the isoelectric point is 
minimal. The β-casein is more hydrophobic than αs1- and κ-casein and with the largest 
average hydrophobicity temperature has the largest effect on solubility.  
Figure 4 shows the solubility of whole casein in water at different pH values (Strange et 
al., 1994). The solubility of whole casein in water is of course pH dependent and 
minimal between the pH range of 4.2 to 4.8, which corresponds to the pI of whole 
casein. Caseins may be used in pharmaceutical formulations in the form of caseins or 
caseinates (Konstance and Strange, 1991; Modler, 1985). Caseins have a low aqueous 
solubility whereas e.g. sodium caseinate is freely soluble except near its isoelectric 
point. 
 
Figure 4. Solubility curves of whole casein in water as a function of pH (Strange et al., 
1994). The solubility of whole casein is pH dependent, and at the isoelectric point the 
caseins precipitate. The different symbols (●, ○, Δ) represent three individual 
repetitions. 
Caseins have a tendency to self-assemble into casein micelles in aqueous solutions due 
to their amphiphilic nature (Qi, 2007). Casein micelles are composed of submicelles 
that are held together by hydrophobic interactions and calcium-phosphate linkages. The 
αs1, αs2- and β-caseins have phosphorylation centres capable of binding the colloidal 
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calcium phosphate, whereas the hydrophilic charged κ-casein does not bind calcium 
phosphate but stabilizes the casein micelles through electrostatic and steric repulsion at 
the micelle surface. In other words, casein micelles have a hydrophobic interior 
surrounded by a layer of hydrophilic κ-casein. Casein micelles are an example of 
natural nanovehicles specialized in nutrient delivery, as the diameter of these spherical 
colloidal particles ranges between 50-500 nm (Livney, 2010). Casein micelles are well 
adapted to their tasks of concentrating, stabilizing and delivering calcium, phosphate 
and protein from mammalian mothers to neonates. Figure 5a and 5b contain graphical 
presentations of casein micelles and the amphiphilic structures of different casein 
monomers.  
Figure 5. Structure of casein micelles and different amphiphilic casein monomers (Qi, 
2007): a) Casein micelle where different casein monomers are presented as thread-like 
and calcium-phosphate nanoclusters are presented as dots; b) Casein monomers, 
calcium-phosphate and a dual bonding model of casein micelles. Hydrophobic regions 
of casein monomers are indicated by rectangular bars and hydrophilic regions as 
threads. 
Amphiphilic individual caseins also have the ability to self-assemble in pure solutions 
and e.g. micellization of bovine β-casein, without calcium phosphate, has been studied 
extensively (Moitzi et al., 2008; Portnaya et al., 2006; Portnaya et al., 2008). The β-
casein micelles have approximately 13 nm diameter, which makes them considerably 
smaller than the whole casein micelles (Portnaya et al., 2006). The critical micelle 
concentration (i.e. the concentration above which micelles form) of β-casein ranges 
between 0.5 and 2 mg/ml, and it depends strongly on temperature, solvent composition, 
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pH and ionic strength of the medium. For comparison, the critical micelle concentration 
of whole casein micelles is 1 mg/ml (Esmaili et al., 2011). Hydrophobic interactions are 
the driving force for micellization of β-casein, while steric constraints and electrostatic 
repulsions oppose the self-assembly process (Moitzi et al., 2008). The hydrophobic core 
of β-casein micelles has been recently harnessed for the delivery of hydrophobic 
compounds and drug molecules (see section 3.3.1 for examples). 
3.2 Allergenicity and digestibility of caseins 
The allergenicity of caseins could limit the use of caseins as pharmaceutical excipients 
in formulations, because caseins have been recognised as the major allergenic 
component of cow’s milk (Docena et al., 1996; Shek et al., 2005). Cow’s milk is an 
ideal casein source due to the abundance of available material.  Casein allergy induces 
an immune response to casein in the human body, and the allergic fraction of population 
has casein-specific IgE antibodies in their blood serum that promote the immune 
response (Docena et al., 1996; Shek et al., 2005). However, the cow’s milk allergy is 
still quite rare, and therefore casein based pharmaceutical formulations could be suitable 
for the majority of population (Lam et al., 2008; Vila et al., 2008).  
Caseins can be easily crosslinked successfully with a variety of different crosslinkers 
due to the open structure of caseins (Schorsch et al., 2000; Stanic et al., 2010). 
Crosslinking has been used in food technology applications to stabilize and reduce the 
allergenicity of caseins. Stanic and colleagues have reduced the allergenicity of bovine 
β-casein by enzymatic crosslinking with four different crosslinkers that have varying 
abilities and mechanisms to crosslink proteins (Stanic et al., 2010). High crosslinking 
degree of β-casein was obtained with both Trichodermareesei tyrosinase and 
transglutaminase. When Agaricus bisporus tyrosinase and Trameteshirsuta laccase were 
used as crosslinkers, some of the monomeric β-casein remained uncrosslinked. 
Nevertheless, in this study Trameteshirsuta laccase and Agaricus bisporus tyrosinase 
had the highest potential in reducing the allergenicity and IgE binding of the β-casein in 
vitro. It was suggested that the reason for reduced allergenicity of crosslinked β-casein 
may be attributed to changes in the protein structure at the region of the epitope (part of 
an antigen that is recognized by the immune system). 
30 
 
  
Glutaraldehyde is one of the most effective and widely used protein crosslinking 
reagents available (Jayakrishnan and Jameela, 1996; Migneault et al., 2004). It reacts 
rapidly with amine groups and is efficient in generating thermally and chemically stable 
crosslinks. The high reactivity of glutaraldehyde with proteins is based on many 
different possible reaction mechanisms due to the several reactive residues in proteins 
and to several possible molecular forms of glutaraldehyde present in aqueous solution 
(Migneault et al., 2004). In dilute solutions, and in the pH range of 3.0 to 8.0, 
glutaraldehyde has been found to exist almost entirely in monomeric dialdehyde form. 
Habeeb and Hiramoto have studied the reaction of proteins with glutaraldehyde 
(Habeeb and Hiramoto, 1968). They have reported that the major reaction of 
glutaraldehyde occurs with the free amino groups of proteins within 30 minutes to two 
hours, but also a partial reaction with e.g. phenolic rings, imidazole rings and sulfhydryl 
groups is possible. The crosslinking reduced the allergenicity of proteins also in this 
study. Reduced allergenicity was attributed to damaged or masked epitopes in protein 
structures due to the chemical crosslinking. Therefore, glutaraldehyde has probably the 
ability to reduce the allergenicity of caseins as well. 
Digestibility of proteins is another factor that can be controlled by crosslinking 
(Monogioudi et al., 2011; Stanic et al., 2010). Crosslinking delayed the digestion of β-
casein by pepsin in simulated gastric fluids in vitro when compared to uncrosslinked 
native β-casein. It has also been shown that intermediately crosslinked β-casein is more 
easily digested by pepsin than the fully crosslinked β-casein materials (Monogioudi et 
al., 2011). Higher resistance against pepsin digestion in the gastrointestinal tract can be 
achieved with the more compact protein structure that crosslinked proteins possess in 
comparison to the native protein structures. Reduced digestibility of crosslinked protein 
material may also be attributed to the chemical nature of the actual crosslinks as 
different crosslinkers may form bonds with varying mechanisms and stabilities. 
Results of these studies clearly show that allergenicity and digestibility of caseins can 
be reduced by crosslinking, but different crosslinkers have varying abilities to reduce 
these properties. When selecting a suitable crosslinker to a pharmaceutical protein based 
nanovehicle formulation the toxicity, ability to form stable crosslinks and ability to 
reduce allergenicity of protein vehicle should all be considered. It may also be possible 
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to affect the rate of digestibility by choosing the correct degree of crosslinking. Reduced 
digestibility by crosslinking may be beneficial in prolonging the integrity of 
nanocarriers, which will result in longer transit time in gastrointestinal tract. Longer 
transit time in turn will increase the probability of nanocarriers reaching their target 
destination. By choosing the right kind of crosslinker the cargo of nanocarriers may be 
released in the stomach or intestine by enzymatic digestion of crosslinked proteins by 
proteases making it possible to target either stomach or intestine. It may be possible to 
prolong drug release from nanocarriers by crosslinking the surface, which should slow 
the digestion by proteases. 
3.3 Casein nanocarriers 
3.3.1 Casein nanosized micelles  
Casein micelles can be thought of as natural nanocapsules for the delivery and 
encapsulation of hydrophobic nutraceuticals and bioactive compounds (Semo et al., 
2007). Lipophilic vitamin D2 has been nanoencapsulated into the hydrophobic core of 
casein micelles. The casein micelles have the ability to stabilize vitamin D2 in aqueous 
environment, and protect vitamin D2 against heat and UV-light induced degradation 
(Haham et al., 2012; Semo et al., 2007). The high bioavailability of vitamin D2 that was 
nanoencapsulated into β-casein micelles was confirmed with a clinical trial with healthy 
volunteers, which further confirms that β-casein micelles could be used to promote the 
stability and bioavailability of other hydrophobic compounds as well (Haham et al., 
2012).  
Another hydrophobic nutraceutical omega-3 fatty acid docosahexaenoic acid (DHA) has 
also been encapsulated into casein micelles and nanoparticles (Zimet et al., 2011). DHA 
loaded casein micelles as well as nanoparticles displayed remarkable protection against 
oxidation of DHA. Caseins ability to protect DHA against oxidation may be explained 
by steric shielding against penetration of oxidizing agents, and by anti-oxidative and 
free radical quenching capabilities of caseins. The ability of casein micelles to protect 
against oxidation of encapsulated compounds as well as the strong UV-light absorption 
properties of caseins could serve as a shield against degradation of sensitive bioactive 
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compounds. Casein based nanocarriers could be excellent in the conservation of 
sensitive bioactive compounds throughout the shelf-life of pharmaceutical products.  
A few studies have been focused on the entrapment of hydrophobic anticancer drugs 
and compounds into casein micelles (Esmaili et al., 2011; Sahu et al., 2008; Shapira et 
al., 2010a). Curcumin, which is a natural polyphenol with potent anticancer and 
antioxidant properties, has been entrapped within the hydrophobic regions inside whole 
casein micelles (Esmaili et al., 2011; Sahu et al., 2008). The hydrophobic curcumin 
molecules interact with the casein micelles by binding to the low-polarity regions of 
casein micelles. The major problem, with the use of curcumin as an anticancer drug, is 
the extremely low aqueous solubility of curcumin, which in turn results in poor 
bioavailability and clinical efficacy. However, the aqueous solubility of curcumin can 
be increased significantly (approximately 2500 fold) by encapsulation of curcumin into 
β-casein micelles (Esmaili et al., 2011). The β-casein micelle nanocarriers also 
increased the anti-oxidative properties of curcumin as well as the cytotoxicity of 
curcumin against human leukemia cell line K-562. 
Shapira and colleagues have studied the use of β-casein-based micellar nanoparticles in 
the entrapment of hydrophobic anticancer drugs mitoxantrone, vinblastine, irinotecan, 
paclitaxel and docetaxel (Shapira et al., 2010a; Shapira et al., 2010b; Shapira et al., 
2010c). The loading of mitoxantrone into the β-casein micelles was executed in pH 7, 
where mitoxantrone has poor colloidal stability due to only a slight positive charge 
(Shapira et al., 2010a). Whereas, β-casein micelles carry a high negative ζ-potential 
value of -42 mV in pH 7, and exhibit excellent colloidal stability. The high negative ζ-
potential value of casein micelles remained during the loading of mitoxantrone up to the 
molar ratio of 4:1 of mitoxantrone to casein. As the mitoxantrone molar ratio was 
increased in relation to casein, the net ζ-potential values of the drug loaded casein 
micelles decreased, and reached zero above 8:1 molar ratios of mitoxantrone to casein. 
Consequently, overloading of mitoxantrone into β-casein micelles resulted in the 
destabilization and aggregation of the whole drug delivery system. However, with an 
optimal molar ratio of mitoxantrone to casein, this nanoscale β-casein drug delivery 
system improved the thermodynamic stability of hydrophobic mitoxantrone in aqueous 
solution significantly.  
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It was suggested that mitoxantrone first binds to the hydrophobic core of β-casein 
micelles mainly by hydrophobic interactions (Shapira et al., 2010a). And after the 
hydrophobic core is loaded, mitoxantrone starts to bind electrostatically to the 
negatively charged surface of β-casein nanoparticles. But also a spontaneous co-
assembly of mitoxantrone with β-casein, below and above the critical micelle 
concentration of β-casein, could have been the underlying mechanism of mitoxantrone 
loading into β-casein micelles (Shapira et al., 2010b).  
These theories were further studied with vinblastine, irinotecan, paclitaxel and 
docetaxel (Shapira et al., 2010c). Chemical structures of these compounds and 
mitoxantrone are presented in Figure 6. The main properties governing the co-assembly 
of these drugs with β-casein were hydrophobicity and charge at pH 7 (Shapira et al., 
2010c). Vinblastine and irinotecan are both hydrophobic and positively charged at pH 7 
similarly to mitoxantrone, whereas docetaxel and paclitaxel are hydrophobic but 
uncharged at pH 7. It was concluded that the initial association of these drugs with β-
casein was controlled by hydrophobic interactions, but electrostatic interactions were 
also significant at higher drug concentrations. 
 
Figure 6. Chemical structures of chemotherapeutic drugs (A) vinblastine (B) irinotecan 
(C) mitoxantrone (D) paclitaxel and (E) docetaxel (Shapira et al., 2010c). 
The β-casein micelles have been promoted as potential target-activated oral drug 
delivery vehicles for hydrophobic chemotherapeutics in the treatment of gastric 
carcinoma (Shapira et al., 2010a; Shapira et al., 2010b). The possible drug targeting to 
stomach tumours was suggested as β-casein nanoparticles are expected to be easily 
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digested in the stomach and to release their drug cargo there. It was also proposed that 
complementary nano-coatings made of other biopolymers could enable a programmed 
degradation pattern and release of antitumor drug cargo at the desired site in the 
gastrointestinal tract (Shapira et al., 2010c). The entrapment of drug combinations 
within the β-casein nanoparticles could significantly increase the efficacy of drug 
therapy in the treatment of gastrointestinal cancers. 
The cytotoxicity of paclitaxel-loaded β-casein nanoparticles has been evaluated with 
human gastric carcinoma cell line (Shapira et al., 2012). Paclitaxel retained its cytotoxic 
potential during encapsulation into β-casein nanoparticles, and also during simulated in 
vitro gastric digestion with pepsin. Maximal amount of paclitaxel was released within 
20 minutes from β-casein nanoparticles during the in vitro digestion studies at pH 2, 
which in turn should correlate with site specific release of paclitaxel in the stomach in 
vivo. The intact paclitaxel loaded β-casein nanoparticles did not show cytotoxicity, and 
therefore it was suggested that β-casein nanoparticles can protect the upper GI tract 
(mouth and esophagus) from paclitaxel during ingestion. The results from the studies 
conducted by Shapira and colleagues seem promising, because suitable drug carriers for 
the oral delivery of chemotherapeutic drugs that would release their cargo at the target 
site and otherwise protect the healthy tissues and cells are needed. Target-activated drug 
release in the gastrointestinal tract could also increase the therapeutic efficacy of 
encapsulated drugs. And if the therapeutic efficacy can be gained with a smaller drug 
dose, then the side-effects of highly toxic drugs could perhaps be reduced. 
3.3.2 Crosslinking and gelation methods 
In general, nanogel (1-1000nm) particles are crosslinked gel particles capable of 
delivering a wide variety of drugs to various parts of body for a sustained period (Oh et 
al., 2008). Nanogels can be termed as hydrogels if they are composed of water soluble 
and swellable polymer chains. Caseins have excellent gelation properties (Livney, 
2010). Acid gelation of caseins is based on isoelectric precipitation, in other words 
caseins precipitate near their isoelectric points. Gelation can also be achieved by 
proteolytic cleavage (rennet induced gelation) of κ-caseins hydrophilic “hairy layer” 
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which results in micelle aggregation. These are both commonly used gelation methods 
in food technology applications.  
Nano- and microscale food protein hydrogels are potential candidates for controlled 
drug delivery as the small size of these systems enables the response to the 
environmental stimulation immediately (Pan et al., 2007). The pH responsive properties 
of hydrogels can offer reversible sites to drug binding and release. And the network 
structure and low density of hydrogels can offer multiple binding sites and space to 
loaded drugs. Furthermore, crosslinking can be used to suppress the dissociation of self-
assembled structures (van Nostrum, 2011). For example, crosslinking of whole casein 
micelles, with the enzyme transglutaminase, results in the formation of stable nanogel 
particles that consist of a covalently linked casein network (Huppertz and de Kruif, 
2008). Transglutaminase induced crosslinking of casein micelles formed intra-micellar 
bonds, but the substructure of crosslinked casein micelles remained similar to that of 
native casein micelles. In addition, the intra-micellar crosslinking increased the stability 
of casein micelles.  
Another example is the self-assembly of β-casein and lysozyme (one of the main 
proteins in hen egg), which results in the formation of polyelectrolyte complex micelles 
(Pan et al., 2007). Lysozyme and β-casein are both natural polyelectrolytes with 
isoelectric points of approximately 5.0 for β-casein and 10.7 for lysozyme. The micelles 
were heated, which caused the gelation of lysozyme and the entrapment of β-casein in 
the gel, producing narrowly dispersed spherical nanoparticles. The molar ratio of β-
casein to lysozyme, as well as the pH of the heat treatment, affected the size of 
nanoparticles, because these factors have an effect on the self-assembly of these two 
proteins. The synthesis of β-casein-lysozyme nanoparticles was essentially a 
combination of polyelectrolyte complex formation and heat induced gelation. These 
nanoparticles exhibited pH dependent hydrophobicity, which may be useful in the 
encapsulation and release of relatively hydrophobic compounds. 
Genipin crosslinked casein nanoparticles have been prepared by spray-drying (Elzoghby 
et al., 2012a). Genipin is a natural crosslinking reagent that is approximately 10 000 
times less toxic than glutaraldehyde (Sung et al., 1999). Due to low toxicity of genipin 
its use in pharmaceutical formulations could provide an alternative to the more toxic 
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chemical crosslinkers. A hydrophilic drug alfuzosin, which is used in the treatment of 
benign prostatic hypertrophy, was encapsulated into genipin crosslinked casein 
nanoparticles during the spray-drying process (Elzoghby et al., 2012a). The in vitro 
drug release of alfuzosin could be controlled by varying the degree and time of genipin 
crosslinking. This example demonstrates that it is possible to affect the drug release 
rate, of encapsulated compounds, from protein nanoparticles by varying the crosslinking 
degree.  
Another interesting observation of casein and the spray-drying process was caseins 
ability to perform as a stabilizing agent during the drying process, which obviated the 
need of drying adjuvants (Elzoghby et al., 2012a). This feature has also been observed 
during freeze-drying of celecoxib loaded casein micelles as this formulation was 
successfully lyophilized without any cryoprotectants (Bachar et al., 2012). Therefore, 
casein itself, as a component of formulation, can be used to ensure fully reversible 
reconstitution of the drug loaded carrier structures upon rehydration. This is extremely 
beneficial feature as it could ensure the functionality of powdered pharmaceutical 
formulations that have better shelf-lives than the liquid dosage forms. The need of 
stabilizers in casein-based dried powdered nanoformulations could be minimal or non-
existent, which in turn may lead to a higher drug loading efficacy of pharmaceutical 
nanosized drug carriers (Bachar et al., 2012). This could enhance the efficacy of the 
carrier system to perform as a drug reservoir. 
3.3.3 Casein-poly(acrylic acid) polyelectrolyte complex nanoparticles 
The structural features of casein enable it to form complexes with multivalent cationic 
as well as anionic macromolecules (Anal et al., 2008; Ye et al., 2006). The interactions 
can be either attractive or repulsive. Attractive interactions, which almost always arise 
from electrostatic interactions between two oppositely charged polymers/biopolymers, 
induce inter-polymer complexes as previously described in the section 2.4. The pH and 
ionic strength are important factors that influence the formation of these complexes, 
because both of these factors affect the number of charges present on the backbone of 
polymers/biopolymers, and therefore influence the intensity of electrostatic interactions. 
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Liu and colleagues have prepared cell-penetrating biocompatible hollow casein spheres 
in aqueous solution based on the molecular self-assembly of casein in the absence of 
surfactant, organic solvent, template core or emulsion phase (Liu et al., 2010). The 
hollow casein spheres were prepared by polymerizing acrylic acid monomers in the 
presence of caseins and propionic acid, followed by the crosslinking of caseins, and 
removal of the poly(acrylic acid). Figure 7 shows the proposed formation mechanism of 
hollow full casein nanospheres.  
 
Figure 7. The synthesis of hollow casein spheres in aqueous solution (Liu et al., 2010). 
The initial synthesis step includes the polymerization of acrylic acid monomers in the 
presence of caseins. The shell formation is caused by adsorption of positively charged 
casein micelles onto the surface of negatively charged colloidal polyelectrolyte complex 
composed of casein monomers and poly(acrylic acid). The casein component on the 
shell is then crosslinked and hollow full casein nanospheres are obtained by raising the 
pH to 7, which causes the removal of poly(acrylic acid). 
40 nm sized casein micelles, highly hydrophilic κ-casein monomers and αs1, αs2-, β-
casein monomers, acrylic acid monomers and propionic acid were all present in the 
synthesis solution before the polymerization of acrylic acid (Liu et al., 2010). The 
propionic acid was used to increase the solubility of caseins. When the acrylic acid was 
polymerized in the synthesis solution, the generated poly(acrylic acid) polymers 
interacted first with the positively charged free casein monomers. This resulted in the 
formation of surface-negatively charged colloidal casein-poly(acrylic acid) 
polyelectrolyte complexes. After that the positively charged casein micelles adsorbed 
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onto the colloidal polyelectrolyte complex surface, which initiated the formation of the 
shell structure. The casein component of the nanospheres was fixed by crosslinking the 
caseins with glutaraldehyde, which improved the stability of the spheres in simulated 
physiological environment, and enabled the casein spheres to stay intact while 
poly(acrylic acid)  was removed by dialyzing against water at pH 7-8. 
Poly(acrylic acid) can be removed from the core since the interaction between caseins 
and poly(acrylic acid) is non-covalent, whereas glutaraldehyde forms covalent bonds 
with casein (Liu et al., 2010; Migneault et al., 2004). Circular and hollow morphology 
of the casein spheres was confirmed with electron microscopy (Liu et al., 2010). Mean 
hydrodynamic diameter in aqueous solution at pH 3 was 360 nm and 350 nm before and 
after the crosslinking respectively. Also, hydrodynamic diameters of about 379 nm at 
pH 3.2 and 500 nm at pH 7.4 were observed for the casein spheres (Liu et al., 2011). 
The ζ-potential values of casein spheres were 20 mV at pH 3.2 and -33mV at pH 7.4. 
The pH-dependent ζ-potential variation was caused by the acid-base chemistry 
associated with amino and carboxyl groups in casein.  
An antitumor agent cisplatin was loaded into the casein spheres via the complex 
interaction between the positively charged platinum of cisplatin and negatively charged 
carboxyl groups of the casein spheres (Liu et al., 2010). In vitro drug release profile of 
cisplatin was continuous for 168 hours after the initial burst release effect.  It was also 
described that casein spheres and the single components αs1-, αs2-, β- and κ-casein all 
have the ability to penetrate cell membranes at 4°C and 37°C without inducing cell 
damage or cytotoxicity (Liu et al., 2011). It has been also reported in another study that 
proline rich peptides have cell membrane penetrating abilities, and caseins themselves 
have high proline content (Sadler et al., 2002; Swaisgood, 1993).  
Caseins and casein spheres can directly deliver cargoes into the cytoplasm of cells 
making them potential nanoscale cell-penetrating and protein-based drug carriers (Liu et 
al., 2011). Development of nanosized drug carriers that can penetrate the cells 
themselves and avoid lysosomal degradation is highly desirable, because it would 
enable effective targeted drug delivery and drastically improve the therapeutic efficacy 
of encapsulated compounds. Caseins and casein nanospheres hold significant promise in 
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the development of novel drug and gene delivery systems with superior 
biocompatibility in the future. 
D.Sc. Timo Laaksonen has developed a polymer-templated synthesis for the preparation 
of casein-poly(acrylic acid) (CS-pAA) polyelectrolyte complex nanoparticles in 2011 
(unpublished observation Laaksonen, 2011). Polymer templated synthesis of CS-pAA 
nanoparticles is driven by the electrostatic attractive forces between oppositely charged 
macromolecules. The positively charged CS forms complexes with the negatively 
charged polyanion pAA and condensates onto the surface of pAA in aqueous solution at 
pH values where these macromolecules have opposite charges (Figure 8). Crosslinking 
of the CS shell of these nanoparticles with glutaraldehyde (GA) makes the shell more 
dense and rigid, which enables the removal of pAA template by a change in the pH 
without destroying the particles. Rise in the pH of the medium to 7 breaks the 
complexation, and results in the removal of pAA core. Transmission electron 
microscopy (TEM) imaging was used to confirm the core shell structure of CS-pAA 
nanoparticles and the hollow interior of these nanoparticles after the pAA core removal. 
 
Figure 8. Polymer templated synthesis of casein-poly(acrylic acid) (CS-pAA) 
nanoparticles (unpublished observation Laaksonen, 2011). Positively charged CS forms 
complexes and condensates onto the pAA template, which leads to the formation of CS-
pAA nanoparticles. Crosslinking of the CS shell leads to a more compact shell structure, 
which stays intact while the pAA core is removed by a change in the pH value of the 
aqueous medium. TEM imaging confirmed the core shell structure of CS-pAA 
nanoparticles and the hollow interior after the pAA core removal. 
The pAA has pH-dependent swelling properties, because at low pH values (where the 
carboxyl groups are protonated) it has a more compact globule conformation (Molnar et 
al., 2009). Whereas, at higher pH values pAA has a more extended coil conformation, 
due to the charge repulsion between deprotonated carboxyl groups. The removal of 
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pAA from the core of CS shell crosslinked CS-pAA nanoparticles in the pH values 
above its pKa value of approximately 4.9 is based on the globule-to-coil transformation 
of pAA. Also when the pH is above 4.9, the complexation breaks which results in the 
pAA core removal (unpublished observation Laaksonen, 2011). 
The complexation between CS and pAA is pH sensitive, and opposite charges of pAA 
and CS are prerequisites for the electrostatically driven complex formation (unpublished 
observation Laaksonen, 2011). Electrostatic complexation between CS and pAA is not 
possible at the pI of these molecules, because pI is the pH value at which molecules or 
surfaces carry no net electrical charge. The complexation is possible between pH values 
of 3.3 to 4.9, which are also the pIs of pAA and CS respectively (Figure 9). The pH-
dependent ζ-potential values of pAA and CS arise from the degree of ionization of 
functional groups. As caseins are polyampholytes by their nature, the ζ-potential values 
shift from positive to negative after the pI of caseins (Holt and Sawyer, 1993; Modler, 
1985). The pH 4 of aqueous medium was observed to be the most suitable for the 
synthesis of CS-pAA nanoparticles, as CS has a positive ζ-potential value of 25 mV at 
pH 4, whereas pAA has a negative ζ-potential value of -20 mV, which should ensure 
effective complexation (unpublished observation Laaksonen, 2011).  
 
Figure 9. Surface ζ-potential values of casein and poly(acrylic acid) in aqueous medium 
as a function of pH (unpublished observation Laaksonen, 2011). Complex formation 
driven by the electrostatic attraction is possible at pH values where casein and 
poly(acrylic acid) are oppositely charged. The pH 4 seems to be the most suitable pH 
value for the complexation due to high opposite charges of casein and poly(acrylic 
acid). 
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Particle synthesis at various pH values in 1:5 mass ratio of CS to pAA resulted in 
complex formation only between pH values of 3 to 5 (unpublished observation 
Laaksonen, 2011). The formed particles had negative ζ-potential values up to -30 mV, 
which stabilized the colloidal particles effectively. Size of CS-pAA nanoparticles that 
were formed between pH values of 3 to 5 also changed with respect to pH. The smallest 
particles with approximately 100 nm diameters were formed in pH 4, which further 
confirmed that pH 4 was optimal for the synthesis.  
The small size of particles that were formed at pH 4 was most likely caused by the 
effective complex formation between CS and pAA as opposed to other pH values where 
the complex formation was not as effective and the particle sizes were larger 
(unpublished observation Laaksonen, 2011). Negative ζ-potential values of CS-pAA 
nanoparticles were caused by the negative charge of pAA template at pH values above 
3.3, which resulted in the negative net charge of the particles. When the thickness of the 
CS shell is increased, it should mask the negative charge of pAA template. This should 
result in lower negative ζ-potential values for these particles, up to the CS to pAA ratio 
that leads to aggregation of particles due to neutral surface charge, caused by the 
complete masking of the pAA template.  
The effect of template size on particle size and ζ-potential values was tested with 15 
kDa and 100 kDa pAA templates in the syntheses performed at pH 4 (unpublished 
observation Laaksonen, 2011). With 15 kDa template the particle size increased as the 
mass ratio of CS to pAA was increased, which indicated coating of the particles. 
However, the 100 kDa pAA template was more stable during the synthesis yielding 
smaller particles, and enabling three times larger CS amounts to be used during the 
synthesis without particle aggregation. With the 15 kDa template particle aggregation 
occurred already at CS to pAA mass ratio of 0.35:1, whereas with the 100 kDa template 
the particle aggregation did not occur even at 1.4:1 mass ratio. 
Table 4 contains results of dynamic light scattering characterization of size and PDI 
values of CS-pAA nanoparticles that were prepared with different pAA molecular 
weight templates and GA mass ratios to CS (unpublished observation Laaksonen, 
2011). Nanoparticles that were prepared with the 15kDa pAA templates had low PDI 
values in the complex form, but in the hollow form the PDI values were high indicating 
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polydispersity. Whereas, nanoparticles that were prepared with the 100kDa template 
and 1:1 mass ratio of glutaraldehyde to casein were the most stable ones based on the 
size and PDI values of complex and hollow nanoparticles. Zambaux and colleagues 
have studied the influence of polymer molecular weight on the size and polydispersity 
of nanoparticles (Zambaux et al., 1998). They also reported that higher polymer weight 
results in the formation of smaller and less polydispersed nanoparticles.  
Table 4. Dynamic light scattering characterization of size and PDI of casein- 
poly(acrylic acid) nanoparticles synthesized with different pAA molecular weight 
templates and glutaraldehyde mass ratios to casein (unpublished observation 
Laaksonen, 2011). Nanoparticles that were prepared with 100kDa template and 1:1 
mass ratio of glutaraldehyde to casein were the most stable ones based on the size and 
PDI values of complex and hollow nanoparticles. 
pAA MW GA : 
Casein 
Complex 
size (nm) 
Complex 
PDI 
Hollow 
size (nm) 
Hollow  
PDI 
15 kDa 1 183 0.025 167 0.455 
15 kDa 10 178 0.088 225 0.507 
100 kDa 1 193 0.087 204 0.092 
100 kDa 10 188 0.104 205 0.120 
 
The experimental part of this work is based on the synthesis described above that D. Sc 
Laaksonen has developed in 2011 (unpublished observation Laaksonen, 2011). In order 
to synthesize and study the release kinetics of particles with different CS shell 
thicknesses, the 100 kDa template was chosen to further studies that were performed in 
the experimental part of this work. The objective of the experimental part was to test 
whether the different CS shell thicknesses on the surface of the pAA core control the 
release of encapsulated model compound or not. Also, another crosslinker in addition to 
GA was tested in order to study the effect of surface modification on size, size 
distribution and morphology of CS-pAA nanoparticles.  
4. IN VITRO CHARACTERIZATION OF NANOPARTICLES  
Several features can be examined in the physical characterization of nanoparticles e.g. 
size, morphology, surface area, surface charge, surface hydrophobicity, surface 
adsorbates, density and interior structure (Haskell, 2006). There are many techniques 
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available for the particle size measurements, and the appropriate method is usually 
selected based on the purpose of the measurement and mean size distribution of 
nanoparticles (Haskell, 2006; Peltonen and Hirvonen, 2008). A combination of two or 
more techniques is usually needed to obtain reliable results. Light scattering and 
electron microscopy techniques are among the most widely used techniques for particle 
size measurements. Atomic force microscopy (AFM) is a more demanding technique 
than electron microscopy techniques but ultrahigh resolution is obtainable with this 
technique (Hoo et al., 2008). AFM scans can identify large bimodal size distributions 
regardless of particle shape, and AFM analysis of an unknown particle mixture could 
serve as screening technique prior to light scattering analysis.  
When polyelectrolyte nanocapsules are characterized, electrophoretic mobility and light 
scattering measurements are typically used to follow the layer growth of 
polyelectrolytes onto the spherical templates, whereas for structural characterization 
both electron microscopy and AFM are commonly used (Caruso et al., 1998; Donath et 
al., 1998; Petrov et al., 2005; Sukhorukov et al., 1998). Electrophoretic mobility 
measurements give information of the surface charge and light scattering methods can 
be used to measure size growth. Electron microscopy techniques and AFM can provide 
detailed structural information of the surface and interior structure of micro- and 
nanoparticles. AFM can also be used to study the elasticity of nanocapsules, which may 
provide information of the mechanical and elastic properties (Lulevich et al., 2003). 
Another widely used method is confocal fluorescence microscopy (Han et al., 2010). It 
has been used for the in vitro permeability studies of the shell structures of core-shell 
nanoparticles, and also to study cellular uptake of nanoparticles and the release of 
encapsulated materials.  
An array of more specific methods can be utilized in addition to the above methods, in 
the characterization of polyelectrolyte complex nanoparticles, to gain information of 
morphological and structural features or binding behaviour (Baer et al., 2010; Cooper et 
al., 2005; Lemarchand et al., 2004). For an example, the composition can be analysed 
with methods such as high performance liquid chromatography, size exclusion 
chromatography, infrared spectroscopy, nuclear magnetic resonance spectroscopy and 
quartz crystal microbalance (Cooper et al., 2005). Several methods should be used in 
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parallel to support each other and confirm the interpretation of obtained results. The 
basic principles of analysis methods that were used during the experimental part of this 
work will be described in the following sections 4.1 – 4.3. In vitro release studies for 
colloidal drug carriers will be described in the section 4.4, and the dialysis method in 
the section 4.5. 
4.1 Electron microscopy 
Electron microscopy techniques enable simultaneous characterization of morphology, 
size and shape of nanoparticles. It is possible to gain structural information to 
subnanometre resolution with electron microscopy, and there are two main categories of 
electron microscopy (Hamley, 2007; Klang et al., 2013). Transmission electron 
microscopy (TEM) has a higher resolution than scanning electron microscopy (SEM), 
and it is usually possible to resolve 1 nm features using a TEM compared to 5 nm 
resolution for a SEM. These methods can be used to study dry materials as there is a 
requirement to maintain a high vacuum in the microscope.  
In SEM imaging, an electron beam is scanned across an object, knocking secondary 
electrons out of its surface atoms (Hamley, 2007). These electrons are then detected and 
an image is formed. SEM imaging can be used to characterize the exterior of the sample 
as well as internal structures of particles by cross-sectioning the sample (Kim and Park, 
2004). Coating of the sample is usually necessary for SEM imaging, but it may cause 
problems if the coating alters sample properties (Bilati et al., 2005).  
In TEM imaging, an electron beam is transmitted through the sample, and the intensity 
of transmitted electrons is inversely proportional to the electron density of a section of 
material through which it has passed (Hamley, 2007). An image is formed from the 
interaction of the electrons transmitted through the sample. The high vacuum may be 
problematic with TEM measurements and especially aqueous samples may not survive 
the vacuum as water loss during analysis may alter sample microstructure (Salgueiriño-
Maceira et al., 2004). Also TEM samples may require staining if the electron density 
contrast with a soft material sample is insufficient on its own (Hu et al., 2002). 
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4.2 Dynamic light scattering  
Dynamic light scattering (DLS), also known as photon correlation spectroscopy (PCS), 
is a common technique used for the determination of particle size and size distribution 
in colloidal dispersions. The velocity distribution of particle movement is analysed with 
DLS (Murdock et al., 2008). This is achieved by measuring the temporal dynamic 
fluctuations of laser light scattering intensity caused by the Brownian motion of the 
particle. Analysis of these intensity fluctuations enables the determination of the 
distribution of diffusion coefficients of the particles, which are converted into a size 
distribution using established theories.   
Special algorithms have been formed to transform the light scattering results to particle 
size information and the requirements in these algorithms include e.g. sufficient 
dilution, spherical particle shape and a large difference between the refractive indices of 
the two phases (Peltonen and Hirvonen, 2008). Scattering intensity depends on the size 
and absorption of the particles, the scattering angle, as well as on the refractive indices 
of both the particles and the dispersion medium. Stokes-Einstein equation (Eq. 1) is 
used to determine the hydrodynamic radiuses of particles in solution 
 
  
  
     
 (1) 
where D is the diffusion coefficient, k is Boltzmann’s constant, T is the temperature, η 
is the solvent viscosity and Rh is the hydrodynamic radius of the particles in solution 
(Hoo et al., 2008).  
DLS works well for monodisperse samples but it has been reported that conventional 
DLS measurements are unable to measure accurately particle mixtures with a large 
difference between particle diameters (Hoo et al., 2008). Large particle size deviation 
causes problems with light scattering methods, as the larger particles will be 
overstressed (Ito et al., 2004; Yegin and Lamprecht, 2006). Ultimately the measurement 
may be impossible without sample pre-handling, e.g. size fractioning, if the size 
deviation is very wide (polydisperse samples). The advantages of DLS include speed of 
analysis, sensitivity to submicrometer particles and lack of required calibration 
(Haskell, 2006). Drawbacks include necessity of dilution to avoid concentration effects, 
possible influence of interparticle interactions and cleanliness in sample preparation.  
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4.3 Zeta potential measurements 
Surface charge of colloidal particles is typically assessed through measurements of ζ- 
potential, which is the potential at the hydrodynamic shear plane of colloidal particles 
(Delgado et al., 2007). Particle mobility under an applied electric field (electrophoresis) 
is determined in the ζ-potential measurements, and the mobility depends on the 
effective charge on the surface. The mobility can be related to ζ- potential with the help 
of Smoluchowski’s equation.  
The ζ- potential exists as a characteristic of a charged surface under certain specific 
fixed conditions, and this should be considered while the samples are prepared and 
results are analysed (Delgado et al., 2007). The sample medium properties, like pH and 
electrolyte concentration of the medium, affect the ζ- potential and it is important to 
preserve surface characteristics of colloidal particles upon dilution. Sample dilution is 
usually necessary as many samples are too concentrated for direct measurement. 
Equilibrium between surface and liquid should be preserved, and usually filtered or 
centrifuged original medium or a close imitation of the original medium is used for 
dilution.  
4.4 In vitro release studies for colloidal drug carriers 
Dissolution testing is a very important tool during drug development and quality control 
(Siewert et al., 2003). Dissolution testing was originally developed for immediate 
release solid oral dosage forms, and later extended to controlled and modified release 
solid oral dosage forms. For novel dosage forms, such as liposomes, micro- and 
nanoparticulate systems, there are significant differences in formulation design and 
physicochemical properties, which lead to different release characteristics. Therefore it 
is impossible to design or use a single test system that could be used to study the drug 
release properties of all products. Usually different procedures, techniques and 
apparatus are used or even developed on a case-by-case approach (Abdel-Mottaleb and 
Lamprecht, 2011; Heng et al., 2008). In vitro release studies are generally performed to 
support product development, study the structure and release mechanism of the system, 
evaluate formulation and manufacturing methods, perform biopharmaceutical 
47 
 
  
characterization of the drug product and to ensure consistent product quality within 
defined specifications (D'Souza and DeLuca, 2006; Siewert et al., 2003).  
Method development for the in vitro release studies of novel formulations can be 
extensive, and in some cases a different method can be used in the early stages of 
formulation development as opposed to the final test procedure used for the product 
quality control (Siewert et al., 2003). Methods that are used during formulation 
screening or release mechanism studies can simply be impractical for quality control 
purposes. In general, a multipoint drug release test is required to characterize the 
dissolution/release profile from novel drug products due to complexity of the 
composition and the release mechanism. The experimental test conditions for in vitro 
dissolution/release studies should ideally be tailored, according to the release 
mechanism and conditions at the site of administration, which can be challenging due to 
complexity of the release mechanism and lack of knowledge about the conditions under 
which the release occurs in vivo. Nevertheless, a suitable test should be able to 
characterize biopharmaceutical quality of the dosage form and also differentiate 
between degrees of product performance and manufacturing variables.  
Currently no standardized in vitro release method exists for the determination of drug 
release from nanocarriers. Methods that are widely used to evaluate drug release from 
nanoparticulate systems can be divided into three main categories, which are membrane 
diffusion, sample and separate and in situ methods (Judefeind and de Villiers, 2009). 
The dialysis method, which is a membrane diffusion method, as well as the sample and 
separate method are among the most widely used methods in the determination of drug 
release from nanocarriers. In vitro dissolution/release data of novel dosage forms might 
be strongly influenced by test or equipment parameters, and therefore a scientific 
assessment of the relevance and validity of an in vitro dissolution test should be 
conducted and the obtained results should be interpreted critically.   
In dialysis method, drug-loaded nanoparticles are separated from the release medium by 
a semipermeable dialysis membrane, and samples are withdrawn from the outer release 
medium over time to study the release profile (Gaber et al., 2006; Jiang et al., 2005; Lee 
et al., 2003; Quaglia, 2006). In sample and separate method, the drug release profile is 
studied by dispersing drug-loaded nanoparticles into a vessel that contains the release 
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medium, after which samples are withdrawn from the release medium and nanoparticles 
are separated from the medium by filtration or centrifugation (Lecaroz et al., 2006; Leo 
et al., 2006; Pfeifer, 2005; Shekunov et al., 2006). In situ methods are direct drug 
release measurements from the release medium, where the drug-loaded carriers are 
diluted, and the drug release profile is analysed with UV spectroscopy, fluorescence 
spectroscopy or differential pulse polarography (Charalampopoulos et al., 2003; Chorny 
et al., 2002; Qiu et al., 2001a).  
4.5 Dialysis method 
Dialysis method is experimentally straightforward and easy to perform, but the results 
can be misleading if not interpreted properly (D'Souza and DeLuca, 2006; Washington, 
1990). As the sample is actually inside the dialysis bag or tube, none of the sample is 
directly diluted into a sink medium. It has been proposed that the drug release, from the 
carrier into the surrounding phase inside the dialysis bag/tube, can be thought of as a 
process of non-sink drug partitioning between the drug carrier and the surrounding 
phase followed by drug diffusion across the semipermeable membrane into the sink 
release medium (Washington, 1989). Because the concentration gradient of the drug 
inside the dialysis bag is partition controlled, the drug release rate can be completely 
obscured by partitioning in the sample.  
This problem can be addressed by ensuring sufficiently fast membrane diffusion for the 
released drug (D'Souza and DeLuca, 2006). Suitable membrane molecular weight cut 
off should be selected to ensure that the membrane is not a limiting factor for the drug 
diffusion. The drug binding into the dialysis membrane should always be studied as it 
can be a significant source of error if the binding is significant (Kinget et al., 1979). If 
the tested compound has a high degree of binding into the membrane, it may even rule 
out the dialysis method entirely. Another factor that should be considered is the sample 
volume inside the dialysis bag/tube (D'Souza and DeLuca, 2006). The sample volume 
should be kept at least 6 to 10-fold smaller than the outer release medium to provide a 
driving force for the drug diffusion through the membrane.  
The volume of the release medium that surrounds the dialysis bag/tube should ensure 
sink conditions for the drug release. Usually drug release studies are optimally 
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conducted in good sink conditions, and it has been recommended that the drug 
concentration should be kept below 10 % of saturation in the release medium in order to 
ensure sink conditions (Washington, 1990). A large volume of sink release medium 
may pose a problem for the quantitative analysis of the drug in the sink medium, 
because the drug concentration decreases when the volume of sink medium is increased. 
The release medium should also be constantly agitated throughout the release studies to 
increase the drug diffusion through the dialysis bag as the agitation minimizes unstirred 
water layer effects. The agitation of the release medium shortens the time that is needed 
for the drug concentration to reach equilibrium between the release medium and the 
sample inside the dialysis bag/tube. 
All of the above factors should be considered when an experimental setup, utilizing the 
dialysis method, is designed for the in vitro release studies from colloidal carriers. The 
dialysis method itself is quite easy to perform and sampling is convenient, but the 
results should be considered critically in the light of underlying release mechanism of 
the drug from the colloidal carrier. Although the dialysis method is among the most 
widely used in vitro release study methods for the assessment of drug release from 
colloidal carriers, the suitability and robustness of the dialysis method for a specific 
formulation should be evaluated empirically. The in vitro release studies from casein-
poly(acrylic acid) nanoparticles were conducted with the dialysis method in the 
experimental part of this work. 
II. EXPERIMENTAL PART 
5. GOALS OF THIS STUDY 
The goal of this work was to synthesize casein-poly(acrylic acid) (CS-pAA) 
nanoparticles with different mass ratios and to develop a suitable experimental setup for 
dialysis method to study the release profile of a model compound rhodamine 6G (R6G) 
from these nanoparticles. During the synthesis, pAA functions as a core template and 
influences the formation of CS shell structure of CS-pAA nanoparticles. The formation 
of these nanoparticles is based on pH-sensitive electrostatic complex formation. The CS 
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shell was crosslinked by two different crosslinkers, chemically selective glutaraldehyde 
and chemically non-selective BASED, after the formation of polyelectrolyte complexes 
to study the effect of crosslinker choice on the size, PDI, ζ-potential values and 
morphology of CS-pAA nanoparticles. Crosslinking should condense the CS shell 
structure and possibly reduce the allergenicity of CS by masking the protein shell.  
By controlling the degree of crosslinking, it is possible to affect the hydrodynamic 
diameter of nanoparticles. Crosslinking of the CS shell on the surface creates a higher 
diffusion barrier to small molecules bound to the pAA core. The idea of the R6G release 
studies was to test whether different CS shell thickness on the surface of pAA core 
affect the release profile of R6G or not. The suitability to act as nanocarriers for drugs 
or peptides in controlled release manner would be the ultimate goal for CS-pAA 
nanoparticles. This goal should hopefully be reached by modifying the surface of these 
nanoparticles by varying the CS shell thickness and by selecting a suitable crosslinker to 
further adjust the barrier properties of the CS shell. 
The first part of the experimental work focuses on optimizing the synthesis of CS-pAA 
nanoparticles and purification by dialysis followed by loading and release studies of 
R6G. Suitable analysis method development for quantitative R6G detection by 
automated microplate reader was also done during preliminary tests. DLS was used to 
determine sizes and PDI values of CS-pAA nanoparticles, and ζ-potential measurements 
were done to obtain information about the electrostatic properties. TEM imaging 
provided further insight of the shape and morphology of these nanoparticles.  
In vitro dissolution testing can provide information of the release mechanism from 
nanocarriers and of the efficiency of the delivery system, but currently there is no one 
method as a golden standard for dissolution studies for novel drug delivery systems 
such as nanoparticles, liposomes and microspheres. Dialysis is one of the methods that 
have been used widely during in vitro studies of pharmaceutical nanoformulations. 
Release studies in this work were done by the dialysis method because it is already an 
established method. We also wanted to evaluate its suitability in the in vitro release 
studies of R6G from CS-pAA nanoparticles. It is important to obtain reliable and 
relevant information from in vitro release studies in order to estimate the rate and 
amount of release correctly and to further optimize the critical properties of 
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nanocarriers. Nanoscale drug delivery systems are already a major topic in 
pharmaceutical research work and in the near future there will probably be more clinical 
applications as the need for more sophisticated drug carriers increases due to ever 
growing amount of new complicated active pharmaceutical ingredients and therapeutic 
needs.  
6. MATERIALS AND METHODS 
6.1 Materials and reagents 
Poly (acrylic acid) (pAA, average MW 100 000) solution 35 % (m/m) in water was 
purchased from Sigma-Aldrich, Germany. Stock solution of pAA (10 mg/ml) was 
prepared by weighing 2.86 g of 35% (m/m) pAA solution into 100 ml volumetric flask, 
which was filled with distilled water. Working solution of pAA (1 mg/ml) with pH 3.65 
was prepared from 10 ml of stock solution of pAA and 0.5 ml of 100 mM sodium 
hydroxide (NaOH) pipetted into 100 ml volumetric flask, which was filled with distilled 
water. Sodium caseinate (CS) powder was purchased from Kaslink Foods, Finland. 
Stock solution of CS (2 mg/ml) was prepared by weighing 200 mg of CS into 100 ml 
volumetric flask. Heated distilled water was then added into the vessel and the CS 
solution was stirred overnight with magnetic stirrer. Working solution of CS (1 mg/ml) 
with pH 3.65 was prepared by pipetting CS stock solution fast into 2 mM hydrochloric 
acid (HCl) solution in 1:1 volume ratio of under constant magnetic stirring. 5 M NaOH 
and 1 M HCl used in pH adjustments were purchased from VWR BDH Prolabo, France. 
Glutaraldehyde (GA, M(GA)= 100.12 g/mol) solution 25 % (m/m) was purchased from 
Sigma-Aldrich, Germany. Working solution of GA (20 mg/ml) was prepared by 
weighing 1.6 g of 25 % (m/m) GA solution into 20 ml volumetric flask, which was 
filled with distilled water. Bis[2-(4-azidosalicylamido)ethyl]disulfide (BASED, M 
(BASED)= 474.52 g/mol) was purchased from Fluka Analytical Sigma-Aldrich, France. 
Working solution of BASED (1mg/ml) was prepared in the dark by dissolving BASED 
in dimethyl sulfoxide (DMSO). 
Rhodamine 6G chloride (R6G, M(R6G)=479.01g/mol) fluorescein derivative powder 
was purchased from Sigma-Aldrich, Germany. R6G solution (1mg/ml) was prepared by 
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dissolving R6G in pH 3.5 adjusted Milli-Q water. Sonication was used for 20 minutes to 
speed up the dissolution of R6G in water. Trizma hydrochloride (Tris) crystals were 
bought from Sigma-Aldrich, Germany. Working solution of Tris (20mg/ml) was 
prepared by weighing 500 mg into 25 ml volumetric flask which was filled with Milli-Q 
water. 
0.1 M citrate buffer solution was prepared in volumetric flask by mixing anhydrous 
citric acid (C6H8O7) solution and 0.1 M tri-sodiumcitrate-dihydrate (C6H5O7Na3 · 
2H2O) solution in proper proportions. Anhydrous citric acid was purchased from 
Hawkins Inc., USA and tri-natriumcitrat-dihydrat was purchased from Merck, 
Germany. 0.1 M phosphate buffer was prepared in volumetric flask by mixing 
monobasic potassium phosphate (KH2PO4) and 5 M NaOH in proper proportions. 
Monobasic potassium phosphate was purchased from Sigma-Aldrich, Germany and 
Riedel-de Haën, Germany. Buffer solutions that were used in the in vitro release studies 
of R6G were used within 7 days after preparation. 
Dialysis tubing was bought from Spectrum Laboratories Inc., USA and three different 
molecular weight cut off (MWCO) membranes were used. Biotech regenerated 
cellulose membrane with MWCO 25 kDa was used only during preliminary tests. 
Biotech regenerated cellulose ester membranes with MWCO 1 MDa (flat width 16 mm)  
was used for purification of aqueous colloidal dispersions containing CS-pAA 
nanoparticles and MWCO 100 kDa (flat width 31 mm) was used in the release studies 
of R6G from CS-pAA nanoparticles. Dialysis medium for purification was pH 3.5 
adjusted distilled water.  
6.2 Methods 
6.2.1 Synthesis of casein-poly(acrylic acid) nanoparticles 
Poly(acrylic acid) templated casein nanoparticles were prepared by the synthesis 
method, which D.Sc. Timo Laaksonen has developed,  in aqueous solution by mixing 
negatively charged pAA and positively charged CS (unpublished observation 
Laaksonen, 2011). CS working solution (1mg/ml) was added dropwise to pAA working 
solution (1mg/ml) under constant magnetic stirring. Nanoparticles with 1:5, 2:5 and 1:1 
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(m/m) of CS to pAA were synthesized. The pH value of the synthesis reaction system 
was maintained at 3.65 to ensure electrostatic complexation between negatively charged 
pAA and positively charged CS. After electrostatic complexation a crosslinker was 
added dropwise into the reaction mixture to crosslink CS on the shell of the CS-pAA 
nanoparticles. The two crosslinkers used in this work were GA and BASED. Tris was 
added as a final reaction step to the reaction mixture to terminate crosslinking reaction 
prior to purification by dialysis.   
GA crosslinked nanoparticles with different mass ratios of CS to pAA were prepared by 
pipetting different volumes of CS working solution to pAA working solution while 
maintaining total reaction volumes at 50 ml for all different mass ratios of CS to pAA 
synthesized (Table 5). Electrostatic complexation between CS and pAA was continued 
for 30 minutes after which 5 ml samples of reaction mixtures were retrieved before 
addition of GA. GA working solution (20mg/ml) was added dropwise in 1:1 mass ratio 
to CS to the CS-pAA nanodispersions and the crosslinking reaction was continued up to 
two hours. After this Tris (20mg/ml) was added to the reaction mixture dropwise in 1:1 
mass ratio to GA to react with the remaining unreacted glutaraldehyde for 30 minutes 
and terminate the crosslinking reaction. All reaction steps were performed at ambient 
temperature and after the syntheses the purification by dialysis was performed for 21 
hours. Hollow nanoparticles were prepared by raising pH to 7 by dialysing particles 
against 0.1 M pH 7 phosphate buffer. 
Table 5. Synthesis of glutaraldehyde crosslinked casein-poly(acrylic acid) 
nanoparticles. Synthesis steps included electrostatic complexation between casein and 
poly(acrylic acid) for 30 minutes, crosslinking of casein shell with glutaraldehyde up to 
2 hours, and termination of crosslinking reaction with Tris for 30 minutes. 
Mass ratio 
of CS to 
pAA 
VCS 
(ml) 
VpAA 
(ml) 
Vtot 
(ml) 
CCS 
(mg/ml) 
CpAA 
(mg/ml) 
VGA 
(μl) 
VTris 
(μl) 
1:5 8.33 41.67 50 0.17 0.83 375 375 
2:5 14.29 35.71 50 0.29 0.71 645 645 
1:1 25 25 50 0.5 0.5 1125 1125 
 
BASED crosslinked CS-pAA nanoparticles were also prepared in 1:5, 2:5 and 1:1 
(m/m) of CS to pAA by dropwise addition of CS working solution to pAA working 
solution (Table 6). Total reaction volume was 15 ml for all different mass ratios of CS 
54 
 
  
to pAA synthesized, and the electrostatic complexation between CS and pAA was 
carried out for 30 minutes. After which BASED was added dropwise in 1:5 mass ratio 
to CS to the reaction mixtures, and the reaction mixtures were stirred for 5 minutes 
while the reaction vessels were protected from light.   
Table 6. Syntheses of BASED crosslinked casein-poly(acrylic acid) nanoparticles. 
Synthesis steps included electrostatic complexation between casein and poly(acrylic 
acid) for 30 minutes, crosslinking of casein shell with BASED for 5 or 15 minutes, and 
termination of crosslinking reaction with Tris for 30 minutes. 
Mass ratio 
of CS to 
pAA 
VCS 
(ml) 
VpAA 
(ml) 
Vtot 
(ml) 
CCS 
(mg/ml) 
CpAA 
(mg/ml) 
VBASED 
(μl) 
VTris 
(μl) 
1:5 2.5 12.5 15 0.17 0.83 500 8 
2:5 4.29 10.71 15 0.29 0.71 860 14 
1:1 7.5 7.5 15 0.5 0.5 1500 25 
 
Long wave UV-light (366nm) was used to photoactivate BASED and initiate radical 
crosslinking reaction. Photoactivation of BASED was carried out for 15 and 5 minutes 
by 5000-PC UV curing flood lamp (Dymax, Germany/USA) with 400 W metal halide 
UV curing bulb. Due to material overheating when 15 minutes irradiation time was 
used, also 5 minutes activation time and cooling of the reaction vessels with ice during 
photoactivation was tested. After the crosslinking reaction Tris was added to the 
reaction mixtures in 1:1 molar ratio to BASED to terminate the crosslinking reaction. 
Tris was allowed to react for 30 minutes before purification by 21 hour dialysis. Hollow 
particles were prepared by raising pH to 7 by dialysing particles against 0.1 M pH 7 
phosphate buffer.  
6.2.2 Purification by dialysis 
Aqueous CS-pAA nanoparticle dispersions were purified with dialysis to get rid of non-
particulate matter, e.g. free GA, BASED, pAA and CS, and DMSO. Dialysis 
membranes were soaked for 15-30 minutes in distilled water and rinsed with Milli-Q 
water in order to get rid of toxic sodium azide preservative residues prior to dialysis. 
CS-pAA nanoparticle dispersions were pipetted inside 1 MDa MWCO regenerated 
cellulose ester dialysis membrane bags, enclosed with Spectra/Por standard and 
weighted closures, and dialysed against a large dialysis volume (1 ml of dispersion 
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against 140-180 ml of dialysis medium) for 21-22 hours under constant magnetic 
stirring of the dialysis medium to ensure effective purification.  
Dialysis medium was pH 3.5 adjusted distilled water or pH 7 0.1M phosphate buffer for 
hollow particles. The medium was changed after time periods of 1.5-2 and 3-3.5 hour 
prior to leaving the dialysis medium to equilibriate up to 21 hours. Nanodispersions 
were retrieved with a micropipette from inside the dialysis bags at the endpoint of 
dialysis, and diluted back to their original volumes in volumetric flasks with pH 3.5 
adjusted distilled water or pH 7 0.1 M phosphate buffer due to sample concentrating 
during the dialysis. Loss of sample volume during the dialysis indicated that there was a 
difference in the osmotic pressure of the sample when compared to the osmotic pressure 
of the dialysis medium. 
6.2.3 Particle size and zeta potential measurements 
The mean size and polydispersity index (PDI) of the CS-pAA nanoparticles were 
measured by DLS (Zetasizer 3000 HS, Malvern Instruments, UK) in pH 3.5 adjusted 
distilled water or pH 7 0.1M phosphate buffer medium in the case of hollow 
nanoparticles. All DLS measurements were done with a wavelength of 633.0 nm at 25 
°C with an angle detection of 90 ° in polystyrene cuvettes. Refractive index 1.33 and 
viscosity 1.002 of water were used as medium/dispersant parameters in the 
measurements.  The samples were diluted with pH 3.5 adjusted distilled water or pH 7 
0.1M phosphate buffer in the case of hollow particles to suitable concentrations for the 
measurements. Each sample was repeatedly measured three times and the reported 
values are the mean diameter ± standard deviation and polydispersity index ± standard 
deviation for four replicate individual samples (GA crosslinked) or three replicate 
individual samples (BASED crosslinked). The reported values for BASED crosslinked 
hollow particles prepared by 15 minutes UV-activation time are from three repetition 
measurements of only one single sample. 
The ζ-potential of the CS-pAA nanoparticles was measured with Zetasizer 3000 HS 
(Malvern Instruments, UK). Dielectric constant 80.4 and viscosity 1.002 of water were 
used as medium/dispersant parameters in the measurements. The samples were the same 
that were used in the size measurements. Each sample was repeatedly measured three 
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times and the reported values are the ζ-potential ± standard deviation for four replicate 
samples (GA crosslinked) or three replicate samples (BASED crosslinked). It should be 
noted that ζ-potential values measured in this work can only be regarded as qualitative 
due to suboptimal performance of the measurement equipment. 
Stability studies were conducted only for GA crosslinked nanoparticles. Samples for 
stability studies were taken from nine different syntheses. The samples of all different 
CS-pAA mass ratio nanoparticles were prepared from three separate syntheses. The 
synthesis volumes ranged between 15 ml to 25 ml during the electrostatic complexation, 
and between 10 ml to 20 ml during GA crosslinking. Samples for stability studies were 
preserved in a refrigerator and diluted to suitable concentrations with distilled water 
adjusted to pH 3.5 immediately before the DLS measurements. Size and PDI values 
were measured at day 1, 14 and 28 after the syntheses. Stability studies were not 
continued after 28 days from syntheses as the dispersions contained no preservatives, 
and visible microbial growth was observed in the samples after 56 days from syntheses. 
The reported values are the mean diameter ± standard deviation and polydispersity 
index ± standard deviation for three replicate individual samples. 
6.2.4 Electron microscopy  
Transmission electron microscopy (TEM) (FEI Tecnai F12, Philips Electron Optics, 
The Netherlands) was used to characterize the size and morphology of dried CS-pAA 
nanoparticles. Samples for TEM analysis were obtained by placing a drop of diluted 
(1/10) colloidal dispersions containing CS-pAA nanoparticles on formvar film-coated 
copper grids with mesh size 300 (Agar Scientific, Essex, UK) and dried at ambient 
temperature. Samples without any further modification were then examined using a 
TEM.  
Scanning electron microscopy (SEM) (FEI Quanta 250 Field Emission Gun Scanning 
Electron Microscope) was also used in attempt to characterize the size and morphology 
of dried CS-pAA nanoparticles. Samples for SEM analysis were obtained by placing a 
drop of colloidal dispersions containing CS-pAA nanoparticles onto double sided 
carbon tape (Nisshin EM Co., Ltd, Tokyo, Japan) placed on the flat surface of a SEM 
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pin mount specimen holder. Samples were then dried at ambient temperature and coated 
with 5 nm platinum layer prior to SEM imaging.  
6.2.5 Fluorescence measurements 
Quantitative analysis of R6G concentrations was performed by fluorescence intensity 
measurements of R6G with automated spectral scanning multimode plate reader 
(Varioskan Flash 4.00.53 equipped with SkanIt Software 2.4.3 Research Edition; 
Thermo Fisher Scientific, Finland). Excitation wavelength 528 nm, emission 
wavelength 551 nm and 5 nm bandwidth were used in the fluorescence intensity 
measurements of R6G. 200 µl of samples were pipetted into wells of 96-well NUNC U-
bottom polypropylene plates (NUNC, Denmark) and kept in the dark at least an hour 
before fluorescence measurements.  
When R6G samples from the in vitro release studies were analysed, two series of 
calibration samples and two samples of the dilution medium were pipetted into each 
microplate with R6G concentrations of calibration samples ranging from 1 ng/ml to 2 
µg/ml. Standard calibration samples of R6G were prepared depending on the sample 
medium to be analysed by serial dilution of R6G stock solution (1 mg/ml) with either 
0.1 M citrate buffer or 0.1 M phosphate buffer. All calibration curves had high squared 
correlation coefficients (R
2
 ˃ 0.99) indicating that a high degree of accuracy was 
obtained in the formation of the standard curves (Figure 10). 
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Figure 10. Calibration curve plot of rhodamine 6G in 0.1 M pH 7 phosphate buffer 
medium. Two series of eight standard calibration samples with R6G concentration 
ranging between 0.001-2 μg/ml as well as two samples of the dilution medium were 
pipetted into each individual microplate. All calibration curves, also in pH 3, had high 
squared correlation coefficients (R
2
 ˃ 0.99) indicating a high degree of accuracy. 
6.2.6 Loading and release of rhodamine 6G 
R6G was loaded electrostatically into CS-pAA nanoparticles by pipetting 1 mg/ml 
R6G-solution dropwise into purified colloidal dispersions of CS-pAA nanoparticles 
resulting in 50 μg/ml R6G concentration in the nanodispersions. Dispersions were 
stirred manually during the dropwise addition of R6G and left to equilibriate at ambient 
temperature for 17 hours preserved from light. After the loading period, the in vitro 
release studies and the determinations of encapsulation efficiencies of the nanoparticles 
were conducted.    
Release studies of R6G from GA crosslinked CS-pAA nanoparticles were performed at 
ambient temperature in pH 3 0.1 M citrate buffer and pH 7 0.1 M phosphate buffer 
release mediums. 6 ml samples of R6G-loaded CS-pAA nanoparticle dispersions were 
pipetted into 100 kDa MWCO dialysis membrane bags (length 8-8.5 cm, width 31 mm, 
surface area after closure for 8 cm long bags was 2x(8-1.8-1.8)cmx3.1cm = 27.3 cm
2
 
and for 8.5 cm long bags 2x(8.5-1.8-1.8)cmx3.1cm=30.4 cm
2
), dialysis bags were 
enclosed with Spectra/Por standard closures and immersed into 300 ml of dialysis 
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medium on sink conditions. 6 ml reference samples of 50 µg/ml R6G- solution were 
prepared and release studies of R6G reference samples were conducted similarly as the 
release studies of R6G-loaded CS-pAA nanoparticles.  Three repetitions were 
performed and the reported values are average ± standard deviation.  
8 cm long dialysis bags were used in the pH 3 release studies of 1:5 and 2:5 CS-pAA 
nanoparticles and for two reference samples. 8.5 cm long bags were used in the release 
studies of 1:1 CS-pAA nanoparticles and for one reference sample in pH 3. This caused 
6 % error when R6G release results through 8 cm long dialysis bags were compared 
with R6G release results through 8.5 long dialysis bags. The release studies in pH 7 for 
all CS-pAA nanoparticles and reference samples were done with 8.5 cm long dialysis 
bags, which were more convenient to handle during the sample preparation. Regardless 
of the 6% error, which is inconvenient and unfortunate, the release studies that were 
made with 8 cm long dialysis bags were not repeated with 8.5 cm long bags, because 
the error was quite small and most likely did not greatly alter the release profiles of 
loaded R6G from different mass ratio CS-pAA nanoparticles in regard to one another in 
pH 3. 
Release vessels were identical 500 ml glass bottles covered with lids and aluminium foil 
to protect R6G in the release medium from possible minor photodegradation during the 
release studies. Release medium was constantly agitated with magnetic stirrer at 
constant speed. 1 ml samples were retrieved from the dialysis medium on predetermined 
time points and replaced with 1 ml of fresh medium. Release studies were continued up 
to 23 hours. Samples were stored in refrigerator and analysed within four days. R6G 
concentration of the samples was determined by fluorescence intensity measurements 
with automated spectral scanning multimode plate reader. 
6.2.7 Determination of encapsulation efficiency 
In the determination of the encapsulation efficiency, 0.5 ml samples of R6G loaded 
aqueous CS-pAA nanoparticle dispersions were pipetted into Nanosep 100K omega 
centrifugal devices (Pall life Sciences, lot:11551884) and the nanoparticles were 
separated from the aqueous phase by centrifugation (Eppendorf, Centrifuge 5415D). 
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Centrifugation was done at the speed of 13,000 rpm for 40 minutes to 1:5 mass ratio 
nanoparticles and 60 minutes to 2:5 and 1:1 mass ratio nanoparticles.  
Four individual samples of GA and BASED crosslinked R6G loaded CS-pAA 
nanoparticles with each mass ratio of CS to pAA were centrifuged, and samples of the 
aqueous phase were diluted (1/4) with pH 3 0.1M citrate buffer. R6G concentration of 
the aqueous phase was then determined by fluorescence intensity measurements of 
R6G, and the amount of free R6G in the aqueous phase was calculated. Encapsulation 
efficiencies (EE) were then calculated with the below equation (Eq. 2) and reported 
values are average ± standard deviation of four samples. 
         
                                  
                 
      (2) 
7. RESULTS AND DISCUSSION 
7.1 Preliminary tests and method development 
Synthesis and purification of CS-pAA nanoparticles were performed during the 
preliminary tests with an objective to find suitable and optimal experimental conditions 
for these studies. A quantitative method was developed for the detection of R6G as the 
goal of this work was to synthesize CS-pAA nanoparticles and to study the release 
profile of a model compound R6G from these nanoparticles. Loading studies of R6G 
into CS-pAA nanoparticles led to the choice of optimal R6G concentration for the 
release studies. Based on the results from preliminary tests, an optimized experimental 
setup was developed for the in vitro release studies of a model hydrophilic compound 
R6G by the dialysis method. 
7.1.1 Synthesis and purification 
Series of preliminary syntheses were performed in order to study the effect of different 
mass ratios of CS to pAA on size and PDI values of the nanoparticles. All syntheses 
with GA as the crosslinker were performed at ambient temperature under constant 
magnetic stirring based on the synthesis method described by D.Sc. Timo Laaksonen in 
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2011 (see section 3.3.3, unpublished observation Laaksonen, 2011). Crosslinking with 
BASED, which was the other crosslinker used in this work, was not studied during 
preliminary tests. The same mass ratios of CS to pAA as with GA crosslinked CS-pAA 
nanoparticles were chosen for crosslinking with BASED. Size and PDI values of 
BASED crosslinked nanoparticles are presented in the section 7.2. 
First, nanoparticles were synthesized with small 6 - 10 ml synthesis volumes depending 
on the CS to pAA mass ratio in small 20 ml glass vessels (Table 7). CS solution was 
pipetted dropwise into pAA solution under constant magnetic stirring except in the case 
of 1:1 (m/m) CS-pAA nanoparticles, which were synthesized by fast addition of CS 
solution to pAA solution. Electrostatic complexation between CS and pAA was 
assumed to happen under a time period of 30 minutes after which GA solution was 
added to the aqueous nanodispersions. Nanoparticles with 1:5 and 2:5 (m/m) of CS to 
pAA were crosslinked with GA in 1:1 (m/m) to CS. After GA addition nanodispersions 
were stirred for 1.25 hours to fix casein molecules on the surface of these colloidal 
particles. Crosslinked nanoparticles were then purified by overnight dialysis against 500 
ml of water with pH adjusted to 3.6. 25 kDa MWCO biotech regenerated cellulose 
membrane was used for the purification. 25 kDa corresponds roughly to 3 nm pore 
diameter, but it should be noted that it is impossible to make a direct conversion 
between a 3-dimensional molecular weight (kDa) and 2-dimensional metric length (nm) 
in practise. 
Table 7. Properties of casein-poly(acrylic acid) nanoparticles prepared with small 
synthesis volumes ranging between 6 to 10 ml. The CS shell of 1:5 and 2:5 
nanoparticles was crosslinked with GA.  
Mass 
ratio 
of CS 
to 
pAA 
VCS 
(1mg/ml) 
VpAA 
(1mg/ml) 
VGA 
(20mg/ml) 
Size 
(nm) 
before 
dialysis 
without 
GA 
PDI 
before 
dialysis 
without 
GA 
Size 
(nm) 
after 
dialysis 
with 
GA 
PDI 
after 
dialysis 
with 
GA 
1:5
a
 1 ml 5 ml 50 µl 131.7 0.125 128.9 0.184 
2:5
a
 2 ml 5 ml 100 µl 128.2 0.094 124.5 0.152 
1:1
b
 5 ml 5 ml - 177.9 0.122 - - 
a 
Dropwise addition of CS to pAA, crosslinking with GA and purification with dialysis.
    
b 
Fast addition of CS to pAA, no crosslinking with GA or dialysis.
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Particles with higher amount of CS should have larger hydrodynamic diameter due to 
thicker CS shell layer. When comparing the size values of different CS-pAA 
nanoparticles, it can be seen that 1:5 and 2:5 mass ratio syntheses resulted in 
approximately similar and smaller sized nanoparticles than 1:1 mass ratio synthesis 
prior to crosslinking with GA (Table 7). Significantly larger size of 1:1 mass ratio 
particles could have been caused by the rapid addition of CS to pAA during the 
synthesis as well as the larger mass of CS in the reaction. Crosslinking the CS shell of 
nanoparticles decreased the hydrodynamic diameter, but increased the PDI values in 
case of 1:5 and 2:5 mass ratios. Slightly smaller sizes after crosslinking were most 
likely caused by condensation of the CS shell after the crosslinking (Liu et al., 2010).  
PDI values were expected to decrease after dialysis and removal of unreacted particulate 
material, but actually they were higher after dialysis. Higher PDI values could have 
been caused by continuing crosslinking reaction of GA with CS up to some extent 
during the dialysis. Dialysis membrane MWCO may have also been too small and 
unsuitable for particle purification, which may have attributed to the higher PDI values 
after dialysis.  
Different mass ratios of CS-pAA nanoparticles were also prepared by pipetting CS 
solution either dropwise or quickly to the initial 25 ml volume of pAA solution under 
constant magnetic stirring. The rise of CS mass ratio to pAA core was done in the same 
reaction vessel by gradually increasing the amount of CS, but the crosslinking of 
different mass ratio CS-pAA nanoparticles was done in very small volumes and in their 
own reaction vessels. This was done to further study the effect of CS addition speed to 
synthesis mixture on size and PDI values and also to determine the maximum amount of 
CS that could be used prior to particle aggregation.  
The volume of the CS-pAA nanodispersions in these syntheses ranged from 30 ml to 
71.6 ml depending on the mass ratio to be synthesized. After each CS addition the 
reaction mixture was stirred for 5 minutes to obtain a homogenous dispersion prior to 
sampling and subsequent CS addition to the reaction vessel. 3 ml samples of all 
different mass ratio CS-pAA nanodispersions were retrieved from the reaction mixture 
into small glass vessels. These samples were then stirred for 20-30 minutes prior to 
dropwise addition of GA crosslinker in 1:1 mass ratio to CS. Crosslinking with GA in 
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the small vessels was continued up to 1.5 hours prior to purification by overnight 
dialysis with 25 kDa dialysis membranes against pH 3.5 adjusted distilled water. GA 
has been reported to react with proteins within 30 minutes to two hours in aqueous 
solutions (Habeeb and Hiramoto, 1968). Table 8 summarises the synthesis volumes of 
CS-pAA nanodispersions, appearance of the nanodispersions as well as size and PDI 
values of different mass ratio CS-pAA nanoparticles prepared in above manner.   
Table 8. Appearance, size and PDI values of CS-pAA nanodispersions. The increase of 
CS to pAA mass ratio was done gradually in one vessel by first slow dropwise CS 
addition and after that by fast CS addition (
a
CS solution pipetted dropwise to pAA 
solution, 
b
CS solution pipetted fast to pAA solution). Small 3 ml samples of different 
mass ratio CS-pAA nanoparticles were retrieved from the reaction mixture vessel, 
crosslinked with GA and dialysed after which the size and PDI values were measured 
by DLS. 1:1 mass ratio of CS to pAA was chosen as the upper limit for CS, because 
CS-pAA nanoparticles with higher mass ratio of CS to pAA started to aggregate. 
Mass ratio of 
CS to pAA 
Volume of 
CS  working 
solution  
added to the 
reaction 
mixture 
Total 
volume 
prior to 3ml 
sampling 
and CS 
addition 
Appearance 
of the nano-
dispersion 
Size (nm) 
after 
dialysis 
PDI 
after 
dialysis 
1:5
a
 5 ml 30 ml Transparent 132.8 0.121 
2:5
a
 4.5 ml 31.5 ml Transparent 
slightly 
white 
135.1 0.108 
1:1
a
 12.3 ml 40.8 ml White 
opalescent 
134.9 0.081 
2:1
a
 18.9 ml 56.7 ml Slight 
aggregation 
279.9 0.135 
3:1
a
 17.9 ml 71.6 ml Complete 
aggregation 
N.d. due to 
aggregation 
N.d. due to 
aggregation 
1:5
b
 5 ml 30 ml Transparent 110.7 0.266 
2:5
b
 4.5 ml 31.5 ml Transparent 
slightly 
white 
108.2 0.294 
 
Interestingly, the PDI values of all the syntheses, where CS was added dropwise up to 
the 2:1 mass ratio, were under 0.15-0.2 which generally can be regarded as the 
approximate upper limit for monodispersity (Danhier et al., 2009; Nidhin et al., 2008). 
Synthesis volumes up to 56.7 ml should therefore produce monodisperse 
nanodispersions if CS is added dropwise to the reaction mixture, but small PDI values 
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could have also been attributed to the small 3 ml volumes during the crosslinking 
reactions.  Particles that were synthesized by dropwise addition of CS were larger than 
particles synthesized by fast addition of CS to the reaction vessel, but fast addition of 
CS led to higher PDI values than 0.2 indicating that nanodispersions were polydisperse. 
The goal of these syntheses was to produce monodisperse CS-pAA nanodispersions, 
and therefore the fast addition of CS to the reaction mixture was not regarded as a 
suitable synthesis step based on the higher PDI values gained when compared to small 
PDI values gained by slow CS addition to the reaction mixture. 
In the dropwise CS addition method, the rise of CS mass ratio to pAA up to 1:1 led to 
the formation of approximately same sized nanoparticles. Based on these size 
measurements the effect of different CS shell thickness on the size seemed unclear, 
because 1:5 nanoparticles were the smallest and 2:5 and 1:1 nanoparticles had almost 
the same sizes. Later on more size measurements were done for 1:5, 2:5 and 1:1 
nanoparticles, and based on those measurements it is clear that raising the amount of CS 
in relation to pAA  leads to the formation of larger nanoparticles (section 7.2).  
2:1 mass ratio resulted in the formation of significantly larger nanoparticles (279.9 nm), 
which was caused by the slight visible aggregation and the thicker CS shell layer. 
Synthesis of 3:1 mass ratio led to clear visible aggregation of these nanoparticles, which 
most likely was caused by the neutralized surface charge that destabilized these 
colloidal particles. Rising the CS mass ratio should lead to the formation of thicker CS 
shell layer which in turn masks the negative charge of the pAA template that stabilizes 
these nanoparticles electrostatically. Up to the 1:1 mass ratio no aggregation was 
observed, and that could mean that the stabilizing effect of pAA template remained if 
the pAA core was not fully masked by the CS shell. 2:1 and 3:1 CS-pAA nanoparticles 
were unstable due to lack of adequate electrostatic stabilization by the pAA core, and 
therefore those mass ratios were not regarded as suitable to further studies. 
Based on these preliminary results 1:5, 2:5 and 1:1 (m/m) of CS to pAA were selected 
to study the effect of CS shell thickness to the release profile of a model compound 
rhodamine 6G from these nanoparticles. The purification of protein based nanoparticles 
can be challenging and unsuccessful purification can be a source of error in e.g. size, 
PDI and ζ-potential measurements. Therefore, after the preliminary studies the 25 kDa 
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MWCO membranes that were used during nanoparticle purification by dialysis were 
replaced with 1 MDa MWCO membranes. Also, the dialysis medium was changed in 
further studies two times during the 21 hour dialysis period to ensure more effective 
purification than during preliminary tests. The 1 MDa MWCO corresponds roughly to 
100 nm pore diameter, which is significantly larger than 3 nm pore diameter, and should 
also contribute to more effective purification. 
During the preliminary synthesis studies the overall yields of CS-pAA nanoparticle 
formation during the syntheses could not be determined. Determination of the synthesis 
yield would have required knowledge of the mass of the solid content in dispersions 
after the purification step by dialysis. Mass loss likely occurred during the purification 
step as there was loss of sample volume during the purification step of CS-pAA 
nanodispersions. A few attempts to quantify the solid content were made by weighing 
vacuum oven dried CS-pAA dispersions, but because the amount of the solid content 
was in the scale of just a few milligrams per 10 millilitres of dispersion, it proved to be 
rather difficult to actually quantify the solid content accurately. In the future, the 
synthesis yields could possibly be determined by weighing dried sediments of 
centrifuged dispersions (Shu et al., 2009). 
7.1.2 Quantification of rhodamine 6G 
R6G is a cationic lipophilic fluorescent dye that is commonly used as a label for 
detection and monitoring of molecules in fluorescence microscopy, 
immunohistochemistry, flow cytometry and spectroscopy (Betancourt et al., 2009b; 
Yordanov and Bedzhova, 2011). R6G has also been used in several studies, which have 
been focused on polymeric nanoparticles intended to be used as drug carriers. For 
example, R6G has been used as a model compound in in vitro release studies, and also 
as a fluorescent tag used in in vivo imaging of biodistribution and cell interaction 
studies of nanoparticles (Betancourt et al., 2009b; Doiron et al., 2009; Yordanov and 
Bedzhova, 2011).  
R6G was chosen to be used as a model compound for in vitro release studies from CS-
pAA nanoparticles in this work due to its cationic nature, which enables the electrostatic 
loading of R6G to the negatively charged pAA core. R6G has also high fluorescence 
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quantum yields (Φ) in different solvents making the detection of fluorescence possible 
and easy even in low concentrations (Magde et al., 2002). Fluorescence quantum yield 
describes the efficiency of the fluorescence process and is defined as the ratio of the 
number of photons emitted to the number of photons absorbed. The R6G solutions are 
quite stable, but optimally fluorescein solutions should be freshly prepared. Absorption 
and fluorescence emission peaks of R6G are present at about 530 nm and 550 nm, 
respectively (Betancourt et al., 2009b). In this work, excitation and emission 
wavelengths of 528 nm and 551 nm were used. 
R6G solutions used in this work were water based, and R6G is known to form stable 
ground-state dimers in addition to monomers in water solutions (Penzkofer and 
Leupacher, 1987; Selwyn and Steinfeld, 1972). The solubility limit of R6G in water is 
0.027 mol/l, and up to the solubility limit the fluorescence emitted from dimers is small 
compared to the fluorescence emitted from monomers, and therefore the monomer 
fluorescence of R6G dominates at the highest possible dye concentration in water 
solutions (Penzkofer and Leupacher, 1987). R6G exhibits concentration-dependent 
fluorescence emission, and at higher R6G concentrations in water the fluorescence 
quantum efficiency (i.e. yield) of monomers is quenched by Förster-type energy transfer 
(electric dipole-electric dipole interaction) to weakly fluorescing dimers (Figure 11).  
Quantification of R6G was attempted with two methods: high performance liquid 
chromatography and automated microplate fluorescence measurement. High 
performance liquid chromatography (HPLC) method development was unsuccessful 
and instead a more direct method with automated microplate reader was used to 
quantify R6G. Isocratic HPLC method development included testing of different flow 
rates of eluent and eluent composition ratios of TFA (0.1 % pH 2) to acetonitrile with 
Agilent 1100 HPLC (Agilent Technologies, Germany) and C-18 colon (Gemini-
NX3uC18110A, Phenomenex, USA) (Chiang et al., 2011). Retention times of R6G 
peaks ranged between 4.5 – 4.9 minutes, and the HPLC experiments produced 
incomplete peak separation of R6G, which caused problems in accurate quantification.   
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Figure 11. Fluorescence quantum efficiency (qf) of rhodamine 6G in water as a function 
of concentration (Penzkofer and Leupacher, 1987). The curve represents calculated 
values and triangles are experimental values. The molecular structure formula of 
rhodamine 6G is inserted into the graph. Fluorescence quantum efficiency i.e. quantum 
yield decreases as the rhodamine 6 G concentration increases due to Förster-type energy 
transfer from monomers to weakly fluorescing  dimers. 
In addition to the HPLC method development, quantification of R6G was also 
attempted with automated microplate reader due to the simplicity of method 
development and fast analysis times for multiple samples. Linear range for fluorescence 
measurements of R6G with a microplate reader established in this work was between 
concentration values of 1 ng/ml to 3 µg/ml. The limit of detection for R6G was 1 ng/ml, 
which was also the limit of quantitation, and the upper limit of linearity was 3 µg/ml.  
Exposure to visible light affected the intensity of fluorescence measurements 
considerably when compared to fluorescence intensity measurements of samples that 
were kept in the dark for two hours prior to measurements (Figure 12).  
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Figure 12. The effect of exposure to visible light on rhodamine 6G fluorescence 
intensity. Filled square and triangle symbols represent measurements that were done 
after light exposure, and hollow square and triangle symbols stand for measurements 
that were done after the microplates were kept in the dark for two hours prior to 
measurements. In the pH 3 samples, the medium was 0.1 M citrate buffer. And in the 
pH 7 samples, the medium was 0.1 M phosphate buffer. The fluorescence intensity of 
R6G was lower for samples that were kept in the dark prior to measurements. The pH 
and medium can also affect the fluorescence intensity of R6G. At pH 7 the intensity of 
fluorescence was lower than at pH 3 in both cases with and without exposure to visible 
light. 
Excitation and emission wavelengths of R6G are both in the range of green-yellow 
region of visible spectrum (of the electromagnetic spectrum). Visible light therefore 
excites R6G, and green-yellow emission could easily be detected visually from 
solutions that were exposed to visible light. Visible light excites R6G molecules, and 
therefore the fluorescence intensities were higher for samples that were exposed to light 
prior to measurements. The pH and medium can affect the fluorescence intensity of a 
fluorophore, and the fluorescence intensity of R6G was higher in pH 3 citrate buffer 
than in pH 7 phosphate buffer. 
0
1000
2000
3000
4000
5000
6000
0 0.5 1 1.5 2 2.5 3
F
lu
o
re
sc
en
ce
 i
n
te
n
si
ty
 
Rhodamine 6G concentration (μg/ml) 
The effect of light exposure on fluorescence intensity  
of rhodamine 6G 
pH 3: R6G not in the dark before measurement, y=1875.9x-82.032, R²=0.9993
pH 3: R6G 2h in the dark before measurement, y=1595.7x-49.852, R²=0.9993
pH 7: R6G not in the dark before measurement, y=1738x+25.034, R²=0.9996
pH 7: R6G 2h in the dark before measurement, y=1505.2x-99.255, R²=0.9993
69 
 
  
No one calibration curve could be used for quantification of R6G as the fluorescence 
intensities varied for the same R6G concentrations in different measurements quite 
drastically, and therefore external standards were used for each individual microplate to 
ensure adequate accuracy in quantification of R6G. The established working range was 
1 ng/ml – 2 mg/ml even though 3 mg/ml could have been used as the upper 
concentration limit for R6G.  It should be reasonable to assume that the quantification 
of R6G with fluorescence intensity measurements using the microplate reader 
succeeded as all calibration curves had high squared correlation coefficients (R
2
 ˃ 0.99) 
indicating that a high degree of accuracy was obtained in the formation of the standard 
curves. The concentrations of R6G in standard samples and in the actual samples were 
extremely low, and therefore the quenching of monomer fluorescence due to Förster-
type energy transfer to dimers should not happen. 
To obtain reliable results and minimize R6G excitation by visible light prior to 
measurements, the necessary steps were performed prior to R6G concentration 
measurements from samples obtained during in vitro release studies. All samples and 
standard samples were kept in the dark for at least an hour after pipetting onto the 
microplates and prior to fluorescence measurements. All microplates contained two 
series of eight standard samples and two samples of the dilution medium as an external 
standard so as to minimize the effect of possible differences in fluorescence 
measurement conditions between different plates.  
Automated fluorescence measurements from microplates were fast to perform and the 
method itself is suitable for R6G concentration measurements. Samples taken from the 
in vitro release mediums should not contain components that can quench the 
fluorescence of R6G, because that could lead to false results. Dialysis bags that were 
used during in vitro release studies had 100 kDa MWCO that corresponds roughly to 10 
nm pore size. This pore size should not enable the leakage of nanoparticles (or free pAA 
chains in pH 7) from inside the dialysis bag to the release medium, which could 
potentially affect the results of R6G concentration measurements by automated 
microplate method. When a direct fluorescence measurement method is developed, the 
properties of the fluorophore should be considered as well as the analysis medium 
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(solvent, pH, ions), because the fluorescence measurements are extremely sensitive and 
without proper knowledge, the obtained results could be irrelevant. 
7.1.3 Loading and release of rhodamine 6G 
Due to lack of knowledge of the synthesis yields, it was not possible to approach the 
R6G loading studies with an accurate knowledge of the nanoparticle concentrations in 
the dispersions after the purification step by dialysis. The main concern was therefore to 
perform the loading of R6G into CS-pAA nanoparticles without causing aggregation 
and precipitation of nanoparticles to disruptive extent. Also, the accurate quantification 
of R6G from the in vitro dialysis medium was taken into consideration while the R6G 
concentrations for the loading studies were selected. Another challenging factor for the 
loading studies was the complete lack of knowledge of the ζ-potential values of CS-
pAA nanoparticles. Qualitative ζ-potential values of CS-pAA nanoparticles are 
presented in the section 7.2. The ζ-potential values would have given some insight of 
potential stability differences between different mass ratio CS-pAA nanoparticles 
(Leroueil-Le Verger et al., 1998; Shu et al., 2009). 
Dialysis method was chosen for in vitro release studies of R6G from CS-pAA 
nanoparticles as it has been previously used in in vitro release studies from protein 
based nano- and microparticles and the method itself is relatively simple (Han et al., 
2010). In a dialysis method, a known volume of nanodispersion is pipetted or otherwise 
inserted inside a dialysis membrane bag, which is then closed at both ends and 
immersed into a release medium. It was initially hypothesized that 2 ml samples of 
nanodispersions with 0.5 mg/ml R6G concentration immersed into 400 ml of medium 
could be used in the in vitro release studies. The timescale for the release of free R6G 
through dialysis membrane, and the binding of R6G into the dialysis membranes, were 
studied in 0.1 M pH 3 citrate buffer and in 0.1M pH 7 phosphate buffer release 
mediums in order to choose proper conditions for the actual release studies. 
7 cm pieces of 100 kDa MWCO cellulose ester dialysis membranes with flat width of 
31 mm and total release surface area of 21.08 cm
2
, after the closure, were used in the 
first experimental setup of R6G release studies. Constant surface area in the release 
studies ensures the reproducibility of tests and comparability of results obtained with 
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the same test method. The release vessels were identical 600 ml beakers and the dialysis 
bags that contained the samples were immersed in 400 ml of release medium with the 
aid of glass dialysis weights placed inside each dialysis bag to maintain a vertical 
orientation during dialysis. Even though the experimental setup was similar for all 
samples, small differences in the release profiles may have occurred due to the rotation 
of some dialysis bags versus total immobility of other bags. This problem was later 
resolved by different release vessels, sample sizes and immersion of dialysis bags 
without the glass weights. 
 
Figure 13. Release profile of free rhodamine 6G through 100 000 MWCO cellulose 
ester dialysis membrane (n=3 ± standard deviation). Release mediums were 0.1 M pH 3 
citrate and 0.1 M pH 7 phosphate buffers. The interior of the dialysis bags contained 
initially 2 ml samples of 0.5 mg/ml R6G solution. The release profiles of R6G were 
rather similar in both pH values but the time period of three hours was too short to reach 
the concentration equilibrium at both sides of the dialysis membrane, and therefore 
longer time period than three hours should be more optimal for the release studies. 
Within the time scale of three hours the release profile of R6G was rather similar in 
both release mediums (Figure 13). However, the released amount of R6G did not reach 
the maximum of 1000 µg in either release medium, and therefore a longer time period 
should have been used to reach the concentration equilibrium of R6G in both sides of 
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the dialysis membrane. The lag time of 10 minutes in both release profiles was probably 
caused by the diffusion and permeation of R6G through the dialysis membrane. It is 
also possible that R6G adsorbed to some extent onto the glass surfaces of weights inside 
dialysis bags, which could cause differences in the release profiles. But this should have 
a minimal effect.  
The dialysis bags were entirely coloured after three hours from white to bright pink 
colour. R6G is a dye, and therefore the binding to the dialysis bag was to be expected 
(Milanova et al., 2011; Yordanov and Bedzhova, 2011). In pH 3 citrate buffer medium 
121.7 µg of R6G bound to the bag corresponding to 5.8 µg/cm
2
, whereas in pH 7 
phosphate buffer medium a larger amount of 195.7 µg corresponding to 9.3 µg/cm
2
 
bound to the bag. These results suggest that R6G might bind more tightly into the 
dialysis bags at pH 7. 12.2 – 19.6 % mass loss of R6G from the dialysis medium due to 
binding to the dialysis bag was not significant with regard to quantitative analysis of 
R6G from the release medium. The binding of R6G into dialysis bags has to be 
considered when sample concentration, sample volume and release medium volume are 
selected. Because it has to be ensured that the R6G mass loss from the dialysis medium 
doesn’t affect the quantitative results obtainable by a selected analysis method with a 
specific linear working range.  
Next step was to load R6G into CS-pAA nanoparticles and to study the release profile 
of loaded R6G during 24 hours and compare it to the release profile of free R6G. 
Loading of R6G into CS-pAA nanoparticles is based on the electrostatic attraction 
between oppositely charged R6G and pAA core. Loading of R6G was first attempted 
into 1:5 and 1:1 CS-pAA nanoparticles overnight, in theoretical 1:1 mass ratio of R6G 
to pAA core, to study whether the different thickness of CS shell has an effect on the 
release profile of R6G or not. Because there was mass loss during nanoparticle 
purification by dialysis, and also the yield of the formation reaction of CS-pAA 
nanoparticles was not determined, the tested R6G mass ratio of 1:1 to the pAA core was 
purely theoretical. Presumptions of no mass loss during the purification by dialysis and 
a 100% yield of reaction during the formation of nanoparticles were made for the 
calculations.  
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Nanoparticles and R6G precipitated to some extent during the loading, which could be 
observed visually as well as in the release profiles (Figure 14). Released amount of 
loaded R6G did not reach the maximum in either case, but there were differences in the 
release profiles of loaded R6G.  First it would seem that the thickness of the CS shell 
affects the release profile of R6G, and the thicker shell of 1:1 particles slows the release 
of R6G more than the thinner shell of 1:5 particles. However, the matter of precipitation 
during the R6G loading has to be also considered when interpreting the release profiles. 
Most likely the differences in the release profiles of R6G from the CS-pAA 
nanoparticles were not caused by the different CS shell thicknesses, but because of 
considerable amount of precipitation of R6G and the nanoparticles during the loading of 
R6G.  
 
Figure 14. The release profiles of R6G loaded CS-pAA nanoparticles through 100 kDa 
MWCO cellulose ester dialysis membrane in 0.1 M pH 3 citrate buffer medium. R6G 
was loaded in 1:1 mass ratio to pAA core into 1:5 and 1:1 CS-pAA nanoparticles. 
Differences in the release profiles of loaded R6G from nanoparticles were probably 
caused by the different stabilities of 1:5 and 1:1 CS-pAA nanoparticles as the loading of 
R6G caused aggregation and precipitation of both of these particles to some extent. The 
release of loaded R6G was slower than the release of the reference free R6G indicating 
that controlled release properties with these particles may possibly be achieved. 
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The precipitation was presumably caused by destabilizing effect of loading too much 
positively charged R6G onto the negatively charged pAA core, which reduces the 
electrostatic stabilizing effect of the core and results in aggregation as these particles are 
solely stabilized via electrostatic forces. Shapira and colleagues have also reported that 
drug overloading to electrostatically stabilized nanoparticles results in destabilization 
and aggregation of the whole drug delivery system (Shapira et al., 2010a). Based on the 
graph it would seem that 1:1 particles precipitated to a greater extent than 1:5 particles 
as the maximum released amount of R6G from 1:1 particles is extremely low (374.9 µg) 
when compared to the loaded amount (1000 µg) even when considering that the dialysis 
bag also binds R6G. The only thing that could be interpreted for sure was that the 
release of R6G from nanoparticles was slower when compared to free R6G, and maybe 
the thickness of the CS shell, which should act as a diffusion barrier, can affect the 
release of loaded R6G.  
The fact that the release of R6G was slower from the nanoparticles when compared to 
the free R6G seemed promising for controlled release applications, but the significance 
of the CS shell thickness could not be resolved, and therefore the loading of R6G onto 
the CS-pAA nanoparticles with different mass ratios was attempted with a different 
approach. Loading of R6G was done with three different and lower concentration levels 
of R6G that in the initial loading where the concentration levels of R6G were higher and 
also in 1:1 theoretical mass ratio to the pAA core. The R6G test concentrations used in 
the loading of CS-pAA nanoparticles (1:5, 2:5 and 1:1) were 200 µg/ml, 100 µg/ml and 
50 μg/ml as shown in Figure 15.  
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Figure 15. Loading experiments of R6G into 1:5, 2:5 and 1:1 CS-pAA nanoparticles 
revealed different stabilities of the nanoparticles: a) Test concentration 200 μg/ml 
resulted in the aggregation and precipitation of 2:5 and 1:1 CS-pAA nanoparticles, b) 
With 100 μg/ml R6G concentration only 1:1 CS-pAA nanoparticles precipitated, c) 
Loading was successful to all CS-pAA nanoparticles without precipitation at 50 μg/ml 
R6G concentration, d) Comparison of the appearance of free R6G solution with loaded 
CS-pAA nanoparticles. The fluorescence emission of R6G can be observed visually in 
the free R6G solution, whereas the loaded nanoparticles quench the fluorescence 
emission of R6G to some extent. 
At the R6G concentration of 200 µg/ml, only 1:5 particles did not precipitate, whereas 
at 100 µg/ml concentration only 1:1 particles precipitated, and at 50 μg/ml 
concentration none of the particles precipitated making the 50 μg/ml a suitable R6G 
concentration for the loading and in vitro release studies. These results indicate quite 
nicely that CS-pAA nanoparticles with different CS shell thicknesses have indeed 
different stabilities. The stabilizing effect of the negatively charged pAA core is 
weakest with the particles that have the thickest CS shell thickness, because the shell 
masks the core more effectively. Therefore, the 1:1 CS-pAA particles were the most 
difficult ones to load with R6G without precipitation, and the loading succeeded only at 
the lowest test concentration. 
The R6G concentration 50 μg/ml is tenfold smaller than the initial 0.5 mg/ml 
concentration planned for the loading and release studies of CS-pAA nanoparticles, and 
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therefore the experimental setup for the actual release studies had to be changed. The 
release medium volume was changed from 400 ml to 300 ml, and sample volumes from 
2 ml to 6 ml to ensure quantitative analysis of fluorescence intensities even from 
samples with very dilute R6G concentrations. The 6 ml samples contained in total 300 
µg of R6G, and against 300 ml release medium the maximum released amount of R6G 
from the samples into the release medium would have resulted in 1 µg/ml R6G 
concentration in the release medium. That maximum R6G concentration and also 1 % 
of the maximum concentration could have been easily analysed quantitatively.  
However, there was still the binding of R6G into the dialysis membrane that had to be 
considered. Based on the preliminary binding studies during the three hour time period, 
5.8 µg/cm
2
 and 9.3 µg/cm
2
 of R6G bound to the dialysis membrane in pH 3 and 7 
respectively. In pH 3 with 8 cm long bags this accounts for 158 µg (27.3 cm
2
x5.8 
µg/cm
2
=158 µg) R6G mass loss from the release medium. In pH 7 with 8 cm long bags 
this would have accounted for 253.9 µg (27.3 cm
2
x9.3 µg/cm
2
= 253.9 µg) R6G mass 
loss. These values are alarmingly high in relation to the 300 µg of R6G that the 6 ml 
samples contained. Nevertheless, the limit of detection for R6G was 1 ng/ml, which 
made the quantitative analysis of R6G possible even from the extremely low R6G 
concentrations in the release medium. However, the binding of R6G to the dialysis bag 
was now expected to show significantly in the release studies (see section 7.4.2).  
The loading studies of R6G were not performed at lower concentrations than the 50 
μg/ml, because the goal of this work was to develop a suitable experimental setup for in 
vitro release studies of R6G loaded CS-pAA nanoparticles by the dialysis method. A 
compromise between the sample volume and the release medium volume had to be 
made in order to ensure quantitative results and good sink conditions during the in vitro 
release studies (D'Souza and DeLuca, 2006). 
The glass weights were not used to immerse the dialysis bags in the actual release 
studies, because the dialysis bags would have been too long to immerse into 300 ml of 
the release medium and the possible adsorption of R6G onto the glass surface of 
weights would have been an additional error source. The experimental setup used in the 
actual release studies is shown in Figure 16. 500 ml glass vessels were filled with 300 
ml of the release medium, and the samples inside dialysis bags were immersed entirely 
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into the medium. Magnetic stirrers were used at a constant rate to agitate the release 
medium and the vessels were covered with lids and aluminium foil to protect the R6G 
from possible light catalysed degradation during the release studies. 
 
Figure 16. The experimental dialysis method setup used in the in vitro release studies of 
rhodamine 6G from casein-poly(acrylic acid) nanoparticles. Samples inside 100 kDa 
MWCO cellulose ester dialysis bags were immersed into dialysis medium and the 
vessel were covered with lids and aluminium foil to prevent the possible light induced 
photodegradation of rhodamine 6G. 
The 100 kDa MWCO dialysis bags (width 31mm) had to be as short as possible so that 
they would be entirely immersed in the release medium, and also to minimize the 
binding of R6G into the bags. 8-8.5 cm long bags were used in the release studies. 
There was a 0.5 cm difference in the dialysis bag lengths of some samples during the 
actual release studies in pH 3, which caused 6 % error in some of these results in 
relation to one another. This was described in more detail in the section 6.2.6. The 8.5 
cm long bags were used during the release studies in pH 7. Even though it was tested 
prior to the release studies that 8 cm length of the dialysis bag should provide a 
sufficient volume for the sample and void space after closure, it proved to be rather 
difficult to open the bag seams entirely and enclose the sample inside the bag with void 
space successfully. 
It would have also been possible to use 1 MDa MWCO cellulose ester dialysis 
membranes in the release studies, but those were not chosen. The pAA core of CS-pAA 
nanoparticles diffuses out of the core making these particles hollow at pH 7, and the 
free pAA could bind R6G in the release medium, if the pore size of the dialysis 
membrane was large enough to enable pAA chains to diffuse out of the bag. This could 
possibly affect the fluorescence measurements of R6G from the release medium, and 
therefore the 100 kDa MWCO dialysis membranes were chosen. Cellulose ester, which 
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was the material of the dialysis tubing, has minimal protein binding affinity making it 
optimal for the release studies of protein based nanoparticles. 
7.2 Particle size and surface charge  
Sizes, PDI values and ζ-potentials of GA crosslinked CS-pAA nanoparticles in aqueous 
solutions were determined by DLS and ζ-potential measurements at different synthesis 
steps (Table 9). Purification of uncrosslinked nanoparticles by dialysis at pH 3.5 
reduced PDI values of all different mass ratio nanoparticles, but the PDI values still 
indicated rather polydisperse size distributions as the values were above 0.15 (Danhier 
et al., 2009; Nidhin et al., 2008). The decrease in PDI values after the dialysis was 
expected as dialysis was performed to get rid of all nonparticulate matter. Sizes of 
dialysed uncrosslinked nanoparticles were slightly larger than prior to purification by 
dialysis. This probably reflects the effect of purification as smaller particulate matter 
was no longer present in the same amount as prior to dialysis and not highlighted in size 
measurements. However, after GA crosslinking the PDI values of 1:5 and 1:1 particles 
rose above 0.2 which implies clearly polydispersity. Slight rise in PDI values of CS-
pAA nanoparticles after the GA crosslinking may have been caused by inter-particle 
crosslinking reaction between some adjacent nanoparticles (Qazvini and Zinatloo, 
2011). The possible GA crosslinking induced inter-particle aggregation has been 
reported to cause rise in PDI values of nanoparticles. 
Rise in the PDI values when compared to the results obtained from the preliminary 
syntheses (section 7.1.1) may have been caused by the larger synthesis volumes (50 ml 
during complexation, 45 ml during crosslinking) than during the preliminary tests, 
although it was hypothesized that monodisperse particles could be synthesized up to 56 
ml reaction volumes. Based on the measured PDI values the effect of synthesis volume 
on PDI values should be examined further. The high PDI values indicate that the size 
distribution of CS-pAA nanoparticles was very wide. It might be very challenging to 
perform successful scale-up of the synthesis without proper equipment. Scale-up of the 
preparation process is crucial if the final product is to be prepared in the industrial scale. 
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Table 9. Size, PDI and ζ-potential measurements of GA crosslinked casein- poly(acrylic 
acid) nanoparticles. The average and standard deviation between four repetitions are 
presented in the table. Measurements were done for uncrosslinked particles prior to and 
after the purification by dialysis. GA crosslinked pAA templated and hollow particles 
were analysed only after the dialysis. The ζ-potential values of hollow particles were not 
determined. *Synthesis volume was 50 ml during the electrostatic complexation and 45 
ml before addition of GA crosslinker.  
Mass ratio of CS to pAA* Size (nm) PDI  Zeta potential 
(mV) 
1:5 (uncrosslinked prior to 
dialysis) 
125.3 ± 3.5 0.270 ± 0.047 -14.9 ± 6.0 
2:5 123.4 ± 8.1 0.197 ± 0.040 -16.1 ± 7.0 
1:1 131.0 ± 9.2 0.253 ± 0.143   -6.4 ± 6.5 
1:5 (uncrosslinked after 
dialysis) 
127.3 ± 0.3 0.194 ± 0.043 -26.4 ± 4.8 
2:5 128.2 ± 2.1 0.202 ± 0.007 -18.9 ± 8.3 
1:1 137.4 ± 0.2 0.182 ± 0.005 -17.1 ± 6.8 
1:5 (GA crosslinked after 
dialysis) 
119.0 ± 1.4 0.218 ± 0.017   -7.9 ± 2.4 
2:5 122.4 ± 10.4 0.168 ± 0.023 -14.7 ± 14.1 
1:1 127.9 ± 7.0 0.206 ± 0.077   -1.9 ± 1.2 
1:5 (hollow GA crosslinked) 616.4 ± 417.9 0.957 ± 0.030         n.d. 
2:5 302.7 ± 47.4 0.664 ± 0.147         n.d. 
1:1 248.7 ± 9.3 0.581 ± 0.076         n.d. 
 
Hu and colleagues have observed that it is difficult to produce monodisperse 
polyelectrolyte complex nanoparticles in bulk solution by the dropping method (also 
used in this work) due to instantaneous complex formation between oppositely charged 
polyelectrolytes that are not homogenously mixed in the aqueous phase (Hu et al., 
2002). Polymerization of acrylic acid monomers in the presence of caseins or chitosan 
has been used to synthesize CS-pAA and CH-pAA polyelectrolyte complex 
nanoparticles with monodisperse size distribution, and therefore this approach could be 
better than the use of preformed pAA templates for producing monodisperse CS-pAA 
nanoparticles (Hu et al., 2002; Liu et al., 2011). Also, microfluidic platforms have been 
proposed for large scale manufacturing of monodisperse polyelectrolyte complex 
nanoparticles and other nanoparticles (Sant et al., 2012; Shchukin et al., 2004). As the 
successful scale-up of the CS-pAA nanoparticle synthesis in bulk solution may be 
difficult, alternative approaches should be tested. In the possible future studies, 
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microfluidics could provide means to produce CS-pAA nanoparticles with very narrow 
size distribution and high reaction yield. In other words, microfluidics could enable the 
scale-up of the preparation process. 
Addition of Tris to the reaction mixture to terminate GA crosslinking may have also 
attributed to possible inter-particle bonding, and polydisperse PDI values of CS-pAA 
nanoparticles. Tris has three reactive sites capable of reacting with GA, and 
theoretically Tris could link adjacent GA molecules bound onto the surface of the CS-
pAA nanoparticles. This is however very unlikely, as the majority of GA should have 
reacted with the CS shell during the two hour period of crosslinking prior to addition of 
Tris to the reaction mixture (Habeeb and Hiramoto, 1968). Tris was not used to 
terminate crosslinking during the preliminary syntheses that produced very 
monodisperse PDI values. For therapeutic applications narrow size distribution of the 
carrier vehicles is extremely important in order to avoid variation in the release profiles 
of the loaded cargo. Different sized carriers may contain varying amounts of therapeutic 
agents and this could result in serious adverse side-effects when administered in vivo 
(Averineni et al., 2012).  
Purified uncrosslinked 1:5 and 2:5 (m/m) nanoparticles had approximately similar 
hydrodynamic diameters (127.3-128.2 nm) whereas the 1:1 (m/m) nanoparticles had 
approximately 10 nm larger hydrodynamic diameter (137.4 nm). These results support 
the idea that increasing the mass ratio of CS to pAA during the synthesis consequences 
in different CS shell thicknesses as 1:1 uncrosslinked nanoparticles had larger 
hydrodynamic diameter than 1:5 and 2:5 CS-pAA nanoparticles. GA crosslinked 
nanoparticles had smaller sizes in all mass ratios when compared to uncrosslinked 
particles. Crosslinking of the CS shell probably made the CS shell denser and reduced 
the size of these nanoparticles as it has been observed in other studies as well that the 
shell crosslinking reduces the size of nanoparticles (Liu et al., 2011; Liu et al., 2010).  
The effect of different CS shell thickness on size could also be seen more clearly after 
GA crosslinking as 1:5 particles had the smallest diameter (119 nm), 2:5 particles had 
the intermediate diameter (122.4 nm) and 1:1 particles had the largest diameter (127.9 
nm). Due to different CS shell thicknesses, encapsulated model compounds/drug 
molecules could have different release profiles from CS-pAA nanoparticles, but the 
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differences in the release profiles could also arise from varying stabilities of these 
nanoparticles, as the CS shell masks the stabilizing negatively charged pAA core. Liu 
and colleagues have reported that CS-pAA nanoparticles that were prepared in their 
study had mean hydrodynamic diameters of 360 nm and 350 nm in pH 3 before and 
after the crosslinking (Liu et al., 2010). Therefore, the CS-pAA nanoparticles prepared 
in this study were considerably smaller. This was probably attributed to the use of 
preformed pAA templates in this study as opposed to the polymerization of AA that was 
done in the study that Liu and colleagues have performed (Liu et al., 2010). 
The hollow GA crosslinked CS-pAA nanoparticles had larger sizes and PDI values than 
the intact crosslinked nanoparticles. These hollow particles were made by changing the 
pH value from 3.5 to 7, and based on the values on Table 9 it would seem that the 
hollow particles may have been partially destroyed as the PDI values were quite high. 
Especially the PDI value 0.957 of 1:5 hollow particles indicates complete instability in 
pH 7.  It would seem that hollow particles with higher CS composition were not so 
completely destroyed when the template was removed, because 1:1 hollowed out 
particles had the smallest size and PDI values when compared to 1:5 and 2:5 mass 
ratios. 
The larger size of hollow particles was most likely caused by the lack of pAA core, 
which helped the CS-pAA nanoparticles to maintain dense spherical composition by 
electrostatic attraction between CS shell and pAA core in pH 3.5 (unpublished 
observation Laaksonen, 2011). When the core was removed, the remaining GA 
crosslinked CS shell structure expanded resulting in the larger size. High PDI values 
may indicate that the degree of GA crosslinking was not sufficient enough to keep the 
crosslinked CS shell structure of hollow nanoparticles intact in pH 7, when the pAA 
core was removed.  
Biopolymers do not have as high charge density along their backbone as synthetic 
polymers, and even if the biopolymer shell of nanoparticles is crosslinked to improve 
the shell stability, the shell may still be destroyed upon core removal (Sukhorukov et al., 
2004). Higher GA crosslinking degree could be studied in the future to explore if the CS 
shell integrity upon pAA core removal in pH 7 could be enhanced. Crosslinking degree 
could be studied by sodium dodecyl sulfate polyacrylamide gel electrophoresis, which 
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separates protein fragments according to their molecular weight and has been used to 
study the crosslinking degree of proteins (Monogioudi et al., 2011; Stanic et al., 2010). 
Another and possibly better approach could be the determination of free amino groups 
present in nanoparticles after the crosslinking as GA selectively crosslinks amino 
groups of CS (Leo et al., 1997).  
High PDI values of GA crosslinked particles may have also been caused by too short 
purification time in pH 7 if the free pAA chains remained inside the dialysis bags. 
Finally, the pH of the medium is known to affect the integrity of polyelectrolyte 
complex nanoparticles as the pH affects the attractive interactions between 
polyelectrolytes (Jintapattanakit et al., 2007; Shu et al., 2009). In pH 7 CS and pAA are 
both negatively charged, which may result in charge repulsion, and in the breakdown of 
the entire complex apart from GA crosslinked CS in the shell structure (unpublished 
observation Laaksonen, 2011). The complex breakdown in pH 7 may have also caused 
the high PDI values. 
Results from ζ-potential measurements had very high standard deviation between 
repetitions and were qualitative at best due to the measurement equipment (Table 9). It 
would seem that the purification of uncrosslinked CS-pAA nanoparticles by dialysis led 
to higher ζ-potential values for all different mass ratios of CS-pAA nanoparticles 
presumably because the nonparticulate matter was absent after purification. 
Theoretically the ζ- potential values should have been lower for particles with thicker 
CS shell layers as the shell should mask the negative charge of pAA core.  
The GA crosslinking degree of the CS shell should affect the ζ-potential values as well 
(Ding et al., 2010; Elzoghby et al., 2012a). When GA reacts with amine groups of CS it 
forms stable covalent bonds with amine groups at close proximity (Habeeb and 
Hiramoto, 1968; Liu et al., 2011). This crosslink formation makes the CS shell structure 
more rigid, but also the remaining carbon backbone of glutaraldehyde could slightly 
mask the negative net surface charge caused by the negatively charged pAA core. The 
decrease in the ζ- potential values after crosslinking may have also been attributed to the 
charge neutrality of CS after the crosslinking reaction with GA, which may have led to 
masking of the net charge of entire particles (Weber et al., 2000). Unfortunately the 
results from ζ-potential measurements cannot be considered as quantitative, and the 
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actual ζ-potential values of these particles remain unresolved. It can be however stated 
that GA crosslinked CS-pAA nanoparticles had negative ζ-potential values. The ζ-
potential values of these nanoparticles could have given valuable information of their 
stability and stability differences. 
BASED was the other crosslinker used to crosslink CS shell of CS-pAA nanoparticles 
in this study. It is an arylazide and belongs to the group of photoaffinity reagents that 
are chemically inert and become reactive when exposed to visible or ultraviolet light 
(Das, 1979; Mattson, 1993). Photolyzation of arylazides at wavelengths between 300 
nm to 400 nm should not cause direct photochemical damage to proteins or nucleic 
acids, and result in the formation of a reactive aryl nitrene. The aryl nitrene is capable of 
reacting non-selectively with C-H bonds resulting in the formation of covalent bonds. 
Other possible reaction mechanisms of the aryl nitrene include addition reactions with 
double bonds, insertion into N-H bonds, and also ring expansion to react as a 
nucleophile with primary amines (Thermo Fisher Scientific Inc., 2009). Crosslinking 
with BASED is therefore possible even in the absence of any particular functional 
groups on a protein.  
BASED was selected to this work primarily due to its ability to form crosslinks non-
selectively as it has not been widely used in pharmaceutical applications. The main 
interest in this work was to compare how chemically selective crosslinking with GA 
would compare to chemically non-selective crosslinking with BASED. Suitable 
photoactivation time of BASED varies greatly depending on the light source used in the 
photoactivation (Thermo Fisher Scientific Inc., 2009). 5-30 minutes is recommended 
when using long-wave UV-light (366nm) to obtain effective crosslinking. 
Photoactivation of BASED was performed with long wave UV-light (366nm) for 15 
minutes and for 5 minutes nanodispersions on ice due to considerable heating of the 
material during 15 minutes photoactivation. 
The results of size, PDI and ζ-potential measurements of BASED crosslinked CS-pAA 
nanoparticles are in Table 10. All measurements were done after purification by 
dialysis. 15 minutes activation time resulted in overheating of the synthesis vessels and 
dispersions resulting in aggregation and colour change from transparent/opalescent 
white to light brown colour. 5 minutes photoactivation time and reaction vessels on ice 
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caused only a slight colour change of the material from transparent/opalescent white to 
light yellow producing overall better material. Interesting feature of the nanoparticles 
prepared by 5 minute photoactivation time is the almost 20 nm larger size in all CS-
pAA mass ratios when compared to the corresponding sizes of purified uncrosslinked 
CS-pAA nanoparticles.  
Table 10. Characterization of BASED crosslinked casein-poly(acrylic acid) 
nanoparticles. The average and standard deviation between three repetitions are 
presented in the table (except for hollow 15min photoactivation of BASED n=1). 
Photoactivation of BASED was performed with long wave UV-light of 366 nm and 
irradiation times of 5 and 15 minutes. Measurements were done for all BASED 
crosslinked pAA templated and hollow particles after purification by dialysis. 
*Synthesis volume was 15 ml during electrostatic complexation and before addition of 
BASED crosslinker. 
Mass ratio of CS to pAA* Size (nm) PDI Ζeta 
potential(mV) 
1:5 (5 min photoactivation of 
BASED) 149.0 ± 1.6 0.166 ± 0.008 -2.2 ± 1.5 
2:5 146.2 ± 0.7 0.179 ± 0.018 -6.9 ± 4.7 
1:1 155.4 ± 3.9 0.201 ± 0.074 -3.9 ± 2.8 
1:5 (hollow, 5min 
photoactivation of BASED) 224.4 ± 5.8 0.179 ± 0.089 n.d. 
2:5 249.5 ± 13.6 0.280 ± 0.124 n.d. 
1:1 287.5 ± 9.6 0.382 ± 0.069 n.d. 
1:5 (15 min photoactivation  
of  BASED) 149.0 ± 2.5 0.280 ± 0.051 -12.2 ± 5.1 
2:5 191.4 ± 28.2 0.628 ± 0.113   -6.7 ± 1.6 
1:1 159.6 ± 6.4 0.345 ± 0.080   -7.6 ± 1.6 
1:5 (hollow, 15min 
photoactivation of BASED) 362.8 0.702 n.d. 
2:5 1243.8 1 n.d. 
1:1 282.4 0.327 n.d. 
 
It would seem that crosslinking the CS shell with BASED increased the hydrodynamic 
diameters of these nanoparticles and this feature might be attributed to more effective 
crosslinking that with GA. BASED (MW 474.52 g/mol) is also lager and bulkier 
molecule that GA (MW 100.12 g/mol), and therefore the attachment of BASED onto 
CS-pAA nanoparticles could increase the size more than with GA. Crosslinking 
reaction of BASED is unselective, and it could be that some crosslinks are formed 
between the CS shell and pAA core resulting in better CS shell stability. The 1:1 CS-
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pAA nanoparticles had the largest hydrodynamic diameter also with BASED 
crosslinked (5min) nanoparticles as with GA crosslinked CS-pAA nanoparticles as it 
should be since the CS shell is thickest with these nanoparticles.  
The PDI values of BASED crosslinked (5min) CS-pAA nanoparticles were above 0.15, 
and therefore in the range of polydispersity, but still slightly lower than the 
corresponding values of GA crosslinked nanoparticles (Danhier et al., 2009; Nidhin et 
al., 2008). The longer photoactivation time of 15 minutes damaged the material, which 
can also be seen in significantly higher PDI values when compared to PDI values of 
particles that were prepared by the shorter photoactivation time.  
Hollow BASED crosslinked (5min) CS-pAA nanoparticles were larger in size than the 
intact particles with the core structure. As with GA crosslinked nanoparticles the rise in 
the pH value of the dispersion medium from 3.5 to 7 resulted in the removal of the pAA 
core and in the increase of the hydrodynamic diameter. It would seem that the core 
removal caused dispersions to be more polydisperse as the PDI values were higher than 
those prior to pAA template removal, but the template removal did not destroy BASED 
crosslinked (5 min) particles to the same extent as hollowing out the GA crosslinked 
particles. It could also be possible that even lower PDI values for hollow particles could 
be achieved with longer hollowing out time period in pH 7 phosphate buffer, where the 
nanodispersions were purified by dialysis. Based on these results, BASED crosslinked 
hollow nanoparticles could be more stable in pH 7 over a longer period of time than GA 
crosslinked hollow CS-pAA nanoparticles. 
When the size results of CS-pAA nanoparticles prepared by the longer 15 minutes 
photoactivation time of BASED crosslinker are compared to the size results of those 
nanoparticles that were prepared with the shorter 5 minutes photoactivation time, it can 
be noted that the longer irradiation time produced nanoparticles with almost similar 
sizes in CS to pAA mass ratios 1:5 and 2:5 as only 1:1 nanoparticles were considerably 
larger. PDI values were however considerably larger for those particles that were 
prepared by 15 minutes photoactivation, which further confirms that the material 
suffered from the longer irradiation time and overheating during synthesis. Only single 
measurements were done of the hollow particles prepared by the longer irradiation time 
as PDI values were well over 0.2 and the material was suboptimal. 
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GA crosslinked CS-pAA nanoparticles were smaller than those crosslinked with 
BASED. The size difference at hydrated state in pH 3.5 was about 30 nm with all 
different mass ratios of CS to pAA. It is difficult to compare the sizes of hollow 
particles prepared with these two different crosslinkers as the standard deviation 
between repetitions was quite wide for GA crosslinked nanoparticles. The PDI values of 
GA crosslinked hollow nanoparticles were also much higher that the corresponding 
values of BASED crosslinked hollow nanoparticles. It would seem that BASED 
crosslinked particles were more stable at pH 7, which might indicate that the 
crosslinking was more successful with BASED. Based on this study it is impossible to 
compare ζ-potential values of these nanoparticles and draw conclusions of their 
different stabilities, which would have been interesting.  
7.3 Morphology 
 
Figure 17. Diameter measurements of crosslinked dry casein-poly(acrylic acid) 
nanoparticles based on TEM micrographs (n=30 ± standard deviation). The BASED 
crosslinked nanoparticles were, with and without the poly(acrylic acid) template, larger 
than the GA crosslinked nanoparticles. The diameters of casein-poly(acrylic acid) 
nanoparticles were overall smaller in the dry state than in the hydrated state. 
TEM micrographs confirmed the spherical morphology and nanometre size scale of 
crosslinked CS-pAA nanoparticles in the dry state (Figure 17 and 18). ImageJ image 
processing program was used in the manual measurements of nanoparticle diameters 
(n=30), and the results of these measurements are presented in Figure 17. TEM imaging 
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of all GA crosslinked hollow and BASED crosslinked hollow 1:1 CS-pAA 
nanoparticles was not successful. It can be seen from Figure 17 that the BASED 
crosslinked CS-pAA nanoparticles were larger than the GA crosslinked nanoparticles, 
especially in the case of 2:5 and 1:1 CS-pAA nanoparticles. Hollow BASED 
crosslinked particles seem to be slightly larger or similarly sized when compared to the 
BASED crosslinked particles that contain the pAA core. The standard deviation of these 
measurements is high, and for accurate statistical analysis a larger sampling than the 
measurement of thirty particles should be made. The diameters of all dry CS-pAA 
nanoparticles were smaller than the corresponding values in the hydrated state measured 
by DLS (section 7.2). This phenomena is caused by the collapse of the nanoparticle 
structure as water/solvent evaporates (Molnar et al., 2009; Shu et al., 2009). 
Figure 18 contains several TEM micrographs of CS-pAA nanoparticles. GA crosslinked 
nanoparticles are in the first row (A-C) in the rising order of their CS to pAA mass 
ratios (1:5, 2:5 and 1:1). The second row contains BASED crosslinked nanoparticles 
also in the rising order of their CS to pAA mass ratios (1:5, 2:5 and 1:1). The last row 
(G-H) contains micrographs of hollow 1:5 and 2:5 CS-pAA nanoparticles that were 
crosslinked with BASED. These micrographs confirm the spherical morphology of CS-
pAA nanoparticles. The high PDI values that were measured by DLS (section 7.2) can 
be seen in all micrographs as different sized nanoparticles. Some of the nanoparticles 
existed on their own, but also clusters of aggregated or together clumped nanoparticles 
could be observed. This could indicate that inter-particle aggregation occurred during 
the synthesis, but it may also be a consequence of particle aggregation in the dry state. 
Lighter outer sphere and dark interior of nanoparticles that contained the pAA core 
confirms that these particles in fact had core-shell structure. The CS shell of hollow 
BASED crosslinked nanoparticles can be seen especially in Figure 18H, where the CS 
shell structure has been imaged successfully. 
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Figure 18. TEM micrographs of casein-poly(acrylic acid) nanoparticles. A-C) 
Glutaraldehyde crosslinked nanoparticles in 1:5/2:5/1:1 casein to poly(acrylic acid) 
mass ratios in pH 3.5. D-F) BASED crosslinked nanoparticles in 1:5/2:5/1:1 casein to 
poly(acrylic acid) mass ratios in pH 3.5. G-H) Hollow BASED crosslinked 
nanoparticles in 1:5/2:5 casein to poly(acrylic acid) mass ratios in pH 7. Casein-
poly(acrylic acid) nanoparticles have distinct spherical morphology, but also the high 
size distribution can be seen in these micrographs as nanoparticles of varying sizes. The 
hollow interior of BASED crosslinked nanoparticles in pH 7 can be seen in G and F 
micrographs. 
The use of preformed pAA templates may have attributed to the polydispersity of CS-
pAA nanoparticles, which can be observed in TEM micrographs as particles with 
varying sizes. The template cores have structural effects on the shell formation, and the 
size and shape of nanospheres/capsules can be controlled to some extent with the 
template (Moya et al., 2003; Pastoriza-Santos et al., 2001; Peyratout and Dähne, 2004; 
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Sukhorukov et al., 1998; Sukhorukov et al., 2004; Volodkin et al., 2004). Preformed 
polymer mixtures may contain also other sizes that the average molecular weight, and if 
the 100 kDa pAA template mixture used in the synthesis of CS-pAA nanoparticles 
contained several sizes, it may have resulted in the formation of nanoparticles with 
varying sizes. This could possibly explain the high PDI values of CS-pAA nanoparticles 
(section 7.2). 
Figure 19 contains a SEM micrograph of GA crosslinked 1:1 CS-pAA nanoparticles. It 
was not possible to characterize the surface structure of CS-pAA nanoparticles 
accurately with SEM imaging. Because SEM imaging was not successful, cryo-SEM 
imaging could be tried in the imaging of exterior surface morphology of CS-pAA 
nanoparticles in the future. In cryo-SEM the sample is frozen rapidly and vulnerable 
structures are usually well preserved for imaging, and therefore it would probably be 
more suitable imaging method for these samples (Klang et al., 2013; Martins et al., 
2009). 
 
Figure 19. SEM micrograph of GA crosslinked 1:1 (m/m) casein-poly(acrylic acid) 
nanoparticles. The sample was probably destroyed during the drying and coating 
process, and therefore the exterior surface could not be studied successfully.  
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7.4 Loading and release of rhodamine 6G 
7.4.1 Encapsulation efficiency of the nanoparticles 
Encapsulation efficiency and drug loading capacity are the terms that are used to 
quantitate the drug loading process (Judefeind and de Villiers, 2009). Encapsulation 
efficiency is the relation between the drug mass in nanoparticles and the drug mass in 
the formulation. Encapsulation efficiency describes the efficiency of the preparation 
method to incorporate a drug/model compound into the carriers system. The drug 
loading capacity is the relation between the drug mass in nanoparticles and the mass of 
nanoparticles. These values depend on the physicochemical properties and the 
interactions between the drug/model compound, the carrier system and the surrounding 
medium. The amount of entrapped molecules determines the performance of the drug 
delivery system since it influences the rate and extent of release from the drug carrier 
system. Encapsulation efficiency and drug loading capacity are determined in the early 
phase of formulation development to evaluate the performance of the drug delivery 
system and to compare the performance of different formulations (Han et al., 2010; Hu 
et al., 2007; Zimet et al., 2011). 
CS-pAA nanoparticles had high encapsulation efficiencies of R6G at 50 μg/ml R6G 
concentration, which was the lowest tested concentration of R6G that was successfully 
loaded into all different mass ratio CS-pAA nanoparticles without causing aggregation 
(Table 11). The encapsulation efficiencies of BASED crosslinked nanoparticles were 
slightly higher than the corresponding values of GA crosslinked nanoparticles, but 
overall the encapsulation efficiencies were very high. There was a difference of 8 % 
between the encapsulation efficiencies of BASED and GA crosslinked 1:1 (m/m) CS-
pAA nanoparticles, which may have been caused by differences in the thickness and 
rigidity of the CS shell structure. The encapsulation efficiencies of all GA crosslinked 
nanoparticles were almost similar, and therefore the R6G encapsulation efficiencies 
should not cause significant differences during the in vitro release studies of GA 
crosslinked different mass ratio CS-pAA nanoparticles.  
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Table 11. Encapsulation efficiencies of GA and BASED crosslinked CS-pAA 
nanoparticles. The average and standard deviation between four repetitions are 
presented in the table. The concentration of R6G was 50 μg/ml prior to electrostatic 
attachment of R6G into CS-pAA nanoparticles. *5 minutes UV-activation time of 
BASED. 
Nanoparticle mass 
ratio of CS to pAA 
EE (%) of GA crosslinked 
nanoparticles 
EE (%) of BASED 
crosslinked nanoparticles*  
1:5 91.1 ± 1.0 91.6 ± 0.2 
2:5 91.0 ± 1.2 95.6 ± 0.2 
1:1 86.1 ± 1.6 94.3 ± 0.2 
 
CS-pAA nanoparticles had high efficiency to incorporate R6G into the carrier system. 
The R6G was incorporated into CS-pAA nanoparticles by ionic interactions. Based on 
the encapsulation efficiency results, these nanoparticles are very effective carriers for 
positively charged hydrophilic molecules up to the concentration where the negative 
pAA core is neutralized by positively charged counter ions. Too high degree of loading 
destabilizes these nanoparticles and leads to aggregation (section 7.1.3).  
It would have been interesting to define the drug loading capacity as well, but for that 
the mass of nanoparticles would have been needed. As the synthesis yields were not 
determined, it was not possible to test the drug/model compound loading capacity at 
different R6G concentrations. In the future, more encapsulation efficiency and drug 
loading capacity studies should be performed to fully evaluate the performance of CS-
pAA nanoparticles as a drug delivery system. Furthermore, as the drug loading capacity 
is the relation between the drug mass in nanoparticles and the mass of nanoparticles, 
knowledge of R6G loading capacities of CS-pAA nanoparticles would have also 
simplified the decision making to test certain R6G concentrations during the 
encapsulation efficiency studies. 
7.4.2 Release profile of rhodamine 6G 
The in vitro release studies were conducted to assess whether different CS shell 
thicknesses of different mass ratio CS-pAA nanoparticles could control the release of a 
model compound R6G differently or not. The in vitro release studies of GA crosslinked 
R6G loaded CS-pAA nanoparticles were done with the dialysis method for 23 hours at 
pH 3 and 7. Based on the preliminary binding studies of R6G, the significant binding of 
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R6G into the dialysis bags was expected (section 7.1.3). During the 23 hour time period 
in the actual in vitro release studies, the dialysis bags did bind R6G significantly in 
relation to the experimental setup. 6.0 ± 0.2 µg/cm
2
 and 6.0 ± 0.3 µg/cm
2
 of R6G were 
lost due to binding into the dialysis bags in pH 3 and pH 7 respectively. These values 
were a bit different than the corresponding values that were gained during the 
preliminary studies, but the time period was here longer, which provided more accurate 
results of the R6G binding into the dialysis membranes. The R6G binding into the 
dialysis membranes showed in the release profiles of free and loaded R6G in both pH 
vales that were tested in this study, because the released amount of R6G was below 50 
% of the maximum in both cases (Figure 20 and Figure 21).  
 
Figure 20. The release profiles of loaded and free rhodamine 6G in pH 3 through 100 
kDa MWCO dialysis membrane bags. Up to four hours the release profiles of R6G from 
different mass ratio CS-pAA nanoparticles were rather similar. After that the 
differences in the release profiles were probably caused by stability differences. The 
CS-pAA nanoparticles did control the release of R6G, but the effect of casein shell 
thickness on the release of loaded rhodamine 6G could not be resolved. Error bars 
represent the standard deviation of three repetitions. 
Release profiles of R6G loaded different mass ratio CS-pAA nanoparticles and free 
R6G during an eight hour time period in pH 3 are in presented Figure 20. There was a 
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lag time of approximately 30 minutes present in all release profiles, which was probably 
caused by the diffusion and permeation of R6G through the dialysis membrane. The 
dialysis bag should not limit the membrane diffusion of R6G, but even the release of 
free R6G was rather slow during the experiments, which may have been caused by too 
small MWCO of the dialysis bags, but probably the affinity of R6G to bind into the 
membrane also affected the release rate (D'Souza and DeLuca, 2006). Nevertheless, the 
release of free R6G through the dialysis membrane was faster than the release of loaded 
R6G. The release profile of free R6G should be regarded as a reference.  
Up to four hours the release profiles of loaded R6G were rather similar from all 
different mass ratio CS-pAA nanoparticles in pH 3 (Figure 20). After that the R6G was 
released fastest from 2:5 nanoparticles, and second fastest from 1:1 nanoparticles. It 
would seem that the CS shell thickness may not be the major factor that influenced the 
release rate of R6G in this study. Instead these nanoparticles probably had different 
stabilities in pH 3. At the dialysis endpoint 23 hours there were some aggregates inside 
the dialysis bags at pH 3, except for 1:5 particles, which may indicate that 2:5 and 1:1 
particles in fact had some stability problems during the release studies in pH 3. As 1:5 
nanoparticles did not precipitate notably during 23 hours they might have had the best 
stability, which could explain the slowest release rate of R6G.  
The nanoparticles were prepared at pH 3.65 and the decrease in pH was only 0.65 units 
during the pH 3 release studies. Destabilizing effect of R6G loading may have been one 
cause for different release profiles in pH 3, but also the ionic strength of 0.1 M citrate 
buffer medium may have been too strong. The stability of polyelectrolyte complex 
nanoparticles strongly depends on the ionic strength and pH of the medium. Too high 
ionic strength of the medium may decrease the electrostatic interactions between two 
oppositely charged polyelectrolytes and result in complex breakdown during the in vitro 
release studies (Jintapattanakit et al., 2007; Shu et al., 2009; Ye et al., 2006). This is 
what most likely happened during the in vitro release studies in pH 3 as the differences 
in the release profiles of R6G start to show after four hours. Four hours is also the time 
point where over half of the reference free R6G was released, and therefore the ionic 
strength of the medium inside the dialysis bags must have been higher at this time point 
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than in the beginning. This in turn probably destabilized the CS-pAA nanoparticles 
effectively after four hours. 
Release profiles for eight hour time period in pH 7 are shown in Figure 21. The release 
of free R6G through dialysis bags was faster than the release of loaded R6G also in pH 
7. It would seem that 1:5 nanoparticles degraded as the release profile of R6G from 
those particles was rather similar to the reference release profile of free R6G. The 
stability of CS shell upon pAA core removal may have also been lowest for 1:5 GA 
crosslinked CS-pAA nanoparticles as the PDI values of hollow 1:5 GA crosslinked 
nanoparticles in pH 7 were very high, which also suggests that these particles were 
completely unstable in pH 7 (section 7.2). R6G release from 2:5 and 1:1 nanoparticles 
was almost similar up to 4 hours after which the release of R6G was just slightly faster 
from 1:1 nanoparticles.  
 
Figure 21. The release profiles of loaded and free R6G in pH 7 through 100 kDa 
MWCO dialysis membrane bags. It would seem that 1:5 particles degraded in pH 7, 
because their release profile was rather similar than the release profile of reference free 
R6G. Up to four hours the release profiles of R6G from 2:5 and 1:1 CS-pAA 
nanoparticles were rather similar after which R6G was released from 1:1 nanoparticles 
slightly faster. Error bars represent the standard deviation of three repetitions. 
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Electrostatic binding of R6G into 2:5 nanoparticles may have been more effective than 
into 1:1 nanoparticles, which could explain the slower release of R6G from 2:5 
nanoparticles in pH 7. The free pAA chains inside the dialysis bags probably also 
affected the release profiles of loaded R6G in pH 7, because it seems that the overall 
release of R6G from CS-pAA nanoparticles was lesser than in pH 3. 2:5 nanoparticles 
have thinner CS shell and the pAA core might come out faster and bind R6G inside the 
dialysis bag, whereas the thicker CS shell of 1:1 nanoparticles could provide enough 
time for R6G to diffuse out of the dialysis bag without so much interaction with the free 
pAA chains inside the dialysis bags. 
The results from the in vitro release studies were not easy to interpret. It seem strange 
that R6G release from 1:1 nanoparticles had the intermediate release rate in both pH 
values 3 and 7, whereas the R6G release from 1:5 nanoparticles was slowest in pH 3 
and fastest in pH 7, and the release of R6G from 2:5 nanoparticles was just the opposite 
than from 1:5 nanoparticles. The differences in the release profiles of R6G from CS-
pAA nanoparticles were most likely caused by stability differences in pH 3 and integrity 
of the CS shell in pH 7. There may have also been CS micelles present in 1:1 CS-pAA 
nanodispersions as the CS concentration in the synthesis of 1:1 CS-pAA nanoparticles 
was higher than in the syntheses of 1:5 and 2:5 CS-pAA nanoparticles.  
The CMC of whole CS micelles is 1 mg/ml and for β-CS micelles 0.5 - 2 mg/ml 
(Esmaili et al., 2011; Portnaya et al., 2006). The final concentration of CS in the 
synthesis of 1:1 CS-pAA nanoparticles was 0.5 mg/ml, which has also been proposed as 
the CMC for β-CS micelles (Portnaya et al., 2006). Therefore, it is possible that some 
CS micelles were present in the 1:1 CS-pAA nanodispersions even though the slow 
addition of CS to pAA during the synthesis should have resulted in polyelectrolyte 
complex formation instead of CS micelle formation. The CS micelles have been used as 
carriers for hydrophobic drugs, and as R6G contains a phenyl ring (hydrophobic 
structure) it is possible that the R6G release profiles from 1:1 CS-pAA nanoparticles 
were affected by encapsulation of R6G into CS micelles (Shapira et al., 2010a; Shapira 
et al., 2010b; Shapira et al., 2010c). This could explain the intermediate release rate of 
R6G from 1:1 CS-pAA nanoparticles in both pH values 3 and 7 when compared to the 
R6G release rates from the other CS-pAA mass ratio nanoparticles. 
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Overall the result from the in vitro release studies seem to support the hypothesis that it 
would be possible to achieve controlled release of encapsulated compounds from CS-
pAA nanoparticles with optimal surface modification as the R6G release from CS-pAA 
nanoparticles was slower that the release of free R6G in both pH values. The CS shell 
structure of CS-pAA nanoparticles may have therefore controlled the release rate of 
R6G at least to some extent. This hypothesis is further supported by the study that Liu 
and colleagues have made as they managed to control the release rate of cisplatin from 
CS-pAA nanoparticles by modifying the surface barrier properties of CS-pAA 
nanoparticles (Liu et al., 2010).  
However, the results from in vitro release studies by the dialysis method may not 
present accurately the effect of CS shell thickness on the release rate of loaded R6G, 
because of the underlying partitioning of R6G between the nanoparticles and the 
aqueous phase (non-sink phase) inside the dialysis bags as well as the partitioning of 
R6G between the inner aqueous phase and the dialysis bag and the outer sink phase 
(Washington, 1989). These partition mechanisms of R6G may have obscured the real 
release rate of R6G from the CS-pAA nanoparticles entirely. Further work should be 
made to develop a more accurate method for in vitro release studies of CS-pAA 
nanoparticles. Significant binding of the model compound R6G into the dialysis bags 
may rule out the use of dialysis method entirely, because it can be a significant source 
of error (Kinget et al., 1979). Also due to high binding affinity of R6G into the dialysis 
bags, it was rather challenging to interpret the results from the in vitro release studies, 
because the binding of R6G into the dialysis bags may have obscured the real release 
rate of R6G. 
In the future, other methods, such as sample and separate, could be tested to see whether 
the results of in vitro release studies differ from the ones that were obtained with the 
dialysis method (Lecaroz et al., 2006; Leo et al., 2006; Pfeifer, 2005; Shekunov et al., 
2006). Sample and separate method does not contain a membrane so the binding of R6G 
into a membrane would not cause a rate-limiting release step, but as the nanoparticles 
are separated by centrifugation from the aqueous phase in the sample and separate 
method, the sample concentrating during the centrifugation could be an error source. 
97 
 
  
Possibly the dialysis method could be further tested with a model compound that does 
not have as high binding affinity to the cellulose ester dialysis membrane as R6G. 
It would have also been interesting to see if the release rates of R6G would have been 
different from the BASED crosslinked CS-pAA nanoparticles. Based on the size and 
PDI measurements of BASED crosslinked CS-pAA nanoparticles (section 7.2), these 
particles seemed to be more stable especially in pH 7, and it would have been 
interesting to see how this would have been reflected in the release profiles of loaded 
R6G. These studies could be conducted in the future. 
Crosslinking can be used to stabilize CS-pAA nanoparticles as well as to reduce the 
allergenicity of the CS shell (Liu et al., 2010; Stanic et al., 2010). The CS shell of these 
nanoparticles should improve biocompatibility, whereas the pAA core can be used as a 
reservoir for hydrophilic drugs. CS-pAA nanoparticles have been shown to exhibit very 
low toxicity, and therefore they are suitable carriers for pharmaceutical applications as 
low toxicity of the carrier system is extremely important (Liu et al., 2011).  
It should be possible to affect the degradation rate of the CS shell and the consequent 
drug release in the gastrointestinal tract by varying the crosslinking degree as it has 
been shown in several studies that it is possible to affect the drug release rate from 
nanoparticles by varying the degree of crosslinking (Bayomi and El-Sayed, 1994; 
Elzoghby et al., 2012a; Monogioudi et al., 2011). This could be utilized in the design of 
site specific controlled release properties for CS-pAA nanoparticles in the 
gastrointestinal tract. Potentially it could be possible to target either stomach or the 
intestine by varying the crosslinking degree of the CS shell as the degradation rate of 
the shell also affects the consequent release rate of encapsulated cargo. Furthermore, 
pAA has the ability to inhibit digestive enzymes in the gastrointestinal tract and protect 
encapsulated peptides from degradation (Bai et al., 1996;  Park and Robinson, 1987;  
Perera et al., 2009). Also, the mucoadhesive properties of pAA could be used to 
promote the absorption of peptide and protein drugs.  
To conclude, engineering the surface of CS-pAA nanoparticles with different 
crosslinkers should provide protection against digestive enzymes and diffusion barrier 
to encapsulated compounds. Also other crosslinkers besides GA and BASED, such as 
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the less toxic genipin, could be tested in the future (Elzoghby et al., 2012a). The surface 
modification should optimally result in controlled release of encapsulated compounds. 
Due to above reasons, CS-pAA nanoparticles could be potential new colloidal carriers 
(nanocapsules) for oral delivery and controlled release of sensitive peptide and protein 
drugs. Therefore, the development of CS-pAA nanoparticles is of great interest. 
7.5 Stability studies 
Stability studies were made only for GA crosslinked CS-pAA nanoparticles. Size and 
PDI measurements were done at days 1, 14 and 28 after the syntheses. Measurements 
were not made after 28 days as CS-pAA nanoparticle dispersions did not contain 
preservatives or antimicrobial agents. The microbiological contamination is inevitable, 
and visual growth of mould was observed in over 56 days old samples. The 
microbiological contamination most likely happens in a matter of days, but size and PDI 
measurements still give information of the physical stability of these nanodispersions. 
 
Figure 22. The effect of time on the sizes of glutaraldehyde crosslinked casein-
poly(acrylic acid) nanoparticles. The size of all of these nanoparticles remained rather 
similar during the 28 day period. The measurements were done at day 1, 14 and 28 after 
the syntheses and purification by dialysis. It was impossible to make any conclusions of 
the stability of tested 1:5, 2:5 and 1:1 (m/m) CS-pAA nanoparticles based on these size 
measurements. Error bars represent the standard deviation of three repetitions. 
The size of all different CS-pAA nanoparticles remained approximately the same in 28 
days span, and no dramatic changes in the size of GA crosslinked nanoparticles were 
0.0
20.0
40.0
60.0
80.0
100.0
120.0
140.0
160.0
Day 1 Day 14 Day 28
S
iz
e 
(n
m
) 
Stability study - size 
CS:pAA=1:5 CS:pAA=2:5 CS:pAA=1:1
99 
 
  
observed (Figure 22). An increase in size would have indicated aggregation, but due to 
lack of increase in size these nanoparticles seemed to be rather stable. However, the fact 
that there were no dramatic changes in the size does not necessarily correlate with good 
physical stability.  
The PDI values of all CS-pAA nanoparticle dispersions rose gradually as the time 
passed, making rather monodisperse nanodispersions polydisperse (Figure 23). This 
probably tells more about the physical stability of these nanodispersions than the results 
from size measurements. Up to 14 days after the synthesis the PDI values of 2:5 and 1:1 
CS-pAA nanoparticles were still below 0.15 and therefore these nanodispersions were 
monodisperse up to 14 days (Danhier et al., 2009; Nidhin et al., 2008). 2:5 and 1:1 CS-
pAA nanoparticles had overall lower PDI values than 1:5 nanoparticles during the 
stability studies. The 1:5 CS-pAA nanoparticles seemed to be the most unstable based 
on the biggest rise in PDI values from 0.148 in day 1 to 0.242 in day 28. This was rather 
surprising as 1:5 particles should theoretically have the highest ζ-potential values, and 
therefore the best stability (Leroueil-Le Verger et al., 1998). 
 
Figure 23. The effect of time on the PDI values of glutaraldehyde crosslinked casein-
poly(acrylic acid) nanoparticles. The PDI values of all different mass ratio CS-pAA 
nanoparticles rose gradually during 28 days period of time. It would seem that the 1:5 
nanoparticles were the most unstable ones as the rise in the PDI values was greatest. 
Surprisingly the 1:1 CS-pAA nanoparticles seemed to be the most stable ones as the rise 
in the PDI values was smallest. Error bars represent the standard deviation of three 
repetitions. 
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The size of 1:5 nanoparticles did not increase significantly, but the rise in PDI values 
could indicate that these particles either started to break down or aggregate or both, 
which could indicate stability problems or inadequate crosslinking degree of the CS 
shell (Sukhorukov et al., 1998; Qazvini and Zinatloo, 2011). The 2:5 nanoparticles had 
rather low PDI values of 0.106 at day 1 and 0.164 at day 28 and therefore 2:5 
nanoparticles should remain rather monodisperse during the 28 days period. The 1:1 
nanoparticles had the lowest PDI values at all measured time points from 0.097 at day 1 
to 0.145 at day 28, and the rise in PDI values was also the smallest. This could mean 
that GA crosslinked CS-pAA nanoparticles with 1:1 mass ratio were the most stable 
ones over the 28 day period, which is rather surprising considering that these 
nanoparticles should have the lowest ζ-potential values. Maybe this was attributed to the 
thickest CS shell layer of 1:1 nanoparticles, which may have contained the nanoparticles 
most effectively intact and prevented the possible breakdown.  
Based on the results from the stability studies, 14 days could be recommended as the 
upper time limit for stable CS-pAA nanodispersions without aggregation in the case of 
2:5 and 1:1 CS-pAA nanoparticles. 1:5 CS-pAA nanoparticles may be stable in aqueous 
solutions over a shorter time period than 14 days. Still, it would be advisable to perform 
more stability studies in the future as the syntheses that were used to prepare the 
samples for the stability studies were smaller than the syntheses that were used to 
prepare the samples for the in vitro release studies. Small synthesis volumes (10-25 ml) 
did produce less polydispersed material than the larger (45-50 ml) synthesis volumes 
(section 7.2), and therefore the results from the stability studies in terms of the stability 
of CS-pAA nanoparticles may have been too promising. It would have also been 
interesting to know how the stability of BASED crosslinked CS-pAA nanoparticles 
would have compared to the stability of GA crosslinked nanoparticles, and perhaps this 
could be assessed in the future. 
The stability of CS-pAA nanoparticles could possibly be enhanced in the future by 
drying the material as powdered dosage forms are known to have better stability than 
the aqueous dosage forms. Recently two studies have shown the ability of CS to 
perform as a stabilizing agent during drying process, which could be highly beneficial 
during the drying of CS-pAA nanoparticles (Bachar et al., 2012; Elzoghby et al., 
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2012a). The loading of positively charged molecules onto the pAA core also affects the 
stability of these nanoparticles as electrostatic forces are the only stabilizing factor for 
CS-pAA nanoparticles. Steric stabilization could increase the stability of CS-pAA 
nanoparticles even after the loading of positively charged molecules onto the pAA core 
decreases the ζ-potential values of these nanoparticles (Danhier et al., 2009; Shenoy and 
Amiji, 2005). It would be useful to know if the PDI values of loaded CS-pAA 
nanoparticles change over a course of time. This could also be studied in the future.  
8. SUMMARY AND CONCLUSIONS 
The key results of this study were that the surface modification of casein-poly(acrylic 
acid) (CS-pAA) nanoparticles, by varying the CS shell thickness and the crosslinker, 
affects the diameter of CS-pAA nanoparticles. Furthermore, the results from in vitro 
release studies of a model compound rhodamine 6G (R6G) from CS-pAA nanoparticles 
suggest that it may be possible to achieve controlled release of encapsulated compounds 
from CS-pAA nanoparticles with optimal surface modification in the future.  
CS-pAA polyelectrolyte complex nanoparticles were synthesized in 1:5, 2:5 and 1:1 
mass ratios of CS to pAA. The CS shell of the nanoparticles was crosslinked with two 
different crosslinkers, chemically selective glutaraldehyde (GA) and chemically non-
selective bis[2-(4-azidosalicylamido)ethyl]disulfide (BASED). Dynamic light scattering 
measurements confirmed that the diameters of CS-pAA nanoparticles were in the 
nanometre scale at the hydrated state, but the size distributions were wide. TEM 
imaging was used to confirm the spherical morphology of CS-pAA nanoparticles. In the 
dry state the measured diameters of CS-pAA nanoparticles were slightly smaller than 
the corresponding values in the hydrated state as expected. The high PDI values of CS-
pAA nanoparticles could be observed in TEM micrographs as nanoparticles of varying 
sizes. The effect of synthesis volumes on PDI values should be examined further. 
However, the successful scale-up of the syntheses in bulk solutions may be rather 
difficult, and therefore alternative synthesis approaches should be tested in the future. 
The diameters of CS-pAA nanoparticles rose in accordance with the thickness of the CS 
shell layer in pH 3.5. Crosslinking with GA reduced the size of CS-pAA nanoparticles, 
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whereas crosslinking with BASED had an opposite effect as the sizes of CS-pAA 
nanoparticles increased. These size differences were probably attributed to the size 
differences of the crosslinker molecules as BASED is a bulkier molecule than GA. The 
hollow crosslinked CS-pAA nanoparticles in pH 7 had larger sizes and even higher PDI 
values than the intact crosslinked nanoparticles. GA crosslinked CS-pAA nanoparticles 
were probably destroyed upon the pAA core removal in pH 7 as the PDI values for 
these particles were very high. BASED crosslinked nanoparticles seemed to be more 
stable in pH 7 as the PDI values were smaller than the corresponding values for GA 
crosslinked hollow CS-pAA nanoparticles. This may indicate that the crosslinking was 
more successful with BASED than with GA.  
Results from ζ-potential measurements had very high standard deviation between 
repetitions, and were qualitative at best due to the measurement equipment. 
Theoretically the ζ- potential values should have been lower for particles with thicker 
CS shell layers as the CS shell should mask the negative charge of the pAA core. The 
crosslinking degree of the CS shell should also affect the ζ-potential values. 
Unfortunately the results from ζ-potential measurements could not be considered as 
quantitative, and the actual ζ-potential values of CS-pAA nanoparticles remain 
unresolved. The ζ-potential values of uncrosslinked and crosslinked CS-pAA 
nanoparticles should be characterized in the future to gain information about the 
physical stability and stability differences of CS-pAA nanoparticles. 
The in vitro release studies were performed by the dialysis method in pH 3 and 7 with 
the GA crosslinked CS-pAA nanoparticles to test whether different CS shell thicknesses 
on the surface of CS-pAA nanoparticles control the release rate of R6G differently or 
not. The dialysis method was easy to perform, but the significant binding of R6G to the 
dialysis membranes probably distorted the release profiles of R6G. The release rate of 
R6G was slower from the nanoparticles when compared to the release rate of reference 
free R6G, but the effect of CS shell thickness on the release of loaded R6G remained 
partially unclear. The differences in the release profiles of R6G from CS-pAA 
nanoparticles were most likely caused by stability differences in pH 3 and integrity of 
the CS shell in pH 7. In the future, the in vitro release studies should be performed with 
another method or with a model compound that does not bind significantly to the 
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dialysis membranes. Also, the in vitro release studies could be performed with BASED 
crosslinked CS-pAA nanoparticles that seemed to be more stable in pH 7. 
All in all, modifying the surface of CS-pAA nanoparticles with different crosslinkers 
should alter the barrier properties of the CS shell, which should optimally provide 
controlled release of encapsulated compounds. In the in vivo environment the shell 
crosslinking should also provide protection against digestive enzymes. The CS shell of 
these nanoparticles should improve biocompatibility and enable tuning of the surface 
barrier properties by crosslinking, whereas the pAA core could be used as a reservoir 
for hydrophilic drugs. The development of CS-pAA nanoparticles is of great interest, 
because CS-pAA nanoparticles could be potential new colloidal carriers (nanocapsules) 
for oral delivery and controlled release of sensitive peptide and protein drugs. There is 
still a lot of work that has to be done to fully characterise CS-pAA nanoparticles and 
optimize the synthesis conditions, but the CS-pAA nanoparticles could be in fact 
promising novel nanosized drug carriers for pharmaceutical controlled delivery 
applications. 
9. REFERENCES 
Abdel-Mottaleb, M.M.A., Lamprecht, A., 2011. Standardized in vitro drug release test 
for colloidal drug carriers using modified USP dissolution apparatus I. Drug Dev. Ind. 
Pharm. 37, 178-184.  
Abu Diak, O., Bani-Jaber, A., Amro, B., Jones, D., Andrews, G.P., 2007. The 
manufacture and characterization of casein films as novel tablet coatings. Food Bioprod. 
Process. 85, 284-290.  
Anal, A.K., Tobiassen, A., Flanagan, J., Singh, H., 2008. Preparation and 
characterization of nanoparticles formed by chitosan–caseinate interactions. Colloids 
Surf. B Biointerfaces 64, 104-110.  
Averineni, R.K., Shavi, G.V., Gurram, A.K., Deshpande, P.B., Arumugam, K., 
Maliyakkal, N., Meka, S.R., Nayanabhirama, U., 2012. PLGA 50: 50 nanoparticles of 
paclitaxel: Development, in vitro anti-tumor activity in BT-549 cells and in vivo 
evaluation. Bull. Mater. Sci. 35, 319.  
Baalousha, M., Lead, J., 2012. Rationalizing Nanomaterial Sizes Measured by Atomic 
Force Microscopy, Flow Field-Flow Fractionation, and Dynamic Light Scattering: 
Sample Preparation, Polydispersity, and Particle Structure. Environ. Sci. Technol. 46, 
6134-6142.  
104 
 
  
Bachar, M., Mandelbaum, A., Portnaya, I., Perlstein, H., Even-Chen, S., Barenholz, Y., 
Danino, D., 2012. Development and characterization of a novel drug nanocarrier for 
oral delivery, based on self-assembled beta-casein micelles. J. Controlled Release 160, 
164-171.  
Baer, D.R., Gaspar, D.J., Nachimuthu, P., Techane, S.D., Castner, D.G., 2010. 
Application of surface chemical analysis tools for characterization of nanoparticles. 
Anal. Bioanalytical Chem. 396, 983-1002.  
Bai, J.P.F., Chang, L., Guo, J., 1996. Effects of polyacrylic polymers on the degradation 
of insulin and peptide drugs by chymotrypsin and trypsin. J. Pharm. Pharmacol. 48, 17-
21.  
Batist, G., Barton, J., Chaikin, P., Swenson, C., Welles, L., 2002. Myocet (liposome-
encapsulated doxorubicin citrate): a new approach in breast cancer therapy. Expert 
Opin. Pharmacother. 3, 1739-1751.  
Bayomi, M., El-Sayed, Y., 1994. Casein microbeads as a controlled parenteral drug 
delivery system. Drug Dev. Ind. Pharm. 20, 2607-2617.  
Bender, A.R., Von Briesen, H., Kreuter, J., Duncan, I.B., Rubsamen-Waigmann, H., 
1996. Efficiency of nanoparticles as a carrier system for antiviral agents in human 
immunodeficiency virus-infected human monocytes/macrophages in vitro. Antimicrob. 
Agents Chemother. 40, 1467-1471.  
Betancourt, T., Doiron, A., Homan, K.A., Brannon-Peppas, L., 2009a. Controlled 
Release and Nanotechnology, in: De Villiers, M.M., Aramwit, P., Kwon, G.S. (Eds.), 
Nanotechnology in drug delivery, first ed. Springer, New York, pp. 283-312. 
Betancourt, T., Shah, K., Brannon-Peppas, L., 2009b. Rhodamine-loaded poly (lactic-
co-glycolic acid) nanoparticles for investigation of in vitro interactions with breast 
cancer cells. J. Mater. Sci. Mater. Med. 20, 387-395.  
Bilati, U., Allémann, E., Doelker, E., 2005. Development of a nanoprecipitation method 
intended for the entrapment of hydrophilic drugs into nanoparticles. Eur. J. Pharm. Sci. 
24, 67-75.  
Bingham, E.W., 1971. Influence of Temperature and pH on the Solubility of αs1-, β- and 
κ-Casein. J. Dairy Sci. 54, 1077-1080.  
Bovier, P.A., 2008. Epaxal®: a virosomal vaccine to prevent hepatitis A infection. 
Expert Rev. Vaccines 7, 1141-1150.  
Bulgarelli, E., Forni, F., Bernabei, M.T., 2000. Effect of matrix composition and 
process conditions on casein–gelatin beads floating properties. Int. J. Pharm. 198, 157-
165.  
Caruso, F., Caruso, R.A., Möhwald, H., 1998. Nanoengineering of inorganic and hybrid 
hollow spheres by colloidal templating. Science 282, 1111-1114.  
105 
 
  
Charalampopoulos, N., Avgoustakis, K., Kontoyannis, C.G., 2003. Differential pulse 
polarography: a suitable technique for monitoring drug release from polymeric 
nanoparticle dispersions. Anal. Chim. Acta 491, 57-62.  
Chaturvedi, K., Ganguly, K., Nadagouda, M.N., Aminabhavi, T.M., 2013. Polymeric 
hydrogels for oral insulin delivery. J. Controlled Release. 165, 129-138. 
Chen, Y., Willmott, N., Anderson, J., Florence, A., 1987. Comparison of albumin and 
casein microspheres as a carrier for doxorubicin. J. Pharm. Pharmacol. 39, 978-985.  
Chiang, T.L., Wang, Y.C., Ding, W.H., 2011. Trace Determination of Rhodamine B and 
Rhodamine 6G Dyes in Aqueous Samples by Solid-phase Extraction and High-
performance Liquid Chromatography Coupled with Fluorescence Detection. J. Chin. 
Chem. Soc. 59, 1.  
Chorny, M., Fishbein, I., Danenberg, H.D., Golomb, G., 2002. Study of the drug release 
mechanism from tyrphostin AG-1295-loaded nanospheres by in situ and external sink 
methods. J. Controlled Release 83, 401-414.  
Cooper, C.L., Dubin, P.L., Kayitmazer, A.B., Turksen, S., 2005. Polyelectrolyte–protein 
complexes. Curr. Opin. Colloid Interface Sci. 10, 52-78.  
Danhier, F., Lecouturier, N., Vroman, B., Jérôme, C., Marchand-Brynaert, J., Feron, O., 
Préat, V., 2009. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: In vitro and in 
vivo evaluation. J. Controlled Release 133, 11-17.  
Das, M., 1979. Chemical cross-linking in biology. Annu. Rev. Biophys. Bioeng. 8, 165.  
De Geest, B.G., Jonas, A.M., Demeester, J., De Smedt, S.C., 2006. Glucose-responsive 
polyelectrolyte capsules. Langmuir 22, 5070-5074.  
De Geest, B.G., Sanders, N.N., Sukhorukov, G.B., Demeester, J., De Smedt, S.C., 2007. 
Release mechanisms for polyelectrolyte capsules. Chem. Soc. Rev. 36, 636-649.  
De Jong, W.H., Borm, P.J.A., 2008. Drug delivery and nanoparticles: applications and 
hazards. Int. J. Nanomedicine 3, 133.  
De Kruif, C.G., Weinbreck, F., de Vries, R., 2004. Complex coacervation of proteins 
and anionic polysaccharides. Curr. Opin. Colloid Interface Sci. 9, 340-349. 
Decher, G., 1997. Fuzzy Nanoassemblies: Toward Layered Polymeric Multicomposites. 
Science 277, 1232-1237.  
Delgado, A.V., Gonzalez-Caballero, F., Hunter, R., Koopal, L., Lyklema, J., 2007. 
Measurement and interpretation of electrokinetic phenomena. J. Colloid Interface Sci. 
309, 194-224.  
Delie, F., Blanco-Príeto, M.J., 2005. Polymeric particulates to improve oral 
bioavailability of peptide drugs. Molecules 10, 65-80.  
Delie, F., 1998. Evaluation of nano- and microparticle uptake by the gastrointestinal 
tract. Adv. Drug Deliv. Rev. 34, 221-233.  
106 
 
  
Derjaguin, B.V., Landau, L., 1941. Acta Physicochimica (USSR) 14, 633  
des Rieux, A., Fievez, V., Garinot, M., Schneider, Y.J.,  r at, V., 2006.  anoparticles 
as potential oral delivery systems of proteins and vaccines: A mechanistic approach. J. 
Controlled Release 116, 1-27.   
Ding, Y., Bian, X., Yao, W., Li, R., Ding, D., Hu, Y., Jiang, X., Hu, Y., 2010. Surface-
potential-regulated transmembrane and cytotoxicity of chitosan/gold hybrid 
nanospheres. ACS Appl. Mater. Interfaces 2, 1456-1465.  
Docena, G., Fernandez, R., Chirdo, F., Fossati, C., 1996. Identification of casein as the 
major allergenic and antigenic protein of cow's milk. Allergy 51, 412-416.  
Doiron, A.L., Homan, K.A., Emelianov, S., Brannon-Peppas, L., 2009. Poly(Lactic-co-
Glycolic) Acid as a Carrier for Imaging Contrast Agents. Pharm. Res. 26, 674-682.  
Donath, E., Sukhorukov, G.B., Caruso, F., Davis, S.A., Möhwald, H., 1998. Novel 
Hollow Polymer Shells by Colloid-Templated Assembly of Polyelectrolytes. Angew. 
Chem. Int. Ed. 37, 2201-2205.  
D'Souza, S.S., DeLuca, P.P., 2006. Methods to assess in vitro drug release from 
injectable polymeric particulate systems. Pharm. Res. 23, 460-474.  
El Samaligy, M.S., Rohdewald, P., 1983. Reconstituted collagen nanoparticles, a novel 
drug carrier delivery system. J. Pharm. Pharmacol. 35, 537-539.  
Elzoghby, A.O., Samy, W.M., Elgindy, N.A., 2012a. Novel Spray-Dried Genipin-
Crosslinked Casein Nanoparticles for Prolonged Release of Alfuzosin Hydrochloride. 
Pharm. Res., 1-11.  
Elzoghby, A.O., Samy, W.M., Elgindy, N.A., 2012b. Protein-based nanocarriers as 
promising drug and gene delivery systems. J. Controlled Release 161, 38-49. 
Elzoghby, A.O., El-Fotoh, W.S.A., Elgindy, N.A., 2011. Casein-based formulations as 
promising controlled release drug delivery systems. J. Controlled Release 153, 206-216.  
Esmaili, M., Ghaffari, S.M., Moosavi-Movahedi, Z., Atri, M.S., Sharifizadeh, A., 
Farhadi, M., Yousefi, R., Chobert, J.M., Haertlé, T., Moosavi-Movahedi, A.A., 2011. 
Beta casein-micelle as a nano vehicle for solubility enhancement of curcumin; food 
industry application. LWT - Food Science and Technology 44, 2166-2172.  
Ezpeleta, I., Irache, J.M., Stainmesse, S., Chabenat, C., Gueguen, J., Popineau, Y., 
Orecchioni, A.-., 1996. Gliadin nanoparticles for the controlled release of all-trans-
retinoic acid. Int. J. Pharm. 131, 191-200.  
Gaber, N.N., Darwis, Y., Peh, K.K., Tan, Y.T.F., 2006. Characterization of polymeric 
micelles for pulmonary delivery of beclomethasone dipropionate. J. Nanosci. 
Nanotechnol. 6, 9-10.  
Gaur, U., Sahoo, S.K., De, T.K., Ghosh, P.C., Maitra, A., Ghosh, P.K., 2000. 
Biodistribution of fluoresceinated dextran using novel nanoparticles evading 
reticuloendothelial system. Int. J. Pharm. 202, 1-10.  
107 
 
  
Gunasekaran, S., Ko, S., Xiao, L., 2007. Use of whey proteins for encapsulation and 
controlled delivery applications. J. Food Eng. 83, 31-40.  
Guo, M., Fox, P.F., Flynn, A., Mahammad, K.S., 1989. Heat-induced changes in 
sodium caseinate. J. Dairy Res. 56, 503-512.  
Habeeb, A., Hiramoto, R., 1968. Reaction of proteins with glutaraldehyde. Arch. 
Biochem. Biophys. 126, 16-26.  
Haham, M., Ish-Shalom, S., Nodelman, M., Duek, I., Segal, E., Kustanovich, M., 
Livney, Y.D., 2012. Stability and bioavailability of vitamin D nanoencapsulated in 
casein micelles. Food Funct. 3, 737-744.  
Hamley, I.W., 2007. Experimental Techniques for Investigating Soft Matter, in: Hamley 
I.W. (Ed.), Introduction to Soft Matter: Synthetic and Biological Self-Assembling 
Materials, second edition. John Wiley & Sons, Chichester, pp. 19-33. 
Han,  ., Shchukin, D.,  ang,  ., Simon, C.R.,  uchs, H., M hwald, H., 2010. 
Biocompatible protein nanocontainers for controlled drugs release. ACS Nano 4, 2838-
2844.  
Harada, A., Kataoka, K., 1995. Formation of polyion complex micelles in an aqueous 
milieu from a pair of oppositely-charged block copolymers with poly (ethylene glycol) 
segments. Macromolecules 28, 5294-5299.  
Haskell, J.R. 2006. Physical Characterization of Nanoparticles, in: Gupta, R.B., 
Kompella, U.B. (Eds.), Nanoparticle Technology for Drug Delivery, first edition. 
Taylor & Francis, New York, pp.103-132. 
He, C., Hu, Y., Yin, L., Tang, C., Yin, C., 2010. Effects of particle size and surface 
charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 
31, 3657-3666.  
He, W., Tan, Y., Tian, Z., Chen, L., Hu, F., Wu, W., 2011. Food protein-stabilized 
nanoemulsions as potential delivery systems for poorly water-soluble drugs: 
preparation, in vitro characterization, and pharmacokinetics in rats. Int. J. Nanomedicine 
6, 521-533.  
Heng, D., Cutler, D.J., Chan, H.K., Yun, J., Raper, J.A., 2008. What is a suitable 
dissolution method for drug nanoparticles? Pharm. Res. 25, 1696-1701.  
Herrero-Vanrell, R., Rincón, A.C., Alonso, M., Reboto, V., Molina-Martinez, I.T., 
Rodríguez-Cabello, J.C., 2005. Self-assembled particles of an elastin-like polymer as 
vehicles for controlled drug release. J. Controlled Release 102, 113-122.  
Holt, C., Sawyer, L., 1993. Caseins as rheomorphic proteins: interpretation of primary 
and secondary structures of the αS1-, β-and κ-caseins. J. Chem. Soc. Faraday Trans. 89, 
2683-2692.  
Hoo, C.M., Starostin, N., West, P., Mecartney, M.L., 2008. A comparison of atomic 
force microscopy (AFM) and dynamic light scattering (DLS) methods to characterize 
nanoparticle size distributions. J. Nanopart. Res. 10, 89-96.  
108 
 
  
Horne, D., 2002. Casein structure, self-assembly and gelation. Curr. Opin. Colloid 
Interface Sci. 7, 456-461.  
Hu, Y., Jiang, X., Ding, Y., Chen, Q., Yang, C., 2004. Core‐Template‐Free Strategy for 
Preparing Hollow Nanospheres. Adv. Mater. 16, 933-937.  
Hu, Y., Jiang, X., Ding, Y., Ge, H., Yuan, Y., Yang, C., 2002. Synthesis and 
characterization of chitosan-poly (acrylic acid) nanoparticles. Biomaterials 23, 3193-
3201.  
Hu, Y., Ding, Y., Ding, D., Sun, M., Zhang, L., Jiang, X., Yang, C., 2007. Hollow 
chitosan/poly(acrylic acid) nanospheres as drug carriers. Biomacromolecules 8, 1069-
1076.  
Hung, L., Lee, A.P., 2007. Microfluidic devices for the synthesis of nanoparticles and 
biomaterials. J. Med. Biol. Eng. 27, 1-6.  
Huppertz, T., de Kruif, C.G., 2008. Structure and stability of nanogel particles prepared 
by internal cross-linking of casein micelles. Int. Dairy J. 18, 556-565.  
Ibrahim, N.K., Desai, N., Legha, S., Soon-Shiong, P., Theriault, R.L., Rivera, E., 
Esmaeli, B., Ring, S.E., Bedikian, A., Hortobagyi, G.N., Ellerhorst, J.A., 2002. Phase I 
and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, 
nanoparticle formulation of paclitaxel. Clin. Cancer Res. 8, 1038-1044.  
Illum, L., Davis, S.S., Müller, R.H., Mak, E., West, P., 1987. The organ distribution and 
circulation time of intravenously injected colloidal carriers sterically stabilized with a 
blockcopolymer - poloxamine 908. Life Sci. 40, 367-374.  
International Organization for Standardization. The ISO 10993 series of standards for 
biological evaluation of medical devices. Retrieved 23.11.2012 from internet: 
www.iso.org/iso/home/standards.htm.  
Irache, J.M., Bergougnoux, L., Ezpeleta, I., Gueguen, J., Orecchioni, A.M., 1995. 
Optimization and in vitro stability of legumin nanoparticles obtained by a coacervation 
method. Int. J. Pharm. 126, 103-109.  
Ito, T., Sun, L., Bevan, M.A., Crooks, R.M., 2004. Comparison of nanoparticle size and 
electrophoretic mobility measurements using a carbon-nanotube-based coulter counter, 
dynamic light scattering, transmission electron microscopy, and phase analysis light 
scattering. Langmuir 20, 6940-6945.  
Jayakrishnan, A., Jameela, S., 1996. Glutaraldehyde as a fixative in bioprostheses and 
drug delivery matrices. Biomaterials 17, 471-484.  
Jayakrishnan, A., Knepp, W.A., Goldberg, E.P., 1994. Casein microspheres: Preparation 
and evaluation as a carrier for controlled drug delivery. Int. J. Pharm. 106, 221-228.  
Jiang, B., Hu, L., Gao, C., Shen, J., 2005. Ibuprofen-loaded nanoparticles prepared by a 
co-precipitation method and their release properties. Int. J. Pharm. 304, 220-230.  
109 
 
  
Jintapattanakit, A., Junyaprasert, V.B., Mao, S., Sitterberg, J., Bakowsky, U., Kissel, T., 
2007. Peroral delivery of insulin using chitosan derivatives: A comparative study of 
polyelectrolyte nanocomplexes and nanoparticles. Int. J. Pharm. 342, 240-249.  
 
Judefeind A., De Villiers M.M., 2009. Drug Loading into and In Vitro Release from 
Nanosized Drug Delivery Systems, in: De Villiers, M.M., Aramwit, P., Kwon, G.S. 
(Eds.), Nanotechnology in drug delivery, first edition. Springer, New York, pp. 129-
162. 
Kaur, J., Harikumar S.L., Kaur, A., 2012. Interpolyelectrolyte complexes as prospective 
carriers for controlled drug delivery. Int. Res. J. Pharm. 3, 58-62. 
Kesisoglou, F., Panmai, S., Wu, Y., 2007. Nanosizing - oral formulation development 
and biopharmaceutical evaluation. Adv. Drug Deliv. Rev. 59, 631-644.  
Kim, H.K., Park, T.G., 2004. Comparative study on sustained release of human growth 
hormone from semi-crystalline poly(l-lactic acid) and amorphous poly(d,l-lactic-co-
glycolic acid) microspheres: morphological effect on protein release. J. Controlled 
Release 98, 115-125.  
Kinget, R., Bontinck, A., Herbots, H., 1979. Problems of dialysis techniques in the 
study of macromolecule binding of drugs. Int. J. Pharm. 3, 65-72.  
Klang, V., Valenta, C., Matsko, N.B., 2013. Electron microscopy of pharmaceutical 
systems. Micron 44, 45-74.  
Knepp, W., Jayakrishnan, A., Quigg, J., Sitren, H., Bagnall, J., Goldberg, E., 1993. 
Synthesis, Properties, and Intratumoral Evaluation of Mitoxantrone‐loaded Casein 
Microspheres in Lewis Lung Carcinoma. J. Pharm. Pharmacol. 45, 887-891.  
Konno, T., Kurita, K., Iwasaki, Y., Nakabayashi, N., Ishihara, K., 2001. Preparation of 
nanoparticles composed with bioinspired 2-methacryloyloxyethyl phosphorylcholine 
polymer. Biomaterials 22, 1883-1889.  
Konstance, R.P., Strange, E.D., 1991. Solubility and Viscous Properties of Casein and 
Caseinates. J. Food Sci. 56, 556-559.  
Kratz, F., 2008. Albumin as a drug carrier: Design of prodrugs, drug conjugates and 
nanoparticles. J. Controlled Release 132, 171-183.  
Kreuter, J., 1993. The influence of coatings with surfactants on the body distribution of 
nanoparticles after intravenous injection to rats. Clin. Mater. 13, 131-134.  
Kumari, A., Yadav, S.K., Yadav, S.C., 2010. Biodegradable polymeric nanoparticles 
based drug delivery systems. Colloids Surf. B Biointerfaces 75, 1-18.  
Lai, L.F., Guo, H.X., 2011. Preparation of new 5-fluorouracil-loaded zein nanoparticles 
for liver targeting. Int. J. Pharm. 404, 317-323.  
110 
 
  
Lam, H.Y., Van Hoffen, E., Michelsen, A., Guikers, K., Van Der Tas, C., 
Bruijnzeel‐Koomen, C., Knulst, A., 2008. Cow's milk allergy in adults is rare but 
severe: both casein and whey proteins are involved. Clin. Exp. Allergy 38, 995-1002.  
Lankalapalli, S., Kolapalli, V.R.M., 2009. Polyelectrolyte Complexes: A Review of 
their Applicability in Drug Delivery Technology. Indian J. Pharm. Sci. 71, 481-487.  
Lauber, S., Klostermeyer, H., Henle, T., 2000. Influence of irreversible casein 
crosslinking on the gel strength of yoghurt. Czech J. Food Sci. 18, 69-71. 
Lecaroz, C., Gamazo, C., Renedo, M.J., Blanco-Prieto, M.J., 2006. Biodegradable 
micro-and nanoparticles as long-term delivery vehicles for gentamicin. J. 
Microencapsul. 23, 782-792.  
Lee, H.J., 2002. Protein drug oral delivery: the recent progress. Arch. Pharm. Res. 25, 
572-584.  
Lee, E.S., Na, K., Bae, Y.H., 2003. Polymeric micelle for tumor pH and folate-mediated 
targeting. J. Controlled Release 91, 103-113.  
Lemarchand, C., Gref, R., Couvreur, P., 2004. Polysaccharide-decorated nanoparticles. 
Eur. J. Pharm. Biopharm. 58, 327-341.  
Leo, E., Scatturin, A., Vighi, E., Dalpiaz, A., 2006. Polymeric nanoparticles as drug 
controlled release systems: a new formulation strategy for drugs with small or large 
molecular weight. J. Nanosci. Nanotechnol. 6, 3070-3079.  
Leo, E., Vandelli, M.A., Cameroni, R., Forni, F., 1997. Doxorubicin-loaded gelatin 
nanoparticles stabilized by glutaraldehyde: Involvement of the drug in the cross-linking 
process. Int. J. Pharm. 155, 75-82.  
Leroueil-Le Verger, M., Fluckiger, L., Kim, Y., Hoffman, M., Maincent, P., 1998. 
Preparation and characterization of nanoparticles containing an antihypertensive agent. 
Eur. J. Pharm. Biopharm. 46, 137-143.  
Liu, C., Zhen, X., Wang, X., Wu, W., Jiang, X., 2011. Cellular entry fashion of hollow 
milk protein spheres. Soft Matter 7, 11526-11534. 
Liu, C., Yao, W., Zhang, L., Qian, H., Wu, W., Jiang, X., 2010. Cell-penetrating hollow 
spheres based on milk protein. Chem. Commun. 46, 7566-7568.  
Livney, Y.D., 2010. Milk proteins as vehicles for bioactives. Curr. Opin. Colloid 
Interface Sci. 15, 73-83.  
Lowe, P.J., Temple, C.S., 1994. Calcitonin and insulin in isobutylcyanoacrylate 
nanocapsules: protection against proteases and effect on intestinal absorption in rats. J. 
Pharm. Pharmacol. 46, 547-552.  
Lu, Z., Prouty, M.D., Guo, Z., Golub, V.O., Kumar, C.S.S.R., Lvov, Y.M., 2005. 
Magnetic switch of permeability for polyelectrolyte microcapsules embedded with Co@ 
Au nanoparticles. Langmuir 21, 2042-2050.  
111 
 
  
Lulevich, V.V., Radtchenko, I.L., Sukhorukov, G.B., Vinogradova, O.I., 2003. 
Deformation properties of nanoadhesive polyelectrolyte microcapsules studied with the 
atomic force microscope. J. Phys. Chem. B 107, 2735-2740.  
Magde, D., Wong, R., Seybold, P.G., 2002. Fluorescence Quantum Yields and Their 
Relation to Lifetimes of Rhodamine 6G and Fluorescein in Nine Solvents: Improved 
Absolute Standards for Quantum Yields. Photochem. Photobiol. 75, 327-334.  
Maham, A., Tang, Z., Wu, H., Wang, J., Lin, Y., 2009. Protein‐Based Nanomedicine 
Platforms for Drug Delivery. Small 5, 1706-1721.  
Maher, P.G., Fenelon, M.A., Zhou, Y., Haque, K., Roos, Y.H., 2011. Optimization of 
β‐Casein Stabilized Nanoemulsions Using Experimental Mixture Design. J. Food Sci. 
76, C1108-C1117.  
Martins, S., Silva, A., Ferreira, D., Souto, E., 2009. Improving oral absorption of samon 
calcitonin by trimyristin lipid nanoparticles. J. Biomed. Nanotechnol. 5, 76-83.  
Mattson, G., 1993. A practical approach to crosslinking. Mol. Biol. Rep. 17, 167.  
Mauser, T., Déjugnat, C., Sukhorukov, G.B., 2004. Reversible pH‐Dependent 
Properties of Multilayer Microcapsules Made of Weak Polyelectrolytes. Macromol. 
Rapid Commun. 25, 1781-1785.  
Molnar, R.M., Bodnar, M., Hartmann, J.F., Borbely, J., 2009. Preparation and 
characterization of poly(acrylic acid)-based nanoparticles. Colloid Polym. Sci. 287, 
739-744.  
Meunier, F., Prentice, H., Ringden, O., 1991. Liposomal amphotericin B (AmBisome): 
safety data from a phase II/III clinical trial. J. Antimicrob. Chemother. 28, 83-91.  
Migneault, I., Dartiguenave, C., Bertrand, M.J., Waldron, K.C., 2004. Glutaraldehyde: 
behavior in aqueous solution, reaction with proteins, and application to enzyme 
crosslinking. BioTechniques 37, 790-806.  
Milanova, D., Chambers, R.D., Bahga, S.S., Santiago, J.G., 2011. Electrophoretic 
mobility measurements of fluorescent dyes using on‐chip capillary electrophoresis. 
Electrophor. 32, 3286-3294.  
Modler, H.W., 1985. Functional Properties of Nonfat Dairy Ingredients-A Review. 
Modification of Products Containing Casein. J. Dairy Sci. 68, 2195-2205.  
Moitzi, C., Portnaya, I., Glatter, O., Ramon, O., Danino, D., 2008. Effect of temperature 
on self-assembly of bovine beta-casein above and below isoelectric pH. Structural 
analysis by cryogenic-transmission electron microscopy and small-angle X-ray 
scattering. Langmuir 24, 3020-3029.  
Monogioudi, E., Faccio, G., Lille, M., Poutanen, K., Buchert, J., Mattinen, M.L., 2011. 
Effect of enzymatic cross-linking of beta-casein on proteolysis by pepsin. Food 
Hydrocoll. 25, 71-81.  
112 
 
  
Morishita, M., Peppas, N.A., 2006. Is the oral route possible for peptide and protein 
drug delivery? Drug Discov. Today 11, 905-910.  
Mout, R., 2012. Surface functionalization of nanoparticles for nanomedicine. Chem. 
Soc. Rev. 41, 2539.  
Moya, S.E., Georgieva, R., Bäumler, H., Richter, W., Donath, E., 2003. Composite lipid 
polyelectrolyte capsules templated on red blood cells: Fabrication and structural 
characterisation. Med. Biol. Eng. Comput. 41, 504-508.  
Müller, R.H., Jacobs, C., Kayser, O., 2001. Nanosuspensions as particulate drug 
formulations in therapy: Rationale for development and what we can expect for the 
future. Adv. Drug Deliv. Rev. 47, 3-19.  
Murdock, R.C., Braydich-Stolle, L., Schrand, A.M., Schlager, J.J., Hussain, S.M., 2008. 
Characterization of nanomaterial dispersion in solution prior to in vitro exposure using 
dynamic light scattering technique. Toxicol. Sci. 101, 239-253.  
Neha, A., Tarun, G., Ajay, B., 2012. Review on casein production and casein based 
nano-formulations.  Int. Res. J. Pharm. 3, 41-45. 
Nidhin, M., Indumathy, R., Sreeram, K., Nair, B.U., 2008. Synthesis of iron oxide 
nanoparticles of narrow size distribution on polysaccharide templates. Bull. Mater. Sci. 
31, 93-96.  
Oh, J.K., Drumright, R., Siegwart, D.J., Matyjaszewski, K., 2008. The development of 
microgels/nanogels for drug delivery applications. Prog. Polym. Sci. 33, 448-477.  
Pan, X., Yu, S., Yao, P., Shao, Z., 2007. Self-assembly of beta-casein and lysozyme. J. 
Colloid Interface Sci. 316, 405-412.  
Park, H., Robinson, J.R., 1987. Mechanisms of mucoadhesion of poly (acrylic acid) 
hydrogels. Pharm. Res. 4, 457-464.  
Parveen, S., Misra, R., Sahoo, S.K., 2012. Nanoparticles: a boon to drug delivery, 
therapeutics, diagnostics and imaging. Nanomedicine 8, 147-166. 
Parveen, S., Sahoo, S.K., 2006. Nanomedicine: clinical applications of polyethylene 
glycol conjugated proteins and drugs. Clin. Pharmacokinet. 45, 965.  
Pastoriza-Santos, I., Schöler, B., Caruso, F., 2001. Core-shell colloids and hollow 
polyelectrolyte capsules based on diazoresins. Adv. Funct. Mater. 11, 122-128.  
Peltonen, L., Hirvonen, J., 2008. Physicochemical characterization of nano-and 
microparticles. Curr. Nanosci. 4, 101-107.  
Penzkofer, A., Leupacher, W., 1987. Fluorescence behaviour of highly concentrated 
rhodamine 6G solutions. J. Lumin. 37, 61-72.  
Peracchia, M.T., Fattal, E., Desmaële, D., Besnard, M., Noël, J.P., Gomis, J.M., Appel, 
M., D'Angelo, J., Couvreur, P., 1999. Stealth(®) PEGylated polycyanoacrylate 
113 
 
  
nanoparticles for intravenous administration and splenic targeting. J. Controlled Release 
60, 121-128.  
Perera, G., Greindl, M., Palmberger, T.F., Bernkop-Schnürch, A., 2009. Insulin-loaded 
poly (acrylic acid)-cysteine nanoparticles: Stability studies towards digestive enzymes 
of the intestine. Drug Deliv. 16, 254-260.  
Petrov, A.I., Volodkin, D.V., Sukhorukov, G.B., 2005. Protein-Calcium Carbonate 
Coprecipitation: A Tool for Protein Encapsulation. Biotechnol. Prog. 21, 918-925.  
Peyratout, C.S., Dähne, L., 2004. Tailor-made polyelectrolyte microcapsules: From 
multilayers to smart containers. Angew. Chem. Int. Ed. 43, 3762-3783.  
Pfeifer, B.A., 2005. Poly(ester-anhydride):poly(beta-amino ester) micro- and 
nanospheres: DNA encapsulation and cellular transfection. Int. J. Pharm. 304, 210.  
Pinto Reis, C., Neufeld, R.J., Ribeiro, A.J., Veiga, F., 2006. Nanoencapsulation I. 
Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine 2, 8-
21.  
Portnaya, I., Cogan, U., Livney, Y.D., Ramon, O., Shimoni, K., Rosenberg, M., Danino, 
D., 2006. Micellization of bovine β-casein studied by isothermal titration 
microcalorimetry and cryogenic transmission electron microscopy. J. Agric. Food 
Chem. 54, 5555-5561.  
Portnaya, I., Ben-Shoshan, E., Cogan, U., Khalfin, R., Fass, D., Ramon, O., Danino, D., 
2008. Self-assembly of bovine beta-casein below the isoelectric pH. J. Agric. Food 
Chem. 56, 2192-2198.  
Puthli, S., Vavia, P., 2008. Gamma irradiated micro system for long-term parenteral 
contraception: An alternative to synthetic polymers. Eur. J. Pharm. Sci. 35, 307-317.  
Qi, P.X., 2007. Studies of casein micelle structure: The past and the present. Dairy Sci. 
Technol. 87, 363-383.  
Qiu, X., Leporatti, S., Donath, E., Möhwald, H., 2001a. Studies on the drug release 
properties of polysaccharide multilayers encapsulated ibuprofen microparticles. 
Langmuir 17, 5375-5380.  
Qiu, X., Donath, E., Möhwald, H., 2001b. Permeability of ibuprofen in various 
polyelectrolyte multilayers. Macromol. Mater. Eng. 286, 591-597.  
Quaglia, F., 2006. Nanoscopic core-shell drug carriers made of amphiphilic triblock and 
star-diblock copolymers. Int. J. Pharm. 324, 56.  
Radt, B., Smith, T.A., Caruso, F., 2004. Optically addressable nanostructured capsules. 
Adv. Mater. 16, 2184-2189.  
Rajender Reddy, K., Modi, M.W., Pedder, S., 2002. Use of peginterferon alfa-2a (40 
KD) (Pegasys) for the treatment of hepatitis C. Adv. Drug Deliv. Rev. 54, 571-586.  
114 
 
  
Ringden, O., Meunier, F., Tollemar, J., Ricci, P., Tura, S., Kuse, E., Viviani, M., Gorin, 
N., Klastersky, J., Fenaux, P., 1991. Efficacy of amphotericin B encapsulated in 
liposomes (AmBisome) in the treatment of invasive fungal infections in 
immunocompromised patients. J. Antimicrob. Chemother. 28, 73-82.  
Ruoslahti, E., Bhatia, S.N., Sailor, M.J., 2010. Targeting of drugs and nanoparticles to 
tumors. J. Cell Biol. 188, 759-768.  
Russell-Jones, G.J., Veitch, H., Arthur, L., 1999. Lectin-mediated transport of 
nanoparticles across Caco-2 and OK cells. Int. J. Pharm. 190, 165-174.  
Sadler, K., Eom, K.D., Yang, J.L., Dimitrova, Y., Tam, J.P., 2002. Translocating 
proline-rich peptides from the antimicrobial peptide bactenecin 7. Biochem. 41, 14150-
14157.  
Sahu, A., Kasoju, N., Bora, U., 2008. Fluorescence Study of the Curcumin-Casein 
Micelle Complexation and Its Application as a Drug Nanocarrier to Cancer Cells. 
Biomacromolecules 9, 2905-2912.  
Salgueiriño-Maceira, V., Liz-Marzán, L.M., Farle, M., 2004. Water-Based Ferrofluids 
from FexPt1-x Nanoparticles Synthesized in Organic Media. Langmuir 20, 6946-6950.  
Sant, S., Tao, S.L., Fisher, O.Z., Xu, Q., Peppas, N.A., Khademhosseini, A., 2012. 
Microfabrication technologies for oral drug delivery. Adv. Drug Deliv. Rev. 64, 496-
507.  
Schorsch, C., Carrie, H., Clark, A., Norton, I., 2000. Cross-linking casein micelles by a 
microbial transglutaminase conditions for formation of transglutaminase-induced gels. 
Int. Dairy J. 10, 519-528.  
Selwyn, J.E., Steinfeld, J.I., 1972. Aggregation of equilibriums of xanthene dyes. J. 
Phys. Chem. 76, 762-774.  
Semo, E., Kesselman, E., Danino, D., Livney, Y.D., 2007. Casein micelle as a natural 
nano-capsular vehicle for nutraceuticals. Food Hydrocoll. 21, 936-942.  
Shapira, A., Assaraf, Y.G., Livney, Y.D., 2010a. Beta-casein nanovehicles for oral 
delivery of chemotherapeutic drugs. Nanomedicine 6, 119-126.  
Shapira, A., Markman, G., Assaraf, Y.G., Livney, Y.D., 2010b. β-casein-based 
nanovehicles for oral delivery of chemotherapeutic drugs: Drug-protein interactions and 
mitoxantrone loading capacity. Nanomedicine 6, 547-555.  
Shapira, A., Assaraf, Y.G., Epstein, D., Livney, Y.D., 2010c. Beta-casein Nanoparticles 
as an Oral Delivery System for Chemotherapeutic Drugs: Impact of Drug Structure and 
Properties on Co-assembly. Pharm. Res. 27, 2175-2186.  
Shapira, A., Davidson, I., Avni,  ., Assaraf,  .G., Livney,  .D., 2012. β-Casein 
nanoparticle-based oral drug delivery system for potential treatment of gastric 
carcinoma: Stability, target-activated release and cytotoxicity. Eur. J. Pharm. Biopharm. 
80, 298-305.  
115 
 
  
Shchukin, D.G., Kommireddy, D.S., Zhao, Y., Cui, T., Sukhorukov, G.B., Lvov, Y.M., 
2004. Polyelectrolyte Micropatterning Using a Laminar‐Flow Microfluidic Device. 
Adv. Mater. 16, 389-393.  
Shegokar, R., Müller, R.H., 2010. Nanocrystals: Industrially feasible multifunctional 
formulation technology for poorly soluble actives. Int. J. Pharm. 399, 129-139.  
Shek, L., Bardina, L., Castro, R., Sampson, H., Beyer, K., 2005. Humoral and cellular 
responses to cow milk proteins in patients with milk‐induced IgE‐mediated and 
non‐IgE‐mediated disorders. Allergy 60, 912-919.  
Shekunov, B.Y., Chattopadhyay, P., Seitzinger, J., Huff, R., 2006. Nanoparticles of 
poorly water-soluble drugs prepared by supercritical fluid extraction of emulsions. 
Pharm. Res. 23, 196-204.  
Shenoy, D.B., Amiji, M.M., 2005. Poly (ethylene oxide)-modified poly (-caprolactone) 
nanoparticles for targeted delivery of tamoxifen in breast cancer. Int. J. Pharm. 293, 
261-270.  
Shu, S., Zhang, X., Teng, D., Wang, Z., Li, C., 2009. Polyelectrolyte nanoparticles 
based on water-soluble chitosan–poly (l-aspartic acid)–polyethylene glycol for 
controlled protein release. Carbohydr. Res. 344, 1197-1204.  
Siewert, M., Dressman, J., Brown, C.K., Shah, V.P., Aiache, J.M., Aoyagi, N., Bashaw, 
D., Brown, C., Brown, W., Burgess, D., 2003. FIP/AAPS guidelines to dissolution/in 
vitro release testing of novel/special dosage forms. AAPS PharmSciTech 4, 43-52.  
Sinko, P.J., Singh, Y., 2011. Drug delivery and targeting, in: Sinko, P.J., Singh, Y. 
(Eds.), Martin's Physical Pharmacy and Pharmaceutical Sciences, sixth edition. 
Lippincott Williams & Wilkins, Philadelphia, pp.594-645. 
Song, F., Zhang, L., Yang, C., Yan, L., 2009. Genipin-crosslinked casein hydrogels for 
controlled drug delivery. Int. J. Pharm. 373, 41-47.  
Soppimath, K.S., Aminabhavi, T.M., Kulkarni, A.R., Rudzinski, W.E., 2001. 
Biodegradable polymeric nanoparticles as drug delivery devices. J. Controlled Release 
70, 1-20.  
Stanic, D., Monogioudi, E., Dilek, E., Radosavljevic, J., Atanaskovic-Markovic, M., 
Vuckovic, O., Raija, L., Mattinen, M., Buchert, J., Velickovic, T.C., 2010. Digestibility 
and allergenicity assessment of enzymatically crosslinked beta-casein. Mol. Nutr. Food 
Res. 54, 1273-1284.  
Storm, G., Belliot, S.O., Daemen, T., Lasic, D.D., 1995. Surface modification of 
nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv. Drug 
Deliv. Rev. 17, 31-48.  
Strange, E., Van Hekken, D., Holsinger, V., 1994. Effect of sodium chloride on the 
solubility of caseins. J. Dairy Sci. 77, 1216-1222.  
116 
 
  
Sugahara, K.N., Teesalu, T., Karmali, P.P., Kotamraju, V.R., Agemy, L., Girard, O.M., 
Hanahan, D., Mattrey, R.F., Ruoslahti, E., 2009. Tissue-Penetrating Delivery of 
Compounds and Nanoparticles into Tumors. Cancer Cell 16, 510-520.  
Sukhorukov, G.B., Donath, E., Davis, S., Lichtenfeld, H., Caruso, F., Popov, V.I., 
Möhwald, H., 1998. Stepwise polyelectrolyte assembly on particle surfaces: A novel 
approach to colloid design. Polym. Adv. Technol. 9, 759-767.  
Sukhorukov, G.B., Volodkin, D.V., Günther, A.M., Petrov, A.I., Shenoy, D.B., 
Möhwald, H., 2004. Porous calcium carbonate microparticles as templates for 
encapsulation of bioactive compounds. J. Mater. Chem. 14, 2073-2081.  
Sukhorukov, G.B., Donath, E., Lichtenfeld, H., Knippel, E., Knippel, M., Budde, A., 
Möhwald, H., 1998. Layer-by-layer self assembly of polyelectrolytes on colloidal 
particles. Colloids Surf., A 137, 253-266.  
Sung, H.W., Huang, D.M., Chang, W.H., Huang, R.N., Hsu, J.C., 1999. Evaluation of 
gelatin hydrogel crosslinked with various crosslinking agents as bioadhesives: in vitro 
study. J. Biomed. Mater. Res. 46, 520-530.  
Swaisgood, H.E., 1993. Review and update of casein chemistry. J. Dairy Sci. 76, 3054.  
Qazvini, N.T., Zinatloo, S., 2011. Synthesis and characterization of gelatin 
nanoparticles using CDI/NHS as a non-toxic cross-linking system. J. Mater. Sci. Mater. 
Med. 22, 63-69.  
Thermo Fisher Scientific Inc., 2009. Light sources and conditions for photoactivation of 
aryl azide crosslinking and labeling reagents. Retrieved 28.5.2012 from internet: 
www.piercenet.com/files/TR0011-Photoactivate-aryl-azides.pdf 
Thünemann, A.F., Müller, M., Dautzenberg, H., Joanny, J.F., Löwen, H., 2004. 
Polyelectrolyte Complexes. Adv. Polym. Sci. 166, 113-171.  
Troster, S.D., Muller, U., Kreuter, J., 1990. Modification of the body distribution of 
poly(methyl methacrylate) nanoparticles in rats by coating with surfactants. Int. J. 
Pharm. 61, 85-100.  
Van Furth, R., Cohn, Z., Hirsch, J., Humphrey, J., Spector, W., Langevoort, H., 1972. 
The mononuclear phagocyte system: a new classification of macrophages, monocytes, 
and their precursor cells. Bull. World Health Organ. 46, 845.  
van Nostrum, C.F., 2011. Covalently cross-linked amphiphilic block copolymer 
micelles. Soft Matter 7, 3246-3259.  
Verwey, E.J., Overbeek, J.T.G., 1948. Theory of the Stability of Lyophobic Colloids. 
Elsevier, Amsterdam. 
Vila, L., Beyer, K., Järvinen, K.M., Chatchatee, P., Bardina, L., Sampson, H., 2008. 
Role of conformational and linear epitopes in the achievement of tolerance in cow's 
milk allergy. Clin. Exp. Allergy 31, 1599-1606.  
117 
 
  
Volodkin, D.V., Larionova, N.I., Sukhorukov, G.B., 2004. Protein encapsulation via 
porous CaCO3 microparticles templating. Biomacromolecules 5, 1962-1972.  
Wagner, V., Dullaart, A., Bock, A.K., Zweck, A., 2006. The emerging nanomedicine 
landscape. Nat. Biotechnol. 24, 1211-1218.  
Walsh, T.J., Yeldandi, V., McEvoy, M., Gonzalez, C., Chanock, S., Freifeld, A., Seibel, 
N.I., Whitcomb, P.O., Jarosinski, P., Boswell, G., 1998. Safety, tolerance, and 
pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B 
(AmBisome) in neutropenic patients. Antimicrob. Agents Chemother. 42, 2391-2398.  
Washington, C., 1990. Drug release from microdisperse systems: a critical review. Int. 
J. Pharm. 58, 1-12.  
Washington, C., 1989. Evaluation of non-sink dialysis methods for the measurement of 
drug release from colloids: effects of drug partition. Int. J. Pharm. 56, 71-74.  
Weber, C., Coester, C., Kreuter, J., Langer, K., 2000. Desolvation process and surface 
characterisation of protein nanoparticles. Int. J. Pharm. 194, 91-102.  
Willmott, N., Chen, Y., Goldberg, J., McArdle, C., Florence, A.T., 1989. 
Biodegradation rate of embolized protein microspheres in lung, liver and kidney of rats. 
J. Pharm. Pharmacol. 41, 433-438.  
Yan, H.B., Zhang, Y.Q., Ma, Y.L., Zhou, L.X., 2009. Biosynthesis of insulin-silk 
fibroin nanoparticles conjugates and in vitro evaluation of a drug delivery system. J. 
Nanopart. Res. 11, 1937-1946.  
Ye, A., Flanagan, J., Singh, H., 2006. Formation of stable nanoparticles via electrostatic 
complexation between sodium caseinate and gum arabic. Biopolymers 82, 121-133.  
Yegin, B.A., Lamprecht, A., 2006. Lipid nanocapsule size analysis by hydrodynamic 
chromatography and photon correlation spectroscopy. Int. J. Pharm. 320, 165-170.  
Yordanov, G., Bedzhova, Z., 2011. Poly (ethyl cyanoacrylate) colloidal particles tagged 
with Rhodamine 6G: preparation and physicochemical characterization. Cent. Eur. J. 
Chem. 9, 1062-1070. 
Zambaux, M.F., Bonneaux, F., Gref, R., Maincent, P., Dellacherie, E., Alonso, M.J., 
Labrude, P., Vigneron, C., 1998. Influence of experimental parameters on the 
characteristics of poly(lactic acid) nanoparticles prepared by a double emulsion method. 
J. Controlled Release 50, 31-40.  
Zimet, P., Rosenberg, D., Livney, Y.D., 2011. Re-assembled casein micelles and casein 
nanoparticles as nano-vehicles for ω-3 polyunsaturated fatty acids. Food Hydrocoll. 25, 
1270-1276. 
Zuckerman, S.T., Kao, W.J., 2009. Nanomaterials and Biocompatibility: BioMEMS and 
Dendimers, in: De Villiers, M.M., Aramwit, P., Kwon, G.S. (Eds.), Nanotechnology in 
drug delivery, first edition. Springer, New York, pp. 193-228. 
 
